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2 Abstract 
Liver organ shortage is an increasing problem worldwide and many die each year 
waiting for a new liver. In case of acute liver failure a bioartificial liver (BAL) device 
could “buy” time until a donor liver is available or until the liver has spontaneously 
undergone self-repair.  
For the clinical application of a BAL large quantities of cells should be available 
immediately necessitating cryo-banking. However, cryopreservation of large volumes 
results in increased ice formation and increased cell death. Ice formation can be 
prevented by vitrification, but the high cryoprotectant agent (CPA) concentrations 
needed are normally toxic to mammalian cells. Short exposure time minimizes toxicity 
but can only be achieved in small samples where fast cooling rates can be reached. To 
reduce CPA toxicity a vitrification machine (Liquidus Tracker) designed by Planer plc 
was used, which provides the lowest toxic effect that can be established for a given 
CPA concentration by decreasing the sample temperature to just above the melting 
point of that particular mix. The CPA concentration is then gradually increased as 
temperature is decreased along the liquidus curve.  
The first aspect of this thesis was to standardise a rapid and reliable method to describe 
post-stress viability. A digital imaging system was used to evaluate membrane integrity 
and enzyme activity by quantifying the fluorescence signal of fluorescein and 
propidium iodide.  
To understand the Liquidus Tracking (LT) process but also to pre-test conditions for 
automatic LT, different methods to carry out manual LT were established, evaluated and 
improved. To further increase cell viability a low-toxicity CPA solution was developed 
with the requirement of low viscosity so that it may be used within the Liquidus 
Tracker. Finally improvements were applied to automatic Liquidus Tracking. The 
development of a new stirring system substantially increased post-warming viability. 
In conclusion, an optimised large scale slow cooling vitrification protocol was 
developed for alginate encapsulated liver cells which may be used in a BAL. 
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1 CHAPTER 1 
General Introduction 
Liver failure is a life threatening illness with increasing mortality worldwide. Although 
the liver has an unique ability for natural regeneration, a liver transplant is usually 
inevitable. However, due to an increasing shortage of donor organs many patients die 
while waiting for a liver transplant. Mortality could be reduced by temporarily 
substituting healthy liver function by using a bioartificial liver (BAL) device, until 
either a transplant becomes available or until the liver has spontaneously undergone 
self-repair. Treatment must be available almost immediately for unpredictable 
emergency use, which points out the necessity for a suitable BAL storage method. For 
liver cells, which are the main component of a BAL device, cryopreservation is the only 
measure to maintain cell function over a longer period of time. 
1.1 The Liver 
The liver is the biggest internal organ and the largest gland of the human body with a 
weight of about 1.5kg (Moore et al., 2007). It is incredibly complex and is responsible 
for more than 500 known different functions. In humans, the liver is mostly located in 
the right upper abdomen directly below the diaphragm. The human liver is divided into 
two large lobes. At the bottom of the liver is the so called hilum (porta hepatis), at 
which the portal vein and the hepatic artery enter and bile ducts leave the liver. The 
hepatic artery provides the liver with oxygen-rich blood from the heart and the portal 
vein carries nutrients from stomach and intestines, degradation products from the spleen 
and hormones from the pancreas to the liver. The liver lobes again divided into tiny 
lobules which are of hexagonal formation and consist mainly of hepatocytes which are 
arranged in strings ("liver cell columns"). Capillaries (liver sinusoids) are arranged 
between the liver cells allowing them to be perfused with blood. These sinusoids are 
lined up with a discontinuous endothelium and contain specific macrophages, the 
Kupffer cells, which are mainly responsible for phagocytosis and cytokine production 
(Tacke et al., 2009). The space (Space of Disse) between the liver cells and the 
endothelial cells of liver sinusoids, is where the actual exchange of substances between 
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blood and hepatocytes occurs. Within this space the satellite cells are found which store 
fat droplets and retinoic acid (Kordes et al., 2009). 
1.1.1 Liver functions 
Hepatocytes (parenchymal cells) are responsible for the majority of liver metabolic 
functions and make up 70% to 80% of the liver's cytoplasmic mass. Morphologically, 
they appear cuboidal with a large, central nucleus, which can be diploid or polyploid. 
Hepatocytes are about 20 to 30µm in diameter, and are metabolically very active. Signs 
of the high metabolic activity are the highly developed endoplasmic reticulum and 
Golgi apparatus and a high concentration of mitochondria. They also contain lysosomes, 
peroxisomes, and secretory vesicles. Another characteristic of hepatocytes is 
intracellular glycogen deposits which function as energy sources.  
1.1.1.1 Metabolic functions 
The liver fulfils a large variety of metabolic tasks that are crucial for the rest of the 
body. This includes the formation of clotting factors and the processing of intestinal 
nutrients to endogenous substances, which are then used by other organs. Hepatocytes 
produce a variety of proteins of which albumin is one of the most important. Albumin 
ensures that blood fluids remain in the bloodstream and that poorly soluble substances 
in the blood can be transported by binding to albumin. Additionally, hepatocytes 
synthesise carbohydrates, cholesterol, bile salts, fatty acids, triglycerides, phospholipids, 
glycoproteins, lipoproteins and lipoproteins. Moreover the liver is responsible for 
transamination (amino acid conversion) to produce non-essential amino acids. 
1.1.1.2 Detoxification 
The liver plays an important role in the detoxification of harmful substances for 
example by transforming toxic ammonia into non-toxic urea, which is then excreted in 
urine by the kidneys. Dehydrogenases convert alcohol into acetic acid, which is 
ultimately changed into fat. One of the important enzymes for the removal of toxins and 
drugs is cytochrome P450, which catalyze the oxidation of organic substances. The liver 
also filters hormones and cell debris from the blood. Bacteria and viruses may be 
removed through phagocytic Kupffer cells. Water-insoluble pollutants are emitted via 
bile into the intestine. Water-soluble pollutants are released into the blood stream which 
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carries it to the kidneys where they can be excreted in the urine from the body (Moore et 
al., 2007). 
1.1.2 Liver regeneration 
The liver is the only inner organ that has the capacity to naturally regenerate. The 
physiological size is normally adjusted to match the host for example after 
transplantation or to regain its former size (e.g. size before hepatectomy), which in turn 
depends on complex variables such as normalisation of the body’s blood circulation and 
metabolism. Liver regeneration reportedly occurs mostly during the first two weeks 
after the damaging insult. Under normal conditions hepatocytes of an adult liver barely 
proliferate, but when the liver functional mass is reduced for example by surgical 
removal or following chemical or viral insult, a process of cell hypertrophy, rapid 
proliferation and restoration of functional mass is initiated. Mature, highly differentiated 
hepatocytes re-enter the cell cycle and proliferate for a limited number of divisions. This 
rather unique process of adult cells re-entering the cell cycle is a result of extracellular 
stimuli and intracellular signalling pathways and profound modifications of gene 
expression (Michalopoulos, 2013). Another type of cell that is phenotypically similar to 
hepatoblasts, is also thought to play a role in liver regeneration. The so called “oval 
cells” are found in close proximity to bile ducts (Bird et al., 2008). Although there is 
still some doubt regarding the exact properties of these cells, it is generally accepted 
that oval cells are bipotential liver stem cells, with the potential to differentiate into 
either hepatocytes or cholangiocytes (bile duct epithelial cells). It is believed that they 
are activated in response to growth factors released following disease or injury when 
mitosis of hepatocytes cannot occur. 
Liver regeneration is limited and injury to the liver can be of too long duration or too 
severe to allow full recovery. As a result, the liver creates scar tissue, also called 
fibrosis, which can still be treated with medication in some cases and at early stages. 
However, the continuous build-up of scar tissue leads to cirrhosis, a condition in which 
the liver slowly deteriorates and is unable to function normally. At this point the disease 
is not curable and a liver transplantation is inevitable. 
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1.2 Liver Failure 
Liver failure is the inability of the liver to perform its normal synthetic and metabolic 
function and can be classed into acute and chronic liver failure. 
1.2.1 Acute Liver Failure 
Acute liver failure (ALF) is defined as a rapid loss (80% to 90%) of hepatocellular 
function in a patient without known prior liver disease.
 
ALF can be classified into 
hyperacute (1 week), acute (8-28 days) and subacute (8 weeks) liver failure, describing 
the time from first symptoms until an onset of coagulopathy and encephalopathy 
(O’Grady et al., 1993). Common early symptoms are fatigue, nausea, poor appetite, 
dark urine and jaundice, which is caused by an accumulation of unconjugated bilirubin 
in the blood. Coagulopathy (abnormal blood clotting) occurs as clotting proteins are not 
being synthesised; encephalopathy is a brain dysfunction caused by toxin and ammonia 
build up in the brain. Liver failure can also lead to haemodynamic and cardio-
respiratory compromise, metabolic derangements, inflammation and infection, renal 
failure, cerebral edema, and finally multi-organ failure. Patients with acute and 
hyperacute liver failure are at greater risk of developing cerebral oedema and 
encephalopathy, which is thought to be a consequence of a longer buildup of toxic 
substances in the brain (Hazell & Butterworth, 1999; O’Grady, 2005). There are many 
causes such as viral hepatitis, drug intolerance, paracetamol overdose, alcoholic excess, 
toxins and acute fatty liver of pregnancy. Wilson's disease which is hereditary copper 
accumulation has also been linked to ALF. Despite a number of treatments available, 
liver transplantation, which has a reported 1-year survival rate of more than 83%, is 
oftentimes inevitable (Adam & Hoti, 2009). Without transplantation the fatality rate for 
ALF has been estimated to be greater than 80% (O’Grady et al., 1993). In the United 
States, as in other countries, patients with ALF have the highest priority for donor 
organs (Belle et al., 1995). However, there are not sufficient donor organs available to 
meet this urgent clinical need. A BAL device could provide time until a donor liver is 
available or until the liver has spontaneously undergone self-repair.  
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1.2.2 Acute on-chronic Liver Failure 
Acute-on-chronic liver failure (ACLF) is an acute deterioration of liver functions in 
patients with cirrhosis. Symptoms are similar to those of ALF, but treatment and 
prognosis may vary (Jalan et al., 2012). Predominate causes for liver cirrhosis, 
especially in Europe and the US, are excessive alcohol abuse, hepatitis B and hepatitis 
C, which is mostly caused by illegal drug injection. This unhealthy lifestyle is regarded 
as unfavorable for the qualification for a liver transplant. There are also other life-style 
related liver pathologies such as non-alcoholic fatty liver disease (NAFLD). Although 
reversible in some cases, depending on the severity and nature of the acute and chronic 
insult (Sarin et al., 2009), the necessity for transplantation as a result of progressed 
cirrhosis is most likely. 
1.3 Liver donor shortage 
Liver organ shortage is an increasing problem worldwide. In the US more than 15,000 
people were listed for a liver transplant in 2013 (Organ Procurement and 
Transplantation Network Data). About 9,000 new cases are reported each year, but 
only 5,000 livers from deceased donors are available for liver transplantation and 
approximately 1,400 people die each year waiting for a new liver. In the UK a total of 
726 liver transplants were carried out between 2011 and 2012. However, the number of 
people who need a liver transplant is much higher and an estimated 12% die while 
being on the waiting list. In Germany 1191 liver transplantations were carried out in 
2001, but 1792 new patients were put on the waiting list (Manns, 2013). It is expected 
that donor liver shortage will increase substantially over the next decades. In order to 
determine whose need is most critical, the United Network for Organ Sharing has 
developed a rating system. Patients with ALF, with a life expectancy fewer than seven 
days without transplant have been defined as the most urgent group. People with active 
alcohol or substance abuse problems might not qualify for a transplant as there is a 
high risk that patients will continue with their unhealthy lifestyle, leading the newly 
transplanted liver to fail. Patients with additional severe diseases (cancer other than 
liver cancer, multi-organ failure) also don’t qualify for a transplant as the mortality risk 
is extremely high. Living donation has been developed by surgeons to help overcome 
the organ donor shortage by removing a portion of liver from a live donor and 
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transplanting it into a recipient. However this bears a risk for the live donor with a 
predicted mortality rate of 1:200 (Neuberger et al., 2003). 
1.4 Extracorporeal Liver Devices 
Extracorporeal liver devices are used outside of the body and are supposed to support 
liver functions. There are two types of support systems: Artificial Liver devices and 
Bioartificial Liver devices. 
1.4.1 Artificial Liver Devices 
There are currently two artificial liver devices for toxin removal by chemical and 
physical means which are available including the molecular adsorbents recirculating 
system (MARS) and Prometheus. 
MARS (Gambro Hospal GmbH) is an albumin-based dialysis system that removes both 
water-soluble and fat-soluble toxins. A specific membrane enables the selective 
transport of albumin bound metabolites to the albumin containing dialysate 
compartment, where the loaded transport albumin is cleared by adsorption and returned 
to the patient (Klammt et al., 2002). MARS is the best studied artificial liver device 
with data from about 15,000 patients from 150 centers (Leise et al., 2014). It was 
approved by the Federal Drug Administration (FDA (USA)) for treating drug overdose 
and hepatic encephalopathy (HE) caused by chronic liver disease (Al Sibae & McGuire, 
2009; O’Grady, 2006). The MARS system was demonstrated to be effective in 
removing albumin-bound toxins, such as fatty acids, bile acids and bilirubin (Stange et 
al., 2002). However, there was no beneficial effect on survival in patients with ACLF 
(Bañares et al., 2013). 
The Prometheus device (Fresenius Medical Care, Sweden) is a combination of albumin 
adsorption with high-flux haemodialysis. In a first step endogenous albumin is 
separated from the patient’s blood with the help of a filter. The albumin then passes via 
two absorbers which retain toxic molecules and the purified albumin is returned to the 
patient. Water soluble toxins are removed via dialysis. Studies suggest improved serum 
levels of conjugated bilirubin, urea, bile acids, ammonia, cholinesterase, creatinine, and 
blood pH (Rifai et al., 2003). Both systems rely solely on filtration; many vital liver 
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functions are not carried out, resulting in them being inapplicable for long-term 
supportive treatment with no extension to survival shown. 
1.4.2 Bioartificial Liver Devices 
The bioartificial liver (BAL) device is a system that mimics the functions of a liver by 
perfusing an extracorporeal hepatocyte-containing bioreactor with patient plasma. There 
are several different BAL applications that are under development of which some have 
undergone clinical trials. However until now none of the BAL devices is commercially 
available. Systems differ in reactor and cell types, of which the following have been 
used: primary porcine hepatocytes, immortalized hepatocytes and primary human 
hepatocytes (Allent et al., 2001). 
The HepatAssist or Hepamate (Circe Medical, US) is a porcine hepatocytes based 
hollow fibre bioreactor. The patients’ blood is first separated into plasma and cellular 
components in a plasmapheresis device. The plasma first goes through two charcoal 
filters, which filter out plasma bacteria and particulates. Subsequently plasma is flushed 
through the hepatocyte-lined hollow fiber column. The purified plasma is then reunited 
with the plasma component, and the whole blood is reinfused into the patient. Although 
promising results were gained with ALF patients during clinical phase I and II, 
insufficient efficacy for market approval was reported for phase III studies (Demetriou 
et al., 2004). At the moment a new phase III is being planned.  
Another system is the AMC BAL developed by Chamuleau at the Academic Medical 
Centre of Amsterdam. This system uses nonwoven hydrophilic polyester matrix for cell 
attachment, hollow fibres for the oxygen supply and porcine derived liver cells. The 
system has undergone clinical trial phase I in 2002 with promising results. Six of the 
seven ALF patients were successfully bridged to orthotopic liver transplantation and 
one patient showed improved liver function after two treatments. However no second 
trial phase has been carried out within the last 12 years (van de Kerkhove et al., 2002). 
The Extra-corporeal liver assist device (ELAD) (Vital Therapies, US) uses the 
immortalized human hepatoma cell line C3A, a subclone of the HepG2 cell line. Cells 
are housed within a hollow-fibre cartridge.  Although the ELAD system was proven to 
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be safe, no significant differences between standard medical and ELAD treatment were 
observed during a pilot trial including 24 patients (Ellis et al., 1996). 
1.5 Liver group BAL 
The UCL liver group BAL consists of a fluidised bed-based bioreactor (FBB) that 
contains alginate-encapsulated liver (HepG2) cells (AELC) which mimic many 
functions of adult hepatocytes. A large number of hepatocytes are required to treat ALF. 
It has been estimated that for a clinical setting more than 2x10
11
 cells may be required to 
support a patients’ liver function. The system described here has been used with a 
numbers of cells in the region of 7x10
10
, for clinical usage by increasing the volume of 
alginate beads and by adjusting the geometry of the biomass chamber. In order to treat 
ALF, several stages must be completed. In a first step single cells are encapsulated 
within the alginate matrix. After a culturing period of at least 11-12 days within the 
FBB, cell numbers will have increased to several thousand cells per bead. Once 
sufficient biomass has been produced, the BAL device can be connected to the patients’ 
circulation via a plasmapheresis machine. Plasma, which is separated from the 
remainder of the blood, is perfused through AELC housed within the BAL. HepG2 cells 
simultaneously detoxify plasma and secrete liver-specific proteins into the patient’s 
plasma. The treated plasma undergoes a filtration process to hold back DNA, 
endotoxins, cell debris and alginate particulates before the plasma is finally reinfused 
into the patient to meet regulatory requirements (Figure 1.1). 
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Figure 1.1. The bioartificial liver device  
The extracorporeal bioartificial liver (BAL) device sustains the patient’s liver functions. The 
patient’s plasma is perfused against alginate encapsulated liver cells housed within the fluidized 
bioreactor. HepG2 cells detoxify the plasma and secrete liver-specific proteins. The treated plasma 
undergoes a filtration process to eliminate unwanted bi-products. 
1.5.1 HepG 2 cell line 
The immortal human hepatoblastoma HepG2 cell line was derived from a 15 year old 
Caucasian male. HepG2 cells which are epithelial in morphology, are well characterised 
and perform many of the liver functions (Slany et al., 2010). However they do not 
possess comparable detoxification function of ammonia (Mavri-Damelin et al., 2007) or 
xenobiotics (Hart et al., 2010) compared to adult hepatocytes. The advantage of utilising 
a cell line is that availability is sufficient and that cells are allogeneic. In contrast, 
primary human hepatocytes have the disadvantage that they are not readily available, as 
good-quality explant livers are usually used for transplantation. Primary porcine 
hepatocytes which are available in sufficient numbers bear the risk of zoonosis 
transmission and potential species incompatibility in protein/protein receptor interaction 
(Roussel et al., 2008). Any source of primary liver cells also requires enzymatic 
digestion of the liver, a process which is expensive and not easily standardized. 
1.5.2 Alginate encapsulation 
Alginate (a salt of alginic acid) is a biocompatible anionic polysaccharide that is found 
in the cell walls of brown algae. The raw material after extraction and processing, 
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commonly sold as a dry powder, is known as sodium alginate. Alginate has been used in 
a variety of very different applications due to its ability to reversibly form a hydrogel by 
quickly absorbing water (up to 200-300 times of its own weight) whilst undergoing 
cross-linking induced by calcium ions, and it is innocuous to the human body. It has 
been used in the manufacture of paper and textiles, in the food industry and in various 
pharmaceutical preparations. Alginates from different species of brown seaweed can 
vary in their chemical structure, for example in the ratio of mannuronic and guluronic 
acids. This can have an impact on the hydrogel rigidity and permeability which are 
important factors for the encapsulation and culturing process of AELC. The alginate 
hydrogel for cell encapsulation normally consists of approximately 99% water to allow 
for sufficient diffusion of nutrients and oxygen, and to provide enough space for the 
cells to grow unhindered. Alginate beads are of approximately 450µm +/- 31 (average 
+/- SD, n=100) and contain a few hundred cells over the first few days.  HepG2 cells 
proliferate rapidly within the alginate scaffold forming tissue like spheroids within 2-3 
days of culture (Figure 1.2). Cell mass and cell functions are significantly increased in 
comparison to the same cells in monolayer cell cultures (Bokhari et al., 2007; Coward et 
al., 2009; Selden et al., 1999). In three dimensional HepG2 cultures, cell-cell contacts 
such as gap junctions and desmosomes but also large amounts of extracellular matrix 
have been observed, indicating that 3D alginate encapsulation provides an environment 
for HepG2 cells that is similar to that found in situ. The in-vivo like environment and 
the tissue like growth of AELC is thought to be responsible for the markedly 
upregulated cell function.   
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Figure 1.2. Alginate bead size and cell spheroid formation 
A single cell suspension is used for the alginate encapsulation process. The average bead size is 
450µm +/- 31 (average +/- SD, n= 100). One day after encapsulation cells still exist as single cells, 
with a hundred cells per bead. After 2-3 days cell spehroids start to form. After 12 days most of the 
alginate bead is filled with cells with a few thousand cells per bead. 
 
1.5.2.1 HepG2 cell growth in alginate beads 
A concentration of 1.75 million cells per ml of alginate-media mixture and an average 
bead size of 450µm has shown to be most suitable for rapid cell growth, providing 
sufficient mass transport and cell density. With initially about a hundred cells per bead, 
cell density is increased to several thousand cells per bead after 12 days of growth. The 
initial linear growth rate (day 0 to day 7) of approximately one million/cells per 24 
hours increases to more than three million cells per 24 hours between day 8 and 11. 
After 11 days cell growth slows down and after 12 days the stability of the alginate 
matrix is strongly diminished, leading beads to break and cells to grow outside the 
scaffold. 
 
day 1 day 12 day 3 
450µm 450µm 450µm 
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Figure 1.3. HepG2 cell proliferation in alginate beads  
The graph shows HepG2 cell proloferation in alginate beads over 12 days. Cell numbers were 
measured by nucleocount. The data presents the average of 6 indiviual experiments (n=6 +/-SD). 
Cell density increases from initially 1.75 million cells/ml of beads on day zero to 26 million cells/ml 
of beads on day 12.  
1.5.3 The fluidized bed bioreactor system 
Two main criteria are of special importance when designing a BAL system: the 
availability of sufficient biomass and a high transfer of toxic metabolites from the blood 
to the cells for detoxification, and molecules synthesised by AELC to the patient. Inside 
the fluidized bed bioreactor (FBB) an upward flow of media and downward force of 
gravity are keeping cells in continuous motion. The FBB imposes no physical filtration 
barrier between the biomass and the patient’s plasma circulation. That means that the 
patient’s plasma is in direct access to the alginate hydrogel beads, providing high mass 
transfer. Culturing cells in a FBB provides optimized homogenous distribution of 
nutrition and oxygen, while shear forces are kept to a minimum. Also temperature and 
pH are controlled. All these properties help to increase proliferation rates and maintain 
high viabilities (Coward et al., 2005; David et al., 2004; Erro et al., 2013). 
1.6 Bioartificial Liver preservation 
In many cases the BAL device must be ready for use within a few hours to effectively 
treat ALF. A large number of cells are required to treat an adult patient and even in 
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optimal conditions it takes up to 11 days to obtain sufficient cell mass and to condition 
them in the AELC format to effectively support the patient’s liver functions. In order to 
be applicable for rapidly available routine clinical therapy and for transportation 
purposes to the treating hospital, some sort of preservation technology is needed. 
1.6.1 Short-term preservation 
Storage on ice or at 4°C (fridge) can be used to maintain cell viability and function over 
a short period of time and during transportation. Cold storage or hypothermic storage is 
often used for tissues and organs for which cryopreservation is not suitable, but is also 
applied to preserve single cells, for example for transportation purposes. A reduction in 
temperature slows down the cell metabolism and therefore helps to reduce the oxygen 
and glucose demand, both needed to maintain the mitochondrial adenosinetriphosphate 
(ATP) production. Loss or decreased ATP synthesis can result in membrane ion pump 
failure and a loss of membrane integrity which consequently results in cellular swelling, 
membrane leakage and a cascade of degenerative processes. Cells can overcome a lack 
of oxygen by switching over to an anaerobic metabolism whereby lactate is produced 
(Fuller, 1987; Fuller et al., 2013). However, this process can only provide 5% of the 
normal ATP production. A strategy to minimize oxygen depletion is the addition of 
perfluorodecalins (PFC) to the incubation solution. PFC has shown to dissolve large 
amounts of oxygen and therefore can provide an additional supply of oxygen during 
storage (Baertschiger et al., 2008). 
Organs, such as kidneys, pancreas and liver, and also tissues for transplantation are 
especially prone to ischaemia, which is caused by a restriction in blood supply and a 
resulting shortage of oxygen and glucose. Reperfusion injury which include oxidative 
stress, and inflammatory responses occur as the organ is returned to 37°C and oxygen 
delivery is restored (de Rougemont et al., 2009). Special preservation solutions such as 
the University of Wisconsin (UW) solution have been developed to reduce ischaemia 
and reperfusion injury and PFC is used to sandwich organs between a layer of PFC and 
organ preservation solution to minimize oxygen depletion (Liu et al., 2007). 
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1.6.2 Short-term Bioartificial Liver preservation 
A considerable advantage for hypothermic storage is that there are no special 
requirements for the transport at 4°C and logistics are comparably easy and cost 
effective, thus, making it an attractive option to maintain the cold-chain until delivery. 
A disadvantage is that the storage time is limited, at most to a few days (Massie et al., 
2013). This has several consequences for the BAL production. The estimated cost to 
manufacture a BAL (until use) is in the range of 10000 pounds. This means an 
enormous economic loss for each BAL that is not being used. On the other hand 
availability cannot be assured as quality and sterility problems during the production 
process can lead to the loss of a BAL device. Long-term storage is therefore preferable 
over short-term preservation. It also allows producing AELC on a very large scale, 
which reduces manufacturing costs. Moreover, the amount of AELC needed can be 
adjusted depending on the length of treatment and the patient’s needs. For example, 
children might need less biomass to support their liver functions than an adult male 
patient. As adequate cell mass and cell function are crucial, an appropriate freezing 
method for high volume applications (1-2 litres) must be developed which retains all the 
necessary liver functions during the early post-thaw period. 
1.7 Cryopreservation: long-term preservation 
Cryopreservation is a process whereby cells or tissues are cooled below the temperature 
of their biological activity and down to ultra-low temperatures (below the glass 
transition ~-120°C) which in theory could provide infinite shelf life. For example, 
sperm have been successfully stored for more than 20 years (Yogev et al., 2010). 
Cryopreservation is routinely used to preserve semen, blood, stem cells, oocytes, 
embryos and plant cells, but attempts to freeze larger tissues or even whole organs have 
failed. However, cell suspensions such as red blood cells have been cryopreserved at 
intermediate volumes (Sputtek et al., 2011). Normally samples are cooled to -180°C and 
are stored at -196°C (77K), the boiling point of liquid nitrogen. In practice, 
cryopreservation is a complicated procedure that has to overcome several obstacles 
during the freezing and thawing process. However, if the cells can reach ultra-low 
temperature without injury, cells are relatively safe from further damage during 
prolonged holding in that biopreserved state. There are several additive stresses which 
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result from the freezing and thawing or cooling and warming process and they include 
solution effects, osmotic effects, dehydration, oxidative stress, extracellular and 
intercellular ice formation and particularly intracellular ice crystals, which can all be 
individually or collectively responsible for cell damage. 
1.7.1 Extracellular ice formation 
Extracellular ice formation is a normal event for a slow cooling process and is well 
tolerated for a variety of cells in suspension. On the other hand, intracellular ice 
formation which is in most cases cell damaging has been suggested to be a direct 
consequence of extracellular ice formation. Several theories suggest that extracellular 
ice initiates intracellular ice growth. For example, Mazur hypothesized that external ice 
could grow through aqueous membrane pores and seed the supercooled cytoplasm, but 
that this could only happen if the tip radius of the ice lattice is comparable to the radius 
of the membrane pore (Mazur, 1965). Proteinaceous membrane pores were also 
suggested to serve as ice propagation tunnels (Acker et al., 2001; Acker & McGann, 
1989). As an alternative mechanism, observed in plants, it has been proposed that 
extracellular ice expands through damaged membrane sections (Dowgert & Steponkus, 
1984). It was also suggested that extracellular ice alters the cell membrane so that it acts 
as a nucleation side for intracellular ice formation (Toner et al., 1990). 
1.7.2 Intracellular ice formation 
It has been commonly accepted that intracellular ice formation is a lethal insult to cells. 
This conclusion was based on the observation that fast cooling, which leads to excessive 
intracellular ice formation, results in low cell viability (Mazur, 1960). Furthermore it 
was shown that cell-cell contact is a mediator for ice propagation which partially 
explains lower viability for connected cells such as spheroids and confluent monolayer 
cells (Acker & McGann, 1989). A further aspect is that dehydration of multicellular 
components is more complex, as water must exit cells sequentially from centre to 
periphery (Balasubramanian et al., 2006; Ehrhart et al., 2009). Nevertheless, more 
recent observations have shown that intracellular ice formation can be tolerated to some 
extent and that small fractions of intracellular ice might even provide some 
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cryoprotection by preventing cell dehydration during slow cooling (Acker & McGann, 
2000). 
1.7.3 Intercellular ice formation 
Especially problematic is intercellular ice formation in tissues or multi-component cell 
spheroids where ice crystals can disrupt the tissue structure that is required for 
maintenance of function (Liu & McGrath, 2005; Pegg et al., 2006). Another mechanism 
by which intercellular ice can be damaging in tissues is the formation of ice lenses. 
More and more water is drawn to the ice lenses via capillary action and cells that are in 
close proximity might become dehydrated and suffer from osmotic stress. Also as the 
ice lenses grow they can produce mechanical stress (Muldrew et al., 2000). It has also 
been reported that cell concentration has an effect during freezing as higher hemolysis 
levels were observed for closely packed erythrocytes. Cell-cell contacts, reduced 
dehydration and mechanical forces were suggested as potential causes for an increase in 
cell injury (Nei, 1981; Pegg, 1981). 
1.7.4 Osmotic effects and dehydration 
Osmosis is a process that occurs when two aqueous solutions are separated by a semi- 
permeable membrane which allows only water and selected molecules to diffuse 
through. Cell membranes are semi-permeable. When cells are placed in hypertonic 
solutions, water molecules are osmotically drawn from the cell interior to the 
extracellular environment to maintain a chemical potential equilibrium. This is shown 
by the volume shrinkage of the cell and dehydration of intracellular compartments. 
Extreme dehydration is normally seen during slow cooling procedures with increasing 
salt concentrations outside the cell. During this process cell water can decrease to less 
than 10% of the initial content, which is a lethal irreversible insult for most mammalian 
cells. Cell membranes can continue to permit water flux from the cells even at very low 
temperatures during the slow cooling process. If the cooling is faster, (for example 
between five to ten minutes to below -100°C), the cell cannot dehydrate to balance the 
external increase in osmotic concentrates, and a higher residual cell water is left inside 
the cell, potentially causing ice formation. A reverse osmotic stress occurs especially 
after the thawing and warming process when mobile water molecules become released 
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from the ice - solute matrix or the freezing or vitrification media is exchanged too 
quickly with fresh media and the cells, now loaded with cryoprotectants (CPA – see 
section 1.7.6), may undergo extreme swelling as water molecules will re-enter the cell, 
which can lead to membrane rupture (Acker & McGann, 2000; Farrant & Woolgar, 
1972; Lovelock, 1953). Step-wise addition and removal of CPAs have been shown to 
significantly improve survival of various cell types including oocytes (Isachenko et al., 
2004; Wang et al., 2010) and Islets of Langerhans (de Freitas et al., 1998). To minimize 
osmotic stress non-penetrating CPAs like sugars are oftentimes added to the 
cryoprotectant mix and/or the thawing medium (Terry et al., 2010). 
1.7.5 The Equilibrium Melting temperature of aqueous solutions 
Ice nucleation requires an appropriate temperature and a nucleating centre to achieve 
organisation of water molecules to form an ice nucleus. As ice nucleation is a stochastic 
event within a certain temperature range, an exact freezing temperature cannot be 
consistently determined. The temperature at which a solution freezes is therefore not 
considered as a characteristic property of that particular aqueous mixture, and instead 
the melting point, defined as the temperature at which the last ice crystal disappears, is 
used to indicate the temperature at which ice formation would theoretically be possible. 
It is possible to objectively define this using calorimetric methods. The process of 
aqueous solutions being cooled below their equilibrium melting temperature without ice 
formation is termed supercooling and is a critical event during slow cooling 
cryopreservation (Diller, 1975). As an example: water normally freezes at just below 
0°C, but pure water which has been specifically treated to be free of nucleation sites can 
be "supercooled" at standard pressure to well below 0˚C, and may even approach the 
homogeneous nucleation temperature of -48°C. There are different ways to measure the 
melting point of a solution. When ice forms, energy is released as a result of the phase 
change from liquid to solid. The exothermic event of ice formation causes the 
temperature of the mixture to rise close to the equilibrium melting point, although this is 
restricted in accuracy by sample volume and the surrounding temperature. Another 
method to determine the melting temperature is to visually inspect at which temperature 
the last ice crystal melts, but for exact measurements sensitive differential scanning 
calorimetry has to be used. The melting (freezing) temperature of water and aqueous 
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solutions can be depressed by adding compounds that interact with water molecules. 
The efficacy depends on the ability of the compound to interrupt the formation of 
organized water patterns (i.e. the ice lattices). As the concentration of the introduced 
compound is increased, the more the freezing point temperature is depressed. These 
compounds are also called cryoprotectants in the case where they exhibit cellular 
protective functions against freezing damage, and the process is known as colligative 
action. 
1.7.6 Cryoprotectant agents  
Cryoprotectants agents (CPA) are molecules that protect cells from any sort of cryo-
damage. In nature in extreme environments, there are several animal species like frogs, 
fishes, reptiles and insects which have adapted to sub-zero temperatures. They use 
natural CPAs like sugars or polyols (e.g. glycerol, glucose) to lower the melting 
(freezing) temperature of intracellular water and function as a water substitute for vital 
hydrogen bonding, e.g. to DNA and proteins. Cryoprotectants can be broadly classed 
into two groups: penetrating CPAs and non-penetrating CPAs.  
1.7.6.1 Penetrating CPAs 
Penetrating CPAs are small, non-ionic molecules that can pass relatively quickly 
through the cell membrane. Penetrating CPAs have several functions, but one main 
action is the depression of the freezing point, when they are used in sufficient 
concentrations, usually in terms of 10 to 15% weight per volume, or 1 to 2 mol per litre 
for a slow cooling approach. Me2SO (DMSO or CH32SO), one of the most commonly 
used penetrating CPAs is often used in combination with fetal calf serum (FCS) which 
is an extracellular protein with some cryoprotectant properties. Inside the cell, 
penetrating CPAs may interact with the remaining water molecules and so ice crystal 
formation is minimized or ideally avoided. As CPAs reduce the freezing point inside 
and outside the cells, longer dehydration times can be provided. Additionally, solute 
concentrations which are potentially toxic are reached at lower temperatures at which 
they are supposedly less toxic (Lovelock & Bishop, 1959). Some CPAs such as glycerol 
also stabilise membrane components and macromolecules such as proteins during 
dehydration (Meryman, 2007). 
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The efficacy of penetrating CPAs depends on membrane permeability as firstly the CPA 
must be present intracellular to be effective. To ensure sufficient CPA permeation is a 
comparatively simple process for single cell, but is more complicated for tissues and 
organs as the intracellular CPA concentration will differ between cells located at the 
tissue surface and deep inside the core. Perfusion, longer incubation times or at higher 
incubation temperatures will rectify this; however sustained exposure to CPA at 
temperatures required for permeation may in itself result in cell death (Karlsson et al., 
1993; Mukherjee et al., 2007). Methods to determine the CPA concentration within a 
tissue can give important information of how to improve incubation parameters. For 
example, attempts have been made to determine CPA penetration in cartilage by 
measuring the remaining water using Fisher’s titration (Pegg et al., 2006). 
1.7.6.2 Non-penetrating CPAs 
Non-penetrating CPAs are water-soluble molecules that are too large to pass the cell 
membrane barrier. They typically include sugars such as sucrose, glucose or ficoll or 
carbohydrates such as hydroxyl ethyl starch. They are generally less toxic than 
penetrating CPAs and may be primarily used to reduce the risk of lethal intracellular ice 
formation by decreasing the volume of intracellular mobile water by osmotic 
dehydration (Fuller et al., 2004). The use of non-penetrating CPAs alone is normally not 
sufficient to protect cells during cryopreservation but may be used to reduce the 
required concentration of more toxic penetrating CPAs. This approach has been utilised 
for slow cooling cryopreservation of stem cells where Me2SO was partially substituted 
with sucrose (Petrenko et al., 2008) and is commonly applied in vitrification procedures 
for which high concentrations of toxic penetrating CPAs are needed to prevent any ice 
formation. Additionally some sugars have been shown to have good membrane 
stabilizing effects (Crowe et al., 1987) and can help to reduce osmotic pressure during 
the cooling and warming process. 
1.7.7 Slow cooling protocols   
Controlled-rate or slow freezing has been used over the last 40 years and since then 
many well established protocols to freeze e.g. oocytes, blood products, embryo, sperm 
and stem cells have been developed. Intracellular ice formation is avoided by cell 
dehydration and penetrating CPAs hold non-freezable water fractions within the cell. As 
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pure water molecules are drawn out of solution to form ice lattices, the external solute 
concentration increases, leading to higher osmotic cell pressure. To equilibrate the 
extracellular and intracellular osmotically-active solute concentrations, water molecules 
are drawn to the extracellular environment. With increasing solute concentrations 
outside the cell (as more ice is formed at lower temperatures), the amount of water 
inside the cell decreases and therefore less residual cell water remains to freeze inside 
the cell. Intracellular CPAs interact with remaining water molecules, preventing the 
formation of ice lattices. A slow cooling rate has to be applied to provide cells with 
sufficient time to dehydrate. The optimal cooling rate is dependent on the cell type (e.g. 
cells with membranes that allow fast diffusion of water molecules outside the cells can 
tolerate accelerated cooling rates as they can dehydrate faster). A typical cooling rate for 
many mammalian cells is about -1˚C/minute and can be achieved either by using a 
benchtop portable freezing container or a controlled-rate freezer which can normally 
support cooling rates between -0.1°C and -10°C/minute. As a result of dehydration the 
electrolyte concentration within the cell increases. High electrolyte and CPA 
concentrations inside and outside the cell are cell damaging. It has been suggested that 
these solution effects are the main reasons for cell damage during the slow cooling 
process and exposure time to these hypertonic solutions should be minimised. Hence, 
the optimal cooling rate for a specific cell type will be an intermediate rate, which 
allows dehydration (to avoid intracellular ice formation) but also minimizes exposure to 
toxic solute concentrations (Lovelock & Bishop, 1959; Mazur et al., 1972). 
1.7.7.1 Supercooling and Ice Nucleation 
Another obstacle that has to be overcome during the slow cooling process is the event of 
supercooling. If nucleation is initiated in a supercooled extracellular solution, ice will 
form abruptly leaving less time for cell dehydration. Due to the exothermic reaction of 
ice formation, the temperature will increase to approximately the melting point of the 
solution; however the temperature of the freezer will, if not changed, remain low. Thus 
the cooling rate will differ from the optimal cooling rate as there will be a higher 
difference between sample and freezer temperature. Supercooling can be prevented or 
reduced by adding nucleators such as cholesterol (Massie et al., 2011) or by ice seeding 
which is a method to initiate the formation of ice once the solution has supercooled by 
introducing a nucleation point in form of an ice crystal or cryogen-cooled forceps. 
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“Seeding” is commonly and effectively used for the cryopreservation of small samples 
such as oocytes (Stachecki & Cohen, 2004) and spermatozoa (Songsasen & Leibo, 
1997), but is difficult to apply to larger sample volumes due to strong temperature 
deviations throughout the sample. 
1.7.7.2 Warming process 
Even more problematic than the cooling process can be the warming process. 
Dehydrated cells can be damaged by osmotic injury when the water flux inside the cell 
happens abruptly, leading to cell swelling. On the other hand ice re-crystallization might 
occur during warming as small intracellular ice crystals, (if those have formed during 
the cooling process) will melt first. The now freely mobile water molecules will, if the 
temperature is too low, connect with larger ice crystals to form longer detrimental ice 
lattices. Nevertheless, if the warming rate is high enough, re-crystallization can be 
reduced, but rapid thawing might cause higher osmotic pressure and CPA toxicity 
(Mazur, 1984). 
1.7.8 Vitrification 
A second method to prevent intracellular ice formation is by vitrification. First 
approaches to vitrify small living organisms without CPAs but at very high cooling 
rates go back as far as 1937 (Luyet & Gehenio, 1940; Luyet, 1937). Later, with the 
discovery of glycerol by Polge, post-warming viabilities were substantially increased 
(Polge et al., 1949). 
Vitrification is a process at which a solution is cooled below its glass transition 
temperature without ice crystal formation leading to an amorphous matrix that could 
also be defined as an extremely cold viscous liquid. The glass transition temperature is 
solution specific and determines the point at which all molecular motion is being 
stopped. In cryobiology, vitrification can only be achieved by adding high amounts of 
CPAs (in excess of 40% weight/volume) which interact with the remaining water 
molecules in the whole sample and prevent the formation of necessary organised 
patterns of interacting water molecules (so-called nucleation centres), which initiate the 
ice crystal lattices. Thus, no ice can form, however deep the subzero temperature is. 
However, high CPA concentrations are normally toxic to mammalian cells, and 
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therefore the exposure time should be minimised. This can be achieved in small samples 
such as a few tens of microliters where high but non-vitrifying concentrations of CPA 
can be tolerated and fast cooling (in the order of -500˚C/minute) kinetically outruns the 
potential for ice crystals to nucleate and grow to damaging sizes. Even though high 
cooling rates could be achieved, enough time must be given for CPAs to penetrate into 
the cells. For larger tissues and organs, and also for cell spheroids, this time can be too 
long to avoid CPA toxicity.  
1.7.9 Cooling and warming of bulky samples 
A well-controlled slow freezing cryopreservation protocol normally fails when it comes 
to any kind of bulky sample. A sample volume that exceeds the typical laboratory scale 
of a few micro to millilitres prevents uniform and homogenous thermal transfer 
throughout the whole sample, which is necessary to obtain the optimal cooling rate for 
successful dehydrative cryopreservation and the high warming rates to prevent ice re-
crystallisation for all cells within a sample. In essence, if the cooling profile of a bulky 
object is set to be the optimal measured with cells in small volumes, the surface cells 
within a radius of a few millimetres will cool appropriately; however, deeper in the core 
of the sample, the cooling rate will be lower because the heat transfer properties of the 
sample will not match those of the cooling chamber. This difference will be smaller for 
lower cooling rates but the time in which cells are exposed to high solute concentration 
can be problematic. For cell suspensions, but not for organs or tissues, a more 
homogeneous cooling rate could possibly be established by mixing the suspension. The 
slow cooling process is further complicated by the release of latent heat of ice crystal 
formation. In bulky samples this heat cannot be conducted out of the samples as easily 
and it can be assumed that smaller intracellular ice crystals might melt to then form 
larger, damaging ice lattices.  
Similar difficulties arise for the vitrification of large volumes. There are specific 
requirements for sample volume and cooling rates, which must be imposed to avoid 
non-equilibrium glass transitions (Edgar & Gook, 2012), which are likely to favour 
devitrification (formation of lager ice crystals) during the warming process. Ultra-rapid 
sample manipulation (of a few tens of seconds) and cooling rates normally in excess 
of -500°C/minute, are in general required to avoid toxic effects from high CPA 
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concentrations, and kinetically favour the glass transition. Cooling rates for volumes of 
several hundred millilitres are substantially lower than for volumes of a few hundred 
microliters - the normal volume for vitrification.  Consequently CPA toxicity will be 
detrimental. An additional problem of ultra-fast cooling is the instability of the 
amorphous state, which can lead to the formation of cracks during the vitrification 
process (Pegg et al., 1997; Wassenaar et al., 1997). Cracking or fracturing is caused by 
mechanical stresses such as thermal expansion or contraction, leading to pressure and 
tension. Single cells are not thought to be affected, but tissues and organs for which the 
functionality of the entire unit is important can detrimentally be damaged. It has also 
been reported that fractures might initiate ice nucleation that can lead to devitrification 
(Williams, 1989). Similar mechanical stresses might affect the container material. 
Materials have been developed for cryovials of up to 5ml, but larger containers are more 
problematic as they are more susceptible to mechanical stress. Plunging the container 
into liquid nitrogen bears the risk of not withstand the rapid temperature change. 
1.7.10   Liquidus Tracking 
Liquidus Tracking (LT) is a method of achieving vitrification in an aqueous mixture by 
using incrementally increasing concentrations of penetrating CPAs (up to 70%) at 
decreasing temperatures. It also provides the lowest toxic effect that can be established 
for a given CPA concentration by decreasing the sample temperature to just above the 
melting point of that particular mix. At low temperatures CPA toxicity is reduced due to 
decreased cell activity and reduced CPA permeation. This approach was first carried out 
some 40 years ago by Farrant (Farrant, 1965b) who originally intended to avoid solution 
effects and to maintain a constant electrolyte concentration during the cooling process. 
Later the benefits of avoiding ice per se became more evident. The technique has been 
revived and more clearly defined in recent years by Pegg’s group, and has become 
known as Liquidus Tracking (Pegg et al., 2006; Wang et al., 2007). The main advantage 
of this method is the diminution of CPA toxicity. The liquidus curve defines the 
equilibrium melting point temperature for a given CPA mixture (i.e. the highest sub-
zero temperature at which ice crystals and liquid can co-exist), and this knowledge 
allows prediction of the lowest subzero temperature which can be reached for that given 
CPA mix without ice nucleating. Cryoprotectants are less toxic at lower temperatures 
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(Matheny et al., 1969; Weihe, 1973) and lower concentration. By adding smaller 
amounts of CPA at each step and subsequently cooling the sample to just above its 
freezing point, toxicity is minimized when attempting to achieve the very high CPA 
concentrations required for vitrification. The more increments used, the closer the 
sample can be kept to the liquidus curve of its carrier CPA solution. Due to reduced 
CPA toxicity, and avoidance of ice nucleation, samples can be vitrified without the 
necessity of fast cooling rates, preferable for cooling large volumes, or when longer 
exposure times are required to allow for sufficient CPA penetration - for example for 
organ and tissue vitrification. 
Of equal importance for these larger volumes is the warming process, which must be 
reversed in a controlled (stepwise) fashion to dilute the high CPA concentration whilst 
avoiding any propensity for ice to nucleate. Elford and Walter used the LT approach to 
study the role of anionic composition and pH of the carrier solution needed to deliver 
the increasing concentrations of CPA (Elford & Walter, 1972). Isolated strips of taenia 
coli muscle were progressively cooled to -79°C with a final concentration of 60% (w/v) 
Me2SO to prevent freezing. Muscles showed slow recovery and were severely damaged 
both functionally and structurally when the incubation media had a similar composition 
to that of Krebs solution, but showed better recovery after rewarming when potassium-
rich media containing Na
+
, K
+
, and Cl
-
 were used. The degree of recovery was 
dependent on the size of the anion, showing better contractility of the muscles for 
glycerophosphate, TES or PIPES (N-tris-(hydroxymethyl)-methly-2 amino- or 
piperazine-NN′-bis-2-ethanesulfonates) than for sulfate or ethylsulfate derived anions. 
When using potassium-rich PIPES media, recovery was lower when the pH was 
reduced. 
The technique lay dormant for many years until it was revived by David Pegg and 
colleagues (Pegg et al., 2006; Wang et al., 2007). Pegg used the same protocol as Elford 
and Walter (but with different incubation times) for LT vitrification of articular cartilage 
and found that damage was predominantly associated with the formation of ice during 
standard cryopreservation, which supported the use of a vitrification protocol, but CPA 
toxicity and the need for rapid warming resulted in inadequate recovery. By using the 
LT (equilibrium vitrification) approach, cartilage was successfully recovered with good 
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metabolic activity (based on an incorporation of sulphate into newly synthesized 
glycosaminoglycans (GAGs) at 70% of that of fresh control cartilage). The first 
experiments were carried out using a Dow Corning oil bath for step-wise cooling, and 
manual transfer of the samples to increase CPA sufficiently to suppress ice formation at 
the set temperatures; thereafter a controlled rate Planer freezer was used to achieve 
continuously lowering temperatures which could be held at selected low temperature 
points. For optimisation, David Pegg in collaboration with Planer (a company 
specialising in cryogenic engineering), established an automatic pump and stirring 
system which constantly increases the CPA concentration whilst temperature is 
decreased. For the warming process normally the reverse protocol is used by constantly 
increasing the temperature whilst the CPA concentration is reduced (Figure 1.). 
 
 
Figure 1.4 Equilibrium melting curve (liquidus curve) for Me2SO 
A schematic showing the Tm equilibrium melting curve (liquidus curve) for Me2SO (modified from 
Elford, 1970 and Farrant, 1965). Arrows indicate a scheme for incremental addition of CPA to 
obtain the lowest toxicity for a given CPA concentration. This is achieved by decreasing the sample 
temperature to just above the freezing point (dashed vertical line above the liquidus curve) before 
adding more CPA (solid horizontal line) to prevent freezing at lower temperatures. 
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1.8 Aim of the project  
The overall aim of this project was to develop a cryopreservation protocol which allows 
us to cryo-bank and warm high volumes of alginate-encapsulated liver cells for use in 
the BAL in order to provide a rapid treatment for acute liver failure. To cool a whole 
bioreactor with sufficient AELC to treat an adult patient would be the optimal solution 
for clinical applications. This approach would provide a rapid, easy to apply and more 
sterile product for clinical end-users than a situation in which cells from different small 
containers would be thawed and then mixed together. As cell mass and functional 
activities are crucial for the performance of the BAL, very high viability has to be 
obtained using a cryopreservation process. For rapid treatment high recovery should be 
optioned two days after re-warming.  Due to slow thermal transfer and inhomogeneous 
temperatures in large volumes, neither the slow cooling protocol nor the fast 
vitrification procedure seems to be feasible for large scale cryopreservation (1-2 litres).   
A slow cooling process to freeze a biochamper resulted in almost complete cell death 
after 48 hours of re-warming (Massie, 2011). No information currently exists for the use 
of the LT method for multicellular entities such as alginate encapsulated cell spheroids, 
but from theoretical considerations it may be an appropriate approach. LT is in many 
ways advantageous: 
• It reduces or prevents osmotic injury, as CPA addition and reductions occurs 
continuously.  
• If the chosen CPA concentration is high enough intracellular ice formation during 
cooling and re-crystallisation during the warming process will be suppressed. 
• Solution effects, such as uncontrolled high CPA concentrations changing 
electrolyte concentration, will be prevented, and toxicity of controlled CPA 
concentrations is decreased by utilising low temperatures.  
• However it can be assumed that chilling injuries like oxidative stress and changes 
in the cell membrane will still occur which could be problematic as both cooling 
and warming are slow processes.  
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Thus my aims were: 
Chapter 3: To develop a fast and reliable method to assess cell recovery after the 
preservation process without the need to dissolve the alginate matrix. Viability 
can be determined by measuring the fluorescence of fluorescein diacetate and 
propidium iodide, dyes that stain viable cells green and dead cells red. Two 
methods to measure florescence intensity, a fluorescent microscope for which 
image analysis is used and a fluorescent plate reader will be evaluated.  
Chapter 4: To develop a low toxic but also low viscous CPA solution so it can be 
used in a liquidus tracking procedure. Vitrification properties of the new CPA 
solution will be tested and the liquidus curve of the new CPA solutions will be 
determined. 
Chapter 5:  To evaluate whether Liquidus Tracking is a feasable method to 
cryopreserve AELC. For this it will be investigated whether CPA toxicity is 
reduced at lower temperatures. Different methods to carry out small scale 
manual liquidus tracking will be evaluated. To distinguish between osmotic 
injury and cytotoxicity the impact of osmotic pressure on cell viability will be 
assessed.  
Chapter 6: To set up the automatic Liquidus Tracker and develop a filter system to 
maintain AELC inside the sample carrier. To increase the cooling rate by 
reducing the controlled rate freezer temperature.  
Chapter 7: To optimize post-warming recovery. A simplified manual LT set-up will 
be used to pre-screen conditions which could be beneficial for automatic LT. 
Further stirring effect and CPA toxicity over time will be investigated.
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2 CHAPTER 2 
General Methods and Materials 
 
The following protocols were developed previously to this work either as part of the 
alginate encapsulation process or as a means of quality control of HepG2 cell growth 
and function or for cryopreservation purposes and were implemented as standard 
operation procedures (SOPs) in the UCL Liver Group. The viability imaging analysis 
was developed as part of this thesis (Chapter 3). 
2.1 Cell Culture 
Cell culture was carried out under sterile conditions using a class II cabinet. The cells 
were grown in an incubator at 37C in a humidified atmosphere of 95% air and 5% CO2. 
2.1.1 Preparation of complete media for monolayer cell culture 
Materials 
MEM-Alpha Minimum Essential Medium (PAA, Cat. No. T1059, 2500) 
FCS 10% (Hyclone, Cat. No. SV3016003) 
Insulin Acreacip 9.5 g/ml (Novo Nordisc, Cat. No. 8-0201-01-203-3) 
Penicillin and Streptomycin 100U/ml and 0.1mg/ml (Gibco, Cat. No. 15070-063) 
BSA/Linoleic Acid 50g/ml (Sigma, Cat. No. L9530-5ml) 
Sodium Selenite 0.002g/ml (Sigma,Cat. No. S5261) 
Hydrocortisone 0.04g/ml (Sigma, Cat. No. HO888) 
Thyrotropin Release Hormone (TRH) 0.04g/ml (Sigma, Cat. No. P1319) 
Fungizone 1.25g/ml (Gibco, Cat. No. 15290-26) 
Filter Minisart (Sartorius Stedim, Cat. No. 16534) 
Method 
The previous components were added to a 500ml bottle of Alpha MEM using aseptic 
techniques. Before addition to the bottle supplements were filtered through 0.2µm 
Minisart filter (UCL/Liver Group SOP75). 
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2.1.2 Trypsinising monolayer cells 
Materials 
Trypsin solution pH 7.8, aliquots stored at -20°C: 
Trypsin 0.25g/L, EDTA 0.1g/L (Invitrogen, Cat. No. 15400-054) 
Trisodium citrate 2H20 4.4g/L (VWR, Cat. No. BDH102427X) 
KCl 10g/L (VWR, Cat. No. BDH101983X) 
Hanks BSS Media (PAA, Cat. No. H15-010) 
0.2µm filter (Sartorius Stedim, Cat. No. 16534) 
Complete medium (see 2.1.1) 
37°C warming oven 
Syringes 
21G needle 
Nunc tubes and microfuge tube 
Method 
Trypsin is a serine protease that cleaves proteins mainly at the arginine residues and 
lyses the carboxyl side chains. It is used to cut the adhesion proteins in cell-cell and 
cell-matrix interactions. Calcium ions are essential for adhesion protein interaction, 
which is why EDTA is added as a calcium chelator. By reducing the calcium ion 
concentration protein binding can be further reduced. Cells were trypsinised at 70-80% 
confluency. In a first step cells were washed 3 times with 25ml HBSS media (RT) to 
remove any unattached dead cells. Then 50ml trypsin was added, covering all layers of 
the Triple Layer flask. Before use, trypsin was filtered (0.2µm Minisart) and pre-
warmed in a warming oven (37°C). Trypsin was kept as aliquots in a -20°C freezer and 
was only stored for up to 1 week after thawing at 4°C to avoid post-thaw inactivation. 
After addition, the flask was stored in the incubator for a maximum of 5 minutes as 
trypsin is cytotoxic. Once the cells were detached (slight tapping of the flask might be 
required), 50ml of complete medium was added to stop the reaction and the mixture was 
split into two 50ml centrifuge tubes. Tubes were centrifuged at 300g for 4 minutes at 
room temperature and the cell pellet was re-suspended in 10ml of pre-warmed (37°C) 
complete medium. In order to disaggregate the cells, the mixture was passed 3 times 
through a 21G needle. After measuring cell counts and viability, 5x10
6 
cells and 100ml 
complete medium were added to a new triple layer flask which was kept in the 
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incubator at 37°C. Culture media were exchanged the following day after trypsinisation 
and then every 48 hours (UCL/Liver Group SOP18). 
2.1.3 Cell Count and viability using Trypan blue exclusion test 
Materials 
Hemocytometer: Neubauer Zählkammer 
Trypan blue (Sigma, Cat. No. T-6146) 
Hanks BSS Media (PAA, Cat. No. H15-010) 
Nikon TMS Microscope 
Method 
Trypan blue is a diazo dye that has its name from its ability to kill the parasite 
trypanosome. It traverses the membrane of dead cells and stains them blue, whereas 
living cells maintain their natural translucent colour. To perform cell counts and 
viability, 160µl HBSS, 20µl trypan blue and 20µl cell suspension were mixed in a 
microfuge tube and 9µl of this mixture was loaded into each side of a haemocytometer. 
A Nikon TMS light microscope was used to perform two cell counts using a 10x 
eyepiece and a 10x objective magnification (UCL/Liver Group SOP22). 
Evaluation: 
Cell number:      (average living cells) x 10
5
 cells/ml 
Viability:            100*(number of living cell /total number of cells (living + dead) 
2.1.4 Culture of Encapsulated HepG2s 
Materials 
High glucose medium (complete Medium with 25mM D-glucose): 
0.2 µm filter Minisart (Sartorius Stedim, Cat. No. 16534) 
45% D-glucose solution (Sigma, Cat No. G8769) 
Method 
Encapsulated cells were grown in complete media with additional glucose which was 
filtered before addition. Cells were grown in T175 flasks and the bead to media ratio 
was kept at 1:32 with a maximum of 6ml of beads per flask. For experiments cells were 
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grown in 6 well plates with 8ml media per well and 0.25ml beads (UCL/Liver Group 
SOP18). 
2.2 Encapsulation of HepG2 cells into alginate 
Materials 
Alginic acid (Sigma, Cat. No. A2033) 
Pluronic acid (Sigma, Cat. No. P1300) 
DMEM (PAA, Cat. No. 15883) 
High glucose media (see 2.1.4) 
 0.2µm hydrophilic filter (Sartorius Stedim, Cat. No. 16534) 
0.2µm hydrophobic filter (Sartorius Stedim, Cat. No. 16596) 
Sodium chloride-HEPES buffer (pH 7.4): 
Sodium chloride 0.15M (VWR, Cat. No. 27810,364) 
HEPES 15mM (Gibco, Cat. No. 15630) 
Polymerisation Buffer (pH 7.4): 
Sodium chloride 0.15M (VWR, Cat. No. 27810,364) 
HEPES 15mM (Gibco, Cat. No. 15630) 
Calcium chloride 0.204M (Sigma, Cat. No.12022) 
Material baked at 180C for 3 hours: 
Glass Beads 10-50µm (G. Kisker, Steinfurt, Germany) 
0.5-1L glass beakers 
Material autoclaved at 121C: 
Bottomless beaker 
JetCutter cutting tool 
JetCutter cutting cover 
JetCutter nozzle holder 
JetCutter inlet filter 
JetCutter tubing 
JetCutter 300ml pressure vessel 
Stainless steel forceps 
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Stainless steel spatula 
Magnetic flea 
Materials sterilized using 70% ethanol: 
Elastic band 
Nylon mesh (Clarcor, Cat. No. NY/MO/2001/37/1020) 
JetCutter 350µm nozzle 
JetCutter cutting disc (number of wires = 60, wire diameter = 100) 
JetCutter system (Genialab, Braunschweig, Germany) 
Method 
To make a 2% (w/v) alginate solution, the adequate amount of alginic acid powder was 
slowly added to sodium chloride-HEPES buffer while being stirred and left for further 
stirring overnight. Alginate solution was autoclaved in the small Prestige Medical 
autoclave at 121C for 10 minutes and left on ice to cool down before use. Cells were 
trypsinized and cell number determined according to 2.1.2 and 2.1.3, respectively. For 
encapsulation a 1:1 mixture of high glucose media and alginate solution (final alginate 
concentration 1% w/v) with a final density of 1.75x10
6
cells/ml and 1.75% (w/v) glass 
beads was prepared. Glass beads were filtered using a 200µm nylon mesh before use. 
The 1% alginate mixture was then aseptically added to the 300ml pressure vessel. One 
litre of polymerization buffer was autoclaved using a Prestige Medical autoclave (20 
minutes, reaching 121C) and was left to cool down at 4C. Pluronic acid (0.2g) was 
dissolved in 5ml of the polymerization buffer and filter-sterilized using a 0.2µm 
hydrophilic filter. The filtered solution was returned to the polymerization buffer. 450ml 
were added to a 1L glass beaker for bead collection. 
The JetCutter system was set up as follows: the nozzle holder was connected to the 
inline filter, which in turn had to be connected to the pressure vessel outlet. A nozzle 
(ethanol sterilized) was then screwed into the nozzle holder (Figure 2.1). The 
compressed air line was attached to a sterile hydrophobic filter which was connected to 
tubing attached to the pressure vessel inlet. The filled pressure vessel was attached to 
the overhead stirrer (stirs the alginate-media mixture inside the pressure vessel) and the 
motor was set to 1000rpm for 10 seconds, then to 150rpm. The compressed air line was 
opened as well as the pressure vessel outlet to start the flow through the encapsulator 
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(start pressure at around 0.25bar). For calibrating the system, 7.5ml alginate solution 
was collected in a 15ml centrifuge tube and the time was measured. The pressure was 
adjusted until the flow rate was approximately 20ml/minute. On the JetCutter control 
panel set-up run parameters for a standard run was set to: flow rate = 0.33-0.34ml/sec, 
nozzle size = 350µm, number of wires = 60, wire diameter = 100µm and motor speed = 
3300rpm. The JetCutter software calculated the optimal angle of inclination, which was 
manually set on the JetCutter itself. Subsequently the cutting disc was placed onto the 
cutting tool which was then screwed to the JetCutter, followed by the collection cover. 
The beaker containing the polymerisation buffer and a magnetic flea (lowest stirring 
speed) was placed on a magnetic stirrer below the opening of the JetCutter collection 
disc. After adjust the opening on the collection cover the stream was collected. The 
beads were left for further 10 minutes in polymerization buffer while being stirred. 
Beads were collected in bottomless beaker with a mesh (hold by a rubber band) and 
transferred to a new beaker containing DMEM media (~150ml). Beads were washed 
twice for 10 minutes and processed as described before (UCL/Liver Group SOP142). 
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Figure 2.1 JetCutter set up (modified from geniaLab®)  
The alginate solution within the pressure vessel is stirred by an overhead stirrer. A compressed air 
line is connected to the pressure vessel to create the flow. The alginate, then coming from the 
pressure vessel, goes through the JetCutter filter, the nozzle holder and finally the nozzle, resulting 
in a fine alginate stream which is cut in little beads by the spinning cutting discs. Beads are 
collected in a beaker containing polymerization buffer which is slowly stirred by a magnetic flea. 
2.3 Cell count using the Chemometect Nucleo Counter 
Materials 
EDTA solution (pH 7.4):  
16mM EDTA (Sigma, Cat. No. ED4SS) and 0.15M NaCl (VWR, Cat. No. 27810,364)  
PBS (without Ca
2+
 and Mg
2+
)  
Reagent A100 (Chemometec, Cat. No. 910-0003) 
Reagent B (Chemometec, Cat. No. 910-0002) 
Nucleocassettes (Chemometec, Cat. No. 941-0002) 
Nucleocounter (Chemometec) 
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Method 
The nucleocounter from Chemometec determines the cell number by staining cell nuclei 
from lysed cells with propidium iodide. The fluorescent dye is immobilized in the flow 
channels of a nucleocassette. The cassette takes up approximately 10µl of lysed cell 
suspension. After a few seconds the fluorescent signal can be measured by the 
Chemometect fluorescent reader. For appropriate counts cells have to be removed from 
the alginate matrix. Therefore beads were washed with HBSS in a ratio of 1/32 
(beads/PBS). Beads were then dissolved by adding 16mM ethylenedinitrilotetraacetic 
acid (EDTA) (pH 7.4) at a ratio of 1/8. EDTA chelates calcium ions which are 
necessary to keep alginate chains polymerized. The dissolved alginate and cell mixture 
was centrifuged at 13000rcf (g) for 5 minutes and the cell pellet was resuspended in an 
adequate amount of 1xPBS (Table 2.1) by passing the solution through a 21G needle.  
                                 Table 2.1 Cell count dilution scheme 
Day after encapsulation Volume of 1xPBS (µl) 
0-1 100 
2-3 200 
4-5 300 
6 onwards 500 
 
Chemometec reagent A100 which is a cell lysis buffer was added to the cell suspension 
and the mixture was vortexed for 10 seconds. Then Chemometec reagent B, a stabilising 
buffer was added and the mixture was vortexed for 10 additional seconds. To make up 
the reaction mixture the same volume of cell suspension, reagent A and reagent B was 
used. The nucleocassette was introduced in the cell mixture for 10 seconds before 
fluorescent reading. The reading was then multiplied by the appropriate multiplication 
factor (MF) to obtain the final cell concentration (UCL/Liver Group SOP173): 
MF = VB
 -1 
* Vfinal 
where  VB = volume of alginate beads (in ml) 
and  Vfinal = final volume: PBS+ReagentA+ReagentB 
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2.4 Fluorescin diacetate/propidium iodide staining 
Fluorescein diacetate (FDA) is cell membrane-permeable and when hydrolysed by 
esterases present in metabolically active cell cytoplasm, emits a green fluorescence. PI 
is cell membrane-impermeable and emits a red fluorescence when bound to DNA. 
Therefore, PI staining will occur only when cell membranes are compromised, 
representing non-viable cells, whilst FDA staining diminishes in dying cells. 
Materials 
1mg/ml FDA (Sigma, Cat. No. F7378-5G) in Me2SO 
1mg/ml PI (Sigma, Cat. No. 70335-5ML-F) in water 
1x PBS containing calcium and magnesium 
Microscope slides 
Tissue 
Coverslips 
Method 
Approximately 250µl alginate beads were transferred to a 1.5ml microfuge tube, 
allowed to settle and medium aspirated. Beads were washed with 1ml PBS, then 500µl 
PBS and resuspended in 500µl of PBS. Then 20µl PI and 10µl FDA were added, gently 
mixed and incubated for 90 seconds.  PBS was aspirated and beads washed a further 2 
times as before. Beads were resuspended in 500µl of PBS and transferred to a 
microscope slide. Excess liquid was removed using tissue if required and a coverslip 
was placed over the beads. The beads were then visualised using a fluorescence 
microscope (UCL/Liver Group SOP03). 
2.4.1 Viability assessment in beads – Image analysis 
Materials 
Microscope: Nikon TE200  
Camera: Nikon DS-Fi1c with an 0.67x adapter (means 67% of the Microscope picture 
will be captured with the camera) and a DS-U2 PC control unit 
Software: NIS-Elements AR 4.00.03  
PI excitation filter of 510-560nm and emission filter of 590nm 
FDA excitation filter of 465-495nm and an emission filter of 515-555nm 
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Alginate encapsulated liver cells 
Method 
Cell viability was quantified from captured images using image analysis. Phase contrast, 
live and dead images were captured using a Nikon DS-Filc camera and NIS imaging 
software.  FDA and PI images were captured at x4 magnification at exposures of 150 
and 1000ms respectively. For each sample (slide) 5 images for phase, FDA and PI were 
taken. For both PI and FDA the upper threshold was 256 and the lower threshold 41 for 
AELC cultured for at least 4 days after encapsulation. For AELC 0-3 days after 
encapsulation a lower threshold of 20 was used (see Chaper 3). Viability was calculated 
as below and expressed as the percentage of live cells within the total field. 
100(%) x
tyPIsumIntensityFDAsumIntensi
tyFDAsumIntensi
viability

  
 
2.5 Methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay 
The MTT assay is a colorimetric assay to assess cell viability. Tetrazolium salts such as 
MTT are reduced to formazan by mitochondrial and microsomal reductases which are 
present in metabolically active cells.  The amount of purple formazan can be quantified 
using absorbance readings and be directly related to cell activity. 
Methylthiazolyldiphenyl-tetrazolium bromide (MTT) was used here. 
Materials  
Methylthiazolyldiphenyl-tetrazolium bromide (MTT) (Sigma, Cat. No. M5655) 
Sterile PBS 
4mM HCl in isopropanol 
16mM EDTA in 0.15M NaCl 
Small spatula 
21G needle 
2ml microfuge tubes 
Orbital plate shaker 
Spectrophotometer at 570nm 
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Method 
MTT aliquots of 0.75mg/ml were prepared and stored at -20˚C until use. Per sample 
150µl settled beads were used which were washed twice with sterile PBS and 
transferred to 2ml microfuge tubes. Then 1.5ml 16mM EDTA was added to dissolve the 
alginate matrix. Cells were microfuged at maximum speed for 5 minutes and the 
supernatant was discarded. To each tube 0.25ml of pre-warmed MTT was added. Tubes 
lids were pierced and samples were incubated at 37°C for 3 hours until blue/purple 
crystals had formed. MTT was aspirated and 350µl acidified isopropanol was added to 
each tube. Tubes were left on an orbital plate shaker for 30 minutes until all crystals had 
dissolved. 100µl were transferred to a 96-well plate and absorbance at 570nm was 
measured using a fluorescence plate reader. Each sample was measured in duplicates 
(UCL/Liver Group SOP44). 
2.6 Quantification of hepato-specific proteins synthesised and secreted in 
culture 
Enzyme-linked immunosorbent assays (ELISA) were used to assess cell function by 
quantifying hepato-specific protein synthesis. ELISA assays are antibody-based 
detection methods (assay) which result in enzymatic color reaction, which can be 
measured with spectrophotometer. Antigens (here hepato-specific proteins) are captured 
by a first antibody (Ab) which are coated to a microtiter plate. A second antibody is 
added to detected and quantify the antigen. Typical detection systems include alkaline 
phosphatase and horseradish peroxidise (HRP), as here. The substrate for HRP is 
hydrogen peroxide which is cleaved and coupled to the oxidation of o-
phenylenediamine (OPD) to form an orange product that can be quantified using a 
spectrophotometer.  
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Materials 
96 well Maxisorp plate 
200ml coating buffer containing 0.318g Na2CO3, 0.596g NaHCO3 (pH 9.6) 
Capture antibodies (Table 2.2, all purchased from Abcam unless otherwise stated) 
Clingfilm 
Plate washer 
Wash buffer: 1x PBS containing 0.05% Tween 20 
Blocking buffer: 5% protein in wash buffer (Table 2.2) 
Standards (Table 2.2) 
Detection antibodies (Table 2.2, all purchased from Abcam unless otherwise stated) 
12ml OPD solution: 2 OPD tablets, 6µl hydrogen peroxide 
Aluminium foil 
1M sulphuric acid 
Spectrophotometer at 492nm 
Method 
The capture Ab was diluted in coating buffer and 100µl was added into each well of the 
96-well plate. The plate was covered with clingfilm and incubated at 37˚C for one hour 
or overnight at 4˚C depending on the assay (see). Plates were aspirated and washed 3 
times with 200µl washing buffer using the plate washer. Then 100µl blocking buffer 
was added, plate covered with clingfilm and incubated for one hour a 37˚C (Table 2.2). 
Samples were diluted as necessary and a standard curve which was run on each plate 
was prepared for each protein using serial dilution (200-6.25ng/ml). A standard curve 
was run on each plate. Samples that did not fell within the range of the standard curve 
were diluted. Then 100µl standard and sample was added into the blocking buffer. As 
before the plate was covered with clingfilm and incubated for 90 minutes at 37°C. The 
plate was washed as described above and detection Ab diluted in blocking buffer and 
100µl added to each well (see).  The plate was covered in clingfilm and incubated for 1 
hour at 37°C. Detection Ab was aspirated and plate washed 5 times as described above. 
100µl OPD solution was added to each well at timed intervals, plate covered in foil and 
incubated until orange colour developed.  The reaction was stopped by addition of 50µl 
acid to each well at timed intervals. The absorbance was measured at a wavelength of 
492nm using the plate reader (UCL/Liver Group SOP 37 to 42).  
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Table 2.2 Hepato-specific protein ELISA methodology 
  Albumin 
Alpha-1-
fetoprotein 
Alpha-1-
antitrypsin 
Alpha-1-acid 
glycoprotein 
Fibrinogen 
Capture 
Antibody 
Cat. # Dako A0001 Ab10071 Dako 
A0012 
Dako A0011 ab6666 
Dilution 1/1000 1/1000 1/790 1/1000 1/1000 
Incubation 1h at RT Overnight 
at 4°C 
Overnight 
at 4°C 
Overnight at 
4°C 
Overnight 
at 4°C 
Blocking 
buffer 
 
5% non-fat 
milk 
5% non-fat 
milk 
5% non-fat 
milk 
5% non-fat 
milk 
5% non-fat 
milk 
(removed) 
Incubation 1h at RT 1h at RT 2h at RT 1h at RT 1h at RT 
Detection 
Antibody 
Cat. # ab24458-200 Ab10072 ab7635-s Ab34720-10 ab7539 
Dilution 1/4444 1/3500 1/2000 1/4000 1/1000 
Incubation 1h at 37˚C 1h at 37˚C 1h at 37˚C 1h at 37˚C 1h at 37˚C 
Standard  
Dako 
X0908 
Abcam 
ab38189 
Citrated 
plasma 
Dako 
X0908 
Citrated 
plasma 
 
2.7 Use of controlled rate freezers 
A controlled rate freezer (CRFs) was used to carry out manual and automatic liquidus 
tracking experiments.  
Materials 
Liquid nitrogen supply (for storage in vapour phase) 
CRF nitrogen Dewar 35L 
Kryo10 and baskets (Planer) 
Method 
A Planer Kryo10 CRF with the following specifications was used: cooling rate 
from -0.01 to -50˚C/minute, warming rate from 0.01 to 10˚C/minute and working 
temperature from -180 to 50˚C. The CRFs relies on a nitrogen vapour supply via 
solenoid valve in a feedback loop for cooling. Prior to a cooling run, the CRF nitrogen 
Dewar was filled with liquid nitrogen. Programmes were entered as per the 
manufacturers’ instructions for each CRF. This was done by either using the controller 
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or a personal computer and the Delta T software. The decant valve on CRF Dewar was 
opened and pressure adjusted to between 0.3 and 0.5 bar using the pressure raising coil 
if required. The cooling profile was started once the desired start temperature was 
reached and samples loaded into the CRF chamber. The freezer chamber temperature 
was measured by the integrated freezer thermometer and by using additional 
thermocouples to measure the freezer and sample temperatures (UCL/Liver Group 
SOP20). 
2.8 Storage of cryopreserved samples 
Materials 
Liquid nitrogen supply 
Biostor 5 (Statebourne) 
Method 
Upon completion of the cooling run, samples were normally stored at nitrogen storage 
within a Biostor 5. The Biostor 5 was topped up with liquid nitrogen every 2-3 days to 
ensure that cryogenic storage temperatures were maintained. 
2.8.1 Temperature measurements during cryopreservation 
A Pico Logger for data collection and thermocouples were used to measure the 
temperature of both chamber, samples and CPA solutions. 
Materials 
Type K thermocouple (Pico Technology) 
TC-08 data logger (Pico Technology) 
Laptop 
PicoLog recorder software (Pico Technology) 
Specially adapted cryovials 
Method 
Thermocouples were connected to the data logger which was connected via USB port to 
a laptop. Log settings were applied, typically 10 readings per second for the duration of 
the cooling profile. Data was logged using PicoLog software and exported into Excel 
for analysis. 
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2.9 Statistical analysis 
For statistical analysis Microsoft Excel (MS Office (2007) Student’s t test (two-tailed) 
was used. Values in text, tables and figures were expressed as the mean ± standard 
deviation (SD). The n numbers were given in the accompanying text. A p-value of 
<0.05, expressed as “*”was considered as statistically significant. 
A p-value of <0.01 was expressed as “**” and was considered highly significant.
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3 CHAPTER 3 
Image analysis validation for cell viability quantification 
3.1 Introduction 
To evaluate the success of a cryopreservation method it is important to have a reliable 
test system in place to assess cell recovery after the preservation process. Viability often 
refers to membrane integrity tests, which are valuable techniques to give an estimation 
of cell recovery. A variety of more complex assays, such as specific metabolic assays, 
protein production and cell attachment tests can offer more realistic estimations of cell 
survival. However, in order to develop a complicated and time consuming test system 
such as the Liquidus Tracking (LT) vitrification system for alginate encapsulated liver 
cell (AELC) cryopreservation, a simple and rapid method to test cell recovery was 
needed. Others have demonstrated that the fluorescence intensity of the vital stain 
Fluorescein diacetate (FDA) is dependent on cellular metabolic activity and in particular 
esterase activity (Karmazsin et., 1979; Saruyama et al., 2013). A membrane integrity 
test that uses a fluorescent dye to stain dead cells in combination with FDA to obtain 
additional information about cell function seemed to provide a reasonable compromise. 
3.1.1 Membrane integrity test for single cells 
One possible method to measure membrane integrity is the use of the trypan blue 
exclusion. Another common method to distinguish between viable and dead cells is the 
nucleocounter system. Cell nuclei from dead cells are stained with propidium iodide 
(PI). The fluorescent dye is then immobilized in the flow channels of a nucleocassette 
and is read by a fluorescent reader. From the starting material two samples are taken, 
supposedly containing the same number of cells. The first sample will be lysed, so that 
all cells are dead, giving information about the total cell number. The second non-lysed 
sample accounts for the number of dead cells found in the starting material. The number 
of viable cells is then given by the difference in cell number between sample one and 
two. Viability can then be calculated using the common formula: 
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%Viability = signal PI of sample 2 (lysed)-signal PI of sample 1 (non-lysed)/  
signal PI of sample 2 (lysed)*100 
Trypan blue exclusion and nucleocounter tests are simple to carry out and are efficient 
techniques for day-to-day laboratory use. Flow cytometry is also a common method to 
assess the viability of a cell population and has been shown to have, like the 
nucleocounter approach, very good accuracy (Pan et al., 1996; Shah et al., 2006). 
However, these systems only work for single cell suspensions or small aggregates, and 
cannot be used for larger spheroids. Counting cells, as required for the trypan blue 
exclusion test, cannot be done for a 3D format such as AELC, as only the first layer of 
cells is visible to the viewer. Cell sorting is also not possible as this system is based on 
two distinct signals, either dead or alive, which is not given for spheroids which contain 
both type of cells in an unknown proportion. When measuring cell aggregates with the 
nucleocounter system, fewer cells will be taken up into the flow channel from the non-
lysed sample than for the lysed sample, as it will be more difficult or even impossible 
for aggregates to be drawn into the channel. This leads to deviations when calculating 
cell viability. The error increases for larger aggregates such as AELC, which might 
block the inlet.  
3.1.2 Membrane integrity test for encapsulated cells and cell spheroids 
Cell spheroids can be disaggregated using pipetting, syringing or vortexing but this 
would likely result in a loss of viability due to intensive shear stress. An enzymatic 
digest (e.g. with trypsin) to obtain single cells might be possible, but can be assumed to 
be even more harmful. Either way is time consuming and will temper the true viability 
of the sample. For encapsulated cells and cell spheroids, an additional problem arises, as 
they first have to be released from the alginate matrix. This can be achieved by using 
EDTA to chelate divalent cations, used to crosslink alginate chains. Once 
depolymerised, cells can be separated from alginate via centrifugation. Viaspan, an 
organ preservation solution, has been shown to dissolve alginate beads and could 
provide a more gentle way to release the cells from the alginate scaffold. The Viaspan 
components lactobionic acid and Allupurinol presumably act as calcium binding 
chelators (Isaacson et al., 1989; Malkiel et al., 1993). If cell death can be avoided during 
alginate depolymerisation and subsequent spheroid disaggregation accurate membrane 
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integrity tests for single cell suspension might be possible, however the tight cell-cell 
contact makes this approach difficult. 
Membrane integrity of encapsulated cells and cell spheroids may also be assessed 
without the need to disaggregate spheroids or dissolve the alginate capsule. This can, for 
example, be done by using a fluorescence microscope connected to a camera. The signal 
captured by the camera is transferred into an image with 256 potential intensities. By 
summarizing the intensities of all pixels and by using a standardized method the 
viability can be assessed. Similar to this method a fluorescent plate reader can be used. 
The requirements for any system are the capability to measure the wave lengths of at 
least one dye (normally PI, which can be correlated to dead cells), the ability to quantify 
the signal, and this without the need to disrupt the alginate bead or the spheroids. As for 
the nucleocounter system, an “untreated” sample and a sample with only dead cells have 
to be measured. Viability is then calculated according to the formula for the 
nucleocounter system as described above. 
3.1.3 Viability test for encapsulated cells and cell spheroids 
A vital dye such as FDA might be used to assess the vitality of a cell population without 
the need to dissolve the alginate bead or disaggregate the cell spheroids. For this test 
system either a vital dye that measures cell activity, or a vital dye in combination with a 
dye to stain dead cells can be used. As described in 3.1.2, fluorescence can be measured 
either with a microscope connected to a camera or a plate reader. If only the vital dye is 
used, two samples have to be measured: the positive control and the sample. Viability 
should then be given as a fraction of the positive control and not as absolute viability, as 
the positive control is likely to include some dead cells. The method is only feasible 
when a positive control is available for each test day. When two dyes are used, only one 
sample has to be measured. This has the advantage that cells and the cell number, which 
both alter the sum intensity, are the same for both signals (dead and viable). As before, 
the total intensity of FDA and PI are measured and the viability can be calculated 
following the formula: 
%Viability = signal FDA / (signal FDA + signal PI)*100 
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3.1.4 Fluorescein diacetate staining 
Fluorescein diacetate (FDA) is a non-fluorescent substance that permeates cells freely. 
Inside the cell the FDA molecule is broken into two acetates and one strongly 
fluorescent fluorescein molecule by nonspecific esterases, such as lipase and acylase 
(Gilbert et al., 1992). It was first proposed that the intensity of fluorescence is 
dependent on cellular metabolic activity by Bentley-Mowat back in 1982 (Bentley-
Mowat, 1982). FDA staining has also been used to estimate the activity of microbes 
(Koester et al., 1991; Schnürer & Rosswall, 1982) microalgae (Gilbert et al., 1992) and 
phytoplankton (Jochem, 1999) and (Saruyama et al., 2013). A close correlation between 
cell viability and cell function has also been reported for cultured hepatocytes. Both 
albumin production and lidocaine metabolism (P-450 activity) were significantly 
increased in the high fluorescence group compared to the low fluorescence group 
(Nyberg et al., 1993).  
3.1.5 Digital imaging system 
The digital imaging system is a combination of a microscope, a charge-coupled device 
(CCD) camera, a computer and an imaging software program. The microscope 
magnifies the sample specimen and depending on the microscope will also transfer the 
sample into a visible phase or a fluorescent image which is then captured by the CCD 
camera. The camera sends the information to the computer where it can be stored and 
analysed by the imaging software. 
Photons coming from the sample are captured by the charge-coupled device (CCD) of 
the camera. The CCD chip is composed of a silicon surface that is covered with a 
network of strips defining millions of tiny squares or pixels, which function as light 
sensitive photodiodes. These photodiodes store photoelectrons, derived from incident 
photons. Depending on the size of the pixel (4-25µm) thousands of electrons can be 
stored. The more electrons captured, as a result of higher fluorescence or exposure time 
(time the camera shutter is open), the higher is the signal. The signal is then amplified 
and transmitted as variable voltage to the analogue and digital converter (ADC), which 
converts it into a zero and one binary code. An 8-bit camera (2
8
) gives 256 different 
steps which are converted into a grey-level output between 0-255, with 0 normally 
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being black and 255 being white (Sluder & Wolf, 2007). Higher bit cameras will have a 
higher output range, but the display of a typical computer monitor only ranges from 0-
255. This makes it necessary to split the higher output range into 256 groups, each 
representing one grey-level on the monitor. However, the “real” intensity of each pixel 
is not lost and it will be used by the imaging software for data analysis purposes. Data 
can be stored in different file formats such as TIF or JPEG. TIF files can store more 
data than JPEG files, which means that a higher number of grey levels is recorded. Even 
if the difference might not be visible on the monitor, it will have an effect when using 
the imaging software for data analysis. Images can normally be captured in colour or 
monochrome mode by a colour camera. Colour mode means that the wavelength of red, 
blue and green light is captured by the camera’s photodiodes. This corresponds to the 
red, blue and green receptors of the human eye. Wavelengths are added together in 
various ways to reproduce a broad range of colours. The monochromatic mode has been 
optimized for use with fluorescence specimens where oftentimes only a single colour or 
two colours are being captured.  
3.1.6 Dynamic range 
The dynamic range of a fluorescence instrument indicates the range of fluorescence 
intensity that is detectable and is determined by the minimum and maximum detection 
limits of an instrument. For the microscope images analysis system the dynamic range 
is given by the number of photonelectrons that have to be collected to surpass the 
background signal and the maximum number of photonelectrons the CCD chip is able 
to collect. The exposure time is used to maintain fluorescent intensity within those 
limits.  The fluorescence plate reader uses a photomultiplier tube (PMT) as a detector. 
Instead of the exposure time, gain adjustment is used to regulate the signal. The gain 
controls the amount of voltage that crosses the PMT and thereby making the PMT more 
or less responsive to the intensity of the measured signal. This means that the original 
fluorescent signal can be more or less intensified. 
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3.2 Aims 
The aim of this chapter was to develop and evaluate different quantitative methods to 
determine the viability of alginate encapsulated liver cells and spheroids. The test 
system was intended to be simple, fast and inexpensive but also reliable and without the 
necessity to disaggregate the alginate matrix or cell spheroids, to be suitable for 
developing the Liquidus Tracking (LT) method and to monitor the growth process of 
alginate encapsulated liver cells (AELC). Hence, a standard method to use a 
fluorescence microscope and plate reader to measure the viability of AELC was 
developed and results were compared to enzyme-linked immunosorbent assay (ELISA), 
methylthiazol tetrazolium (MTT) and cell count data. 
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3.3 Methods and Materials 
3.3.1 Microscope viability quantification 
Materials 
Microscope: Nikon TE200  
Camera: Nikon DS-Fi1c with an 0.67x adapter (means 67% of the Microscope picture 
will be captured with the camera) and a DS-U2 PC control unit 
Software: NIS-Elements AR 4.00.03  
PI excitation filter of 510-560nm and emission filter of 590nm 
FDA excitation filter of 465-495nm and an emission filter of 515-555nm 
Alginate encapsulated liver cells 
Method 
The fluorescent signal coming from the fluorescent microscope was captured by a CCD 
camera and analysed using imaging software tools to distinguish between viable and 
dead cells stained with fluorescent dyes. Fluorescein diacetate (FDA) and propidium 
iodide (PI) were used for this purpose. The sum intensity of either green or red 
fluorescence is given by the sum of intensity of each pixel of a chosen area. In theory 
the signal of a population of 100% viable cells has to be equal to the same number of 
100% dead cells of the same population. Fluorescein gives a higher fluorescent signal 
than PI for the same number of stained cells if measured with the same exposure time. 
To obtain approximately the same signal, the exposure time has to be adjusted with 
longer exposure for PI than for FDA. However, the Nikon camera software only allows 
the exposure time to be set in steps (e.g 50, 100, 200). For this reason a fine adjustment 
is not possible. This can be overcome by setting different thresholds for PI and FDA. 
To determine which exposure time to use, a population of AELC was divided in half; 
one half was incubated in 80% (w/v) Me2SO for 20 minutes at room temperature to kill 
all cells. Afterwards beads were washed several times with an excess 1xPBS (+Mg
2+
, 
Ca
2+
). AELC were stained with FDA and PI and images were taken with the fluorescent 
microscope to ensure all cells were dead. The other half remained untreated and was 
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directly stained with FDA and PI. Again, images were taken and AELC were only used 
to set up the standard method when the PI signal was less than 1% of the FDA signal. 
3.3.1.1 FDA threshold setting 
Signal intensities are given in 256 levels of grey-shades and can be set between 0 and 
255 using the threshold tool of the imaging software. Signals captured by the camera 
will predominantly be from fluorescein, apart from some background signals of mostly 
low intensity (100ms), when the filter for green fluorescence is set at the microscope. 
To obtain all available information from the incoming signal, the higher threshold has to 
be set to the maximum of 255. In contrast, when setting the lower threshold at zero, all 
pixels will be selected. The large number of background pixels, although of low 
intensity, will substantially increase the sum intensity in an undefined manner. 
Consequently a lower threshold had to be defined. This was done by taking images of 
FDA stained AELC (viability >=99%) and by capturing all visible cells (Figure 3.1). 
 
 
Figure 3.1 A histogram showing the pixel intensity distribution 
The histogram shows background and signal pixels in the thresholding tool box. The x-axis 
represents the pixel intensity (0-255) and the y-axis the number of pixels. Peak in white 
demonstrates the number of background pixels (corresponding to black pixels in the image); peak 
tail in grey demonstrates the number of signal pixels (corresponds to red “overlay” pixels in the 
image). For this image the lower threshold was set to 21, to grasp all visible cells (overlaid in red), 
but not background signals of lower intensity. 
When setting the lower threshold only cells or cell aggregates should be included in the 
sum intensity. For this reason an image magnification of 400x was chosen to select all 
green spots, by decreasing the lower threshold as much as necessary. Finally a 
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magnification of 100x was used to view the whole image. The threshold value was 
increased when necessary to prevent too much background being picked up (merging 
overlay), although as a consequence some of the “true” signal was left out (Figure 3.2). 
 
 
Figure 3.2 Low threshold setting for FDA 
First an image magnification of 400x was chosen to distinguish between cells and background. 
Finally a magnification of 100x was set to see the whole image. The threshold was increased (here 
from 24 to 40) when necessary to minimise background signals, shown in the image by large parts 
of red overlay that merge with each other (threshold 24, 100x). 
3.3.1.2 Reduction of background pixels 
The background of empty beads was negligible if a lower threshold of more than 10 was 
used. To further reduce background signals the “smooth” and “clean” functions of the 
NIS imaging software were used. The clean function removes single pixels or very 
small objects that are unlikely to result from stained cells. The smooth function is a 
binary function that smoothens the edges of an object, making it easier to distinguish 
between the true signal and background. 
3.3.1.3 PI threshold setting 
For the same reason as described in 3.3.1.1 the higher threshold for PI was set to the 
maximum value of 255. The lower threshold was dependent on the fluorescein signal 
and was used to equalize the sum intensity of fluorescein and PI. AELC, taken from the 
same bead population as used for the FDA threshold setting but with dead cells, were 
stained with PI. Images were taken at different PI exposure times. The low PI threshold 
value was set in a way that the sum intensity was approximately the same as for 
fluorescein. The lower threshold was noted and then used as the high threshold to 
calculate the signal to noise ratio. 
                        low threshold set to 24                                       low threshold set to 40 
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3.3.1.4 Signal to noise ratio 
The signal-to-noise ratio (SNR) is a means to compare the level of a desired signal to 
the level of background (noise). A ratio close to zero indicates a very low signal and a 
high background. A ratio higher than one indicates more signal than noise. The optimal 
threshold is obtained when the highest possible SNR ratio is given. To obtain the sum 
intensity of the target signal, all visible cells have to be picked up. This is done by 
setting the lower threshold to an optimal value and the higher threshold to 255. The 
lower threshold of the target signal was then used as the higher threshold to calculate 
the sum intensity of the background signal while for this purpose the lower threshold 
was set to zero. The sum intensity of signal and background given by the NIS element 
software was used to calculate the SNR ratio. 
3.3.2 Plate reader viability quantification 
3.3.2.1 Volume of beads per well determination 
Materials 
Transparent 96-well plate 
Alginate encapsulated liver cells (grown in FCS for one to 16 days at 37˚C after 
encapsulation) 
Method 
The volume of settled beads necessary to cover the whole well surface of a 96-well 
plate without forming double layers was determined. Therefore 0.75ml of PBS (+Mg, 
+Ca) buffer was added to 0.25ml of settled beads. From this mixture 25ul, 50ul, 75ul, 
100ul and 125ul were added to a transparent 96-well plate. This was repeated six times. 
Images were taken using the Nikon microscope camera.  
3.3.2.2 Omega plate reader sample preparation 
A population of AELC was split in two; one half was incubated in 80% Me2SO for 20 
minutes at room temperature to kill all cells, and the other half remained untreated. 
Me2SO treated beads were washed several times with an excessive of 1xPBS (+Mg
2+
, 
Ca
2+
). Untreated beads were washed with at least 5ml of 1xPBS (+Mg
2+
, Ca
2+
). To 1ml 
of settled beads 1ml of 1xPBS (+Mg
2+
, Ca
2+
) was added. This was done for both 
Me2SO-treated and untreated beads. To the Me2SO-treated beads 80µl of PI and to the 
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untreated beads 40µl of FDA were added, keeping the same ratio as for standard 
FDA/PI staining. After 90 seconds beads were washed three times with 2ml of 1xPBS 
(+Mg
2+
, Ca
2+
). Finally 3ml of 1xPBS (+Mg
2+
, Ca
2+
) were added resulting in a final 
volume of 4ml. This mix was used to prepare the following solutions. Both populations 
were combined as described in Table 3.1 to obtain the fluorescent intensity that 
corresponds to 5-95% viability. 
Table 3.1 Omega Plate reader sample preparation scheme 
%Viability all dead all alive Final volume 
95 50µl 950µl 1000µl 
80 200µl 800µl 1000µl 
65 350µl 650µl 1000µl 
50 500µl 500µl 1000µl 
35 650µl 350µl 1000µl 
20 800µl 200µl 1000µl 
5 950µl 50µl 1000µl 
 
Of each solution, 100µl of well-mixed bead suspension (comprising12.5µl of settled 
beads) was added into each well (5mm diameter). For each condition five replicates 
were tested. Supernatant was tested in triplicates (100µl/well). The whole procedure 
was repeated four times in order to overcome pipetting and staining (PI, FDA) 
variability. The experiment was carried out with beads one day, four days, 10 days and 
16 days after encapsulation as it was assumed that cell density could have an influence 
on the equalization factor. In order to obtain the same number of dead and viable cells 
for the same volume of beads the following had to be considered: 
 After Me2SO treatment all cells had to be dead: therefore 0.25ml of Me2SO 
treated AELC were stained with PI and FDA and microscope images were 
taken. The rest of the unstained beads were only used when no green 
fluorescence was detected.  
 Untreated cells had to be virtually 100% alive: therefore 0.25ml of untreated 
AELC were stained with PI and FDA and microscope images were taken. AELC 
were only used for the plate reader set-up when cell viability was >97%, which 
was measured using the microscope imaging method. 
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3.3.2.3 Staining samples with FDA and PI 
Materials 
Fluorescein diacetate 1mg/ml in Me2SO (Sigma, Cat. No. 31545) 
Propidium Iodide 1mg/ml in water (Sigma, Cat. No. P4864) 
Method 
For sample preparation the same protocol was used as for viability testing using the 
microscope set-up (2.4). After being incubated for 90 seconds in FDA and PI, beads 
were washed twice with 2ml of 1xPBS (+Mg
2+
, Ca
2+
). Then finally 1ml 1xPBS (+Mg
2+
, 
Ca
2+
) was added and 100µl of well-mixed bead suspension was added to each well.  
3.3.2.4 Omega plate reader settings 
Materials 
BMG FLUOstar Omega Plate Reader 
PBS with Mg
2+
 and Ca
2+
 (Sigma, Cat. No. D8662) 
Black 96 well plate (Costar, Cat. No. 3915) 
Method 
The following settings were used to measure the fluorescence of PI and FDA: 
Measuring mode: Endpoint  
Positioning delay: 0.5 seconds 
Flying measurement: off (for plate mode) 
Measurement start time: 0 seconds (no shaking or injection used) 
Number of flashes per well: 10 
Optic: Top optic (black Nunc) 
Wavelength Settings: 
FDA: excitation filter: 465-49m emission filter: 515-55m  
PI: Excitation filter: 510-56m emission filter of 59m  
Gain: 600 to 1200 for FDA and PI 
Path Length Correction: off 
Pause before plate reading: 5 seconds 
Reading direction: From left to right 
Replicate: 1 X 
Concentration/Volume/Shaking: Default setting 
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3.3.2.5 Calculating the equalization factor X 
As fluorescein gives a higher fluorescent signal than PI for the same number of stained 
cells, an equalization factor X was determined (FDAsignal=PIsignal*X). This was done by 
making up samples with different ratios of beads containing exclusively dead or viable 
cells to obtain the fluorescent intensity that corresponds to 5-95% viability. Linear 
regression (Excel 2007) was used to determine the equalization factor.  
 
Step 1: Each sample was measured in five replicates. The signal (fluorescein and PI), 
given in relative light units (RLU), of the supernatant was subtracted from the sample 
RLU value (Table 3.2). Then the average (n=5) was calculated. The average value was 
plotted in a graph using the y-axis for either FDA or PI RLUs (Figure 3.3) and the x-
axis for the corresponding viability (5-95%). A linear trendline was selected and its 
equation (gradient and y-intercept) was used for further calculations (step 2). 
Table 3.2 Example for FDA RLU values and corresponding viability 
Viability % 100 95 80 65 50 35 20 5 
RLU sample  49900 71683 51698 45339 29215 23518 11866 2788 
RLU supernatant 17344 9922 10203 7083 5415 3872 1707 231 
RLU final 32556 61761 41495 38256 23800 19646 10159 2557 
 
 
 
Figure 3.3 Viability-RLU correlation 
Example for target viability (%) and measured FDA and PI RLU values. A linear trendline was 
selected and the gradient and y-intercept were used for further calculations (Step 2). 
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Step 2: On each test day the experiment was repeated four times. The average value of 
the gradient and y-intercept (step1) was calculated. 
 
Step 3: By using the average gradient and y-intercept, corrected FDA and PI RLU 
values were calculated as follows:  
FDARLU-corrected = x *gradient(FDA) +y-intercept(FDA) 
PIRLU-corrected = x *gradient(PI) +y-intercept(PI) 
with x representing any viability value  between 0 and 100. 
 
As an example: the corrected FDA signal with a theoretical viability of 50% (50% 
beads with exclusively dead cells and 50% beads with exclusively viable cells) was 
calculated as: 
FDA corrected (50% viability) = 50 *514.03 - 51.696 = 25648 
‘data used from Figure 3.3 
 
Step 4: To determine the equalization factor X, a theoretical PI value had to be 
calculated. Viability can be determined as for the trypan blue exclusion test (2.1.3) by 
using cell numbers to calculate viability as follows: 
Viability (%) = number of viable cells/ (number of viable cells + number of dead 
cell)*100 
Similarly, viability can be determined when using fluorescence with signal intensity 
corresponding to cell numbers: 
Viability (%) = signal FDA / (signal FDA + signal PI)*100  
By using the corrected FDA value from Step 3 and the corresponding target viability (in 
%), the theoretical PI value was calculated as follows: 
PItheoretical = FDAcorrected/Viability*100-FDAcorrected 
 
Step 5: The theoretical PI RLU value (Step 4) was plotted against the corrected PI RLU 
value calculated in Step 3. A y-intercept of zero was chosen to compensate for test 
variations.  The obtained gradient represents the equalization factor X (Figure 3.4). 
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Figure 3.4 FDA-PI equalization factor X 
Example for a linear trendline of PI theoretical and PI corrected (day one after encapsulation, gain 
900). The theoretical PI value, which corresponds to the FDA value of equal viability, was plotted 
against the corrected value of the measured PI signal. A y-intercept of zero was chosen. The 
gradient denotes the equalization factor X. 
Step 6: The viability of an independent sample was then calculated as follows: 
Viability (%) = signal FDA / (signal FDA + signal PI *X)*100,  
with X = equalization factor. 
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3.4 Results 
3.4.1 Results for microscope viability quantification 
3.4.1.1 Background reduction 
With the smooth function set to “1”, visually clearer edges were obtained, which made 
it easier to distinguish between cells or cell aggregates and background. The sum 
intensity was reduced by less than 0.1%. No further improvement was noted when the 
function was set to “2” or “3”.When the clean function was set to “1-3”, the number of 
small background pixels was still slightly reduced. When the clean function was set to 
“4” some of the cells were omitted. A clean function of “2” was selected as a suitable 
compromise, with a reduction in sum intensity of less than 0.5% (Figure 3.5). 
 
Smooth: 
 
 
Clean: 
 
 
 
 
 
 
 
 
Figure 3.5 Clean and smooth function 
With the smooth function set to “1”, visually clearer edges were obtained and small background 
pixels were reduced. Higher levels than “1” did not show much further improvement. By using the 
clean function small background pixels were reduced. Higher levels than “2” resulted in signal loss. 
 
 
smooth 0 smooth 3 smooth 2 smooth 1 
clean 0 clean 1 clean 2 clean 3 
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3.4.1.2 Minimum FDA exposure time 
Increasing exposure times were used to take images of AELC directly after the 
encapsulation process (day zero). To obtain enough fluorescent intensity to distinguish 
between cells and background an exposure time of at least 150ms had to be used (Figure 
3.6).  
 
 
 
 
 
 
Figure 3.6 Determining the minimum FDA exposure time 
Images show green fluorescent AELC taken with increasing exposure times given in milliseconds 
(ms). Images were taken directly after the encapsulation process (day zero). To clearly distinguish 
between cells and background an exposure time of at least 150ms was required. 
3.4.1.3 FDA exposure time evaluation 
Images of FDA stained AELC were taken at exposure times of 100, 150, 200, 300 and 
400ms. The highest signal-to-noise ratio was obtained with an exposure time of 150ms. 
Higher exposure times showed a constant decrease in the signal-to-noise ratio. A lower 
exposure time (100ms) also decreased the signal to noise ratio (Figure 3.7). 
 
 60ms                             80ms                              100ms 
          150ms                            200ms                            300ms 
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Figure 3.7 Signal to noise ratio for FDA stained AELC  
Images of FDA stained AELC were taken at exposure times of 100, 150, 200, 300 and 400ms and 
the signal-to-noise ratio was determined as described in 3.3.1.4. Highest signal-to-noise ratio was 
obtained with an exposure time of 150ms. Data was n=5 +/-SD. 
3.4.1.4 PI exposure time evaluation 
PI fluorescent images were taken at an exposure time of 600ms, 800ms and 1000ms 
(one second). An exposure time of 600ms was too short to generate a signal similar to 
that of FDA without including a high percentage of background pixels. There was 
visually and in sum intensity little difference between an exposure time of 800ms and 
1000ms when all cells were detected, but the signal-to-noise ratio for an exposure time 
of 800ms was lower (SNR = 75) than for one second (SNR= 115). The next highest 
exposure time possible to be set with the NIS imaging software is two seconds. As a 
result of the high pixel intensity only a few cells had to be included (and many omitted) 
to generate a signal comparable to the FDA signal. An exposure time of one second was 
therefore used for PI (Figure 3.8). 
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Figure 3.8 Threshold setting for PI fluorescence 
Images of PI stained AELC were taken at an exposure time of 600ms, 800ms and 1000ms, (2000ms 
not shown). A merging red overlay indicates that background pixels are “picked up” and included 
in the sum intensity. Little difference was noted between an exposure time of 800ms and 1000ms. 
3.4.1.5 Final set-up: day 3 to 13 after encapsulation 
FDA threshold setting was carried out with AELC of increasing cell density. The low 
threshold had to be set to an increasingly higher number in order to include signal pixels 
but not background pixels as shown in the Table  (Appendix). Most important are 
viability measurements directly after the encapsulation process and at the end of the 
AELC growth process, normally reached after 11-13 days and with cell densities 
between 20 and 30 million cells per ml of beads. For this reason the average of the low 
FDA threshold was calculated using images taken from AELC with a cell density of 
>20 million cells/ ml of beads. The same AELC population was used to define the low 
threshold for PI (Appendix Table 3.4). The low FDA threshold was comparable 
between the four samples taken from two different AELC populations (20.22 and 26.31 
*10
6 
cell/ ml beads), but varied between the two populations for the corresponding PI 
values (Appendix Table 3.3). The average lower threshold for FDA was 41 (SD+/- 3.2) 
and for PI 41 (SD+/- 16.1). 
 
 
 
 
 
              600ms                             800ms                          1000ms   
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3.4.1.6 FDA and PI threshold setting evaluation 
Threshold settings (value of 41 for FDA and PI) that were obtained from high cell 
density beads (>20*10
6
 cells/ml beads) were evaluated using images taken of beads with 
varying cell densities (Table 3.3). The ratio of FDA to PI was supposed to be close to 
one, as a population of 100% viable cells should result in the same pixel sum intensity as 
a population of 100% dead cells when exposure times and thresholds are set correctly. 
The FDA/PI ratio increased with increasing cell densities as shown in Table 3.3. This 
indicates that the sum intensity for PI is stronger than the FDA signal for low cell 
densities beads. With growing cell numbers the sum intensity of both dyes become more 
balanced. 
Table 3.3 FDA/PI ratio 
cell number FDA sum Intensity PI sum Intensity FDA/PI ratio 
3.42*106 5444029 9319880 0.58 
7.51*106 4377027 5277172 0.83 
10.03*106 10756429 9574538 1.12 
11.53*106 11463651 11144068 1.03 
14.88*106 11946256 12077144 0.99 
17.89*106 23729955 20577971 1.15 
20.22*106 31748525 30125468 1.02 
26.36*106 40272173 41124657 0.99 
 
3.4.1.7 Cell density impacts cell viability 
As shown in 3.4.1.6 cell density has an impact on the target FDA/PI ratio of “one” (for 
a equal number of dead and viable cells). A FDA/PI ratio of 0.83 obtained for a cell 
density of 7.51 million cells per millilitre of beads and with the threshold setting for cell 
densities of >20*10
6
 cell/beads was still considered as acceptable. The highest impact 
for any deviation will be seen when the viability is at 50%. As an example: if the true 
FDA signal is the same as the PI signal, a FDA/PI ratio of 0.83 would then result in a 
viability of 54% instead of 50%, demonstrated in the following calculation: 
Viability=50*/(50*0.83+50)*100=54%. 
The deviation from the “true” viability value decreases as either the FDA or PI signal 
approaches 100% of the total signal:  
Viability=100*0.83/(100*0.83+0)*100=100 or  
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Viability=0*0.83/(0*0.83+100)*100=0.  
For viabilities above 80%, a deviation of 2% and for viabilities above 90% a deviation 
of 1% can be expected, considering a FDA/PI ratio of 0.83. This is less than the 
expected intra-sample deviation of 4% and 2% for samples with viabilities between 
80% and 90% and viabilities above 90%, respectively. For viabilities close to 50% an 
intra-sample variation of 7% can be expected. Intra sample deviation given here is the 
maximum average deviation from four independent samples to the viability mean 
calculated from five single measurements (5xPI+5xFDA images). 
3.4.1.8 Threshold setting for low cell density beads 
For the cell growth process of a bioartificial liver device, day zero and day one after 
encapsulation are important days for quality control as viability data will indicate 
whether the encapsulation process was successful and if AELC are suitable to be FBB 
cultivation. The FDA/PI ratio decreased strongly for low cell density beads as shown in 
Table 3.3. Therefore a separate lower threshold was defined using AELC one day after 
encapsulation. The lower FDA and PI threshold of four distinct encapsulations resulted 
in an average value of 21 +/- 1.3 (n=4) for FDA and 20 +/- 1.0 (n=4) for PI with little 
difference between the samples (Appendix Table 3.6). 
3.4.1.9 Viability data compared to cell count, ELISA and MTT data 
In order to investigate whether changes in viability are also reflected in protein 
production, cell count and methylthiazol tetrazolium (MTT) production, AELC of 
decreasing viability had to be tested. To obtain decreasing viability levels (sample 1-3), 
AELC were incubating in Me2SO. Sample viability, cell number and MTT were 
measured 24 hours and 48 hours after treatment. A media change was carried out 24 
hours post-treatment. Media was collected 24 hours after the media change to measure 
the average protein production over the last 24 hours. Viability, cell count and MTT 
measurements refer to a specific time point while protein production is a cumulative 
value. In order to compare the data of the different test systems, viability, cell count and 
MTT measurements had to be conducted at the moment of media change and media 
collection. As seen in Figure 3.9 below, there was no significant difference in cell 
recovery 24 and 48 hours post-treatment. The only exception was the MTT data of 
sample 3. The ranking of the samples (sample 1=high recovery, sample 2=good 
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recovery, sample 2= low recovery) for viability, cell count and protein production 
(alpha acid glycoprotein (AGP), alpha-fetoprotein (AFP), Albumin, Anti-Trypsin and 
Fibrinogen), was the same for all assays (Figure 3.10). The percentage of the positive 
control was calculated for sample 1-3, in order to compare the recovery levels reached 
for the different assays. Viability data mostly correlated to values gained for cell 
number, AFP, Albumin and Anti-Trypsin. Fibrinogen and AGP production of sample 1-
3 in respect to the positive control was more reduced than the remaining parameters. 
MTT results did not correlate with any other test system; clearly lower values for 
sample one in comparison to the control were acquired, and there was no difference 
between sample 1 and 2. Also the difference between sample two and three was less 
pronounced than seen for the remaining methods (Table 3.4).  
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Figure 3.9 Viability determined by image analysis compared to cell count and MTT data 
Samples, treated with Me2SO to reduce viability, were tested 24 and 48 hours after treatment. 
Viability, cell number and MTT data was acquired. There was no significant difference between 
samples tested after 24 and 48 hours. Viability, cell number and MTT production decreased for 
samples in the order one to three. Data was n=5, +/- SD. 
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Figure 3.10 AELC protein production  
Samples (0.25ml of settled beads), treated with Me2SO to reduce viability, were incubated in 8ml of 
complete media and protein secretion was tested 48 hours after treatment and 24 hours after the 
first media change. Protein production was decreased for each sample in the order of sample one to 
three. Data was n=5, +/- SD.  
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Table 3.4 Percentage of positive control for viability, cell count and ELISA data 
 
Viability 
cell 
number 
MTT AFP AGP Albumin 
Anti 
Trypsin 
Fibrinogen 
sample 1 94 101 77 112 71 90 112 57 
sample 2 76 85 69 78 48 48 80 30 
sample 3 23 59 61 48 28 22 42 9 
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3.4.2 Results for plate reader viability quantification 
3.4.2.1 Volume of beads per well 
The microscope pictures that were taken to determine the volume of settled beads to be 
used per well showed that a volume of 12.5µl of settled beads was sufficient to cover 
the whole surface of one well (96 well plate) without double layer formation.  
3.4.2.2 Plate reader gain 
Plate reader measurements were carried out as described in section 3.3.2.4 using a gain 
of 300, 600, 900 and 1200 for both PI and FDA. A gain of 300 for PI resulted in 
underexposure and a gain of 1200 for FDA in overexposure and was therefore not used 
for further calculations. Otherwise the equalization factor X was calculated for all 
possible PI/FDA gain combinations. 
3.4.2.3 Equalization factor X  
As FDA, or specifically fluorescein, gives a higher fluorescent signal than PI for the 
same number of stained cells, an equalization factor X was determined 
(FDAsignal=PIsignal*X). AELC were tested on day 1, 5, 10 and 16 after encapsulation with 
cell numbers of 2.2, 4.3, 12.3 and 19.5 million cells per millilitre of beads. 
Table 3.5 Equalization factor X for day 1,5,10 and 16 after encapsulation 
Day 1 Day 5 Day 10 Day 16 
Gain 
(PI/FDA) 
Equalization 
factor X 
(gradient) 
Gain 
(PI/FDA) 
Equalization 
factor X 
(gradient) 
Gain 
(PI/FDA) 
Equalization 
factor X 
(gradient) 
Gain 
(PI/FDA) 
Equalization 
factor X 
(gradient) 
600/300 4.6 600/300 6.1 600/300 5.4 600/300 6.6 
600/600 194 600/600 236 600/600 211 600/600 251 
600/900 2370 600/900 2931 600/900 2765 600/900 3509 
900/300 0.40 900/300 0.48 900/300 0.45 900/300 0.55 
900/600 17 900/600 19 900/600 18 900/600 20 
900/900 210 900/900 232 900/900 229 900/900 284 
1200/300 0.07 1200/300 0.08 1200/300 0.07 1200/300 0.09 
1200/600 2.9 1200/600 3.1 1200/600 2.9 1200/600 3.4 
1200/900 35 1200/900 38 1200/900 37 1200/900 47 
3.4.2.4 Evaluating plate reader viability test set-up 
To evaluate the plate reader viability test set-up, samples with decreasing cell viability 
were made by incubating AELC (cultured for nine days) for 10 minutes in different 
Me2SO concentrations. Beads used for the set-up contained either dead or viable cell, 
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which could influence the results. Beads used in this experiment contained both: dead 
and viable cells. Samples were stained and pictures were taken using the Nikon 
microscope (Figure 3.11).  
 
 
Figure 3.11 Microscope images of AELC with decreasing viabilities 
Images of AELC incubated in increasing concentrations of Me2SO to decrease cell viability. 
Individual beads used in this experiment contained both dead and viable cells. AELC were used to 
evaluate the equations listed in Table 3.5. 
Samples were measured using the Omega plate reader by using gains of 600, 900 and 
1200 for PI and 300, 600 and 900 for FDA. Each sample (1-4) was measured in four 
repeats (four wells), and the average RLU value of PI and FDA and the equalization 
factor given in (Table 3.5) were used to calculate the viability. The viability level was 
highest for low cell density beads (day 1) and lowest for high cell density beads (day 
Sample 1: Positive 
control 
 
 
 
 
 
Sample 2: AELC 
incubated in 40% 
Me2SO (v/v) for 10 
minutes  
 
 
 
Sample 3: AELC 
incubated in 50% 
Me2SO (v/v) for 10 
minutes  
 
 
 
Sample 4: AELC 
incubated in 80% 
Me2SO (v/v) for 10 
minutes  
 
 
PI (dead)                      FDA (live) 
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16), regardless of the PI/FDA combination. Differences in viability were more 
pronounced between cell densities (up to 10%) then between PI/FDA gain 
combinations, for which the variation in viability was less than 3%. 
3.4.2.5 Final equation for Omega plate reader viability measurements 
Viability data obtained from the same PI/FDA gain combination but calculated with one 
of the four different equalization factors for varying cell densities (day one, five, 10 and 
16) (Appendix Table ), were averaged and the standard deviation was calculated (Figure 
3.12). This was done to determine the PI/FDA gain combination and corresponding 
equalization factor that would provide the lowest deviation in viability across varying 
cell densities, so that the same gain settings and formula could be used to determine 
AELC viability. The PI/FDA gain combination 900/600 and 1200/600 showed the 
lowest standard deviation. However the 900/600 combination was assumed to be the 
better choice for samples with high PI signals as the risk of overexposure is lower. The 
average gradient of data from day 1, 5, 10 and 16 with a gain of 900 for PI and 600 for 
FDA was calculated (18.48 +/- 1.42) giving the final formula: 
 %Viability = signal FDA / (signal FDA + signal PI *18.48)*100 
Viabilities calculated with the equalization factors for distinct cell densities (day 1, 5, 10 
and 16) differed from the viability calculated with the average equalization factor by 
less than 2% (total viability). This was equal to an intra-sample deviation of 2%. For 
high viability samples (viability >90%) the deviation was below 1% and comparable to 
an intra-sample deviation of 1.3%. Intra sample deviation given here is the maximum 
average deviation from three independent samples to the viability mean, calculated from 
five single measurements. 
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Figure 3.12 Viability standard deviation comparison for equalization factor and gain combination 
evaluation 
Standard deviation of average viability obtained from the same PI/FDA gain combination but 
calculated with the four different equalization factors for varying cell densities (day 1, 5, 10 and 16) 
(Table 3.5). The lowest SD was obtained for a gain combination of 900/600 and 1200/600 (PI/FDA). 
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3.5 Discussion 
In this chapter a method was established to assess cell viability of alginate encapsulated 
liver cells (AELC) by analysing fluorescent microscope images. Automated and semi-
automated image analysis to quantify features of interest and separate the background 
by using differences in size, shape, density, brightness, or colour has been previously 
used by others (King et al., 2002; Ruifrok, 1997). The criteria or combination of criteria 
to choose depends on the complexity of the specimen and on the capability of the 
imaging software. For AELC viability measurements two different wavelengths were 
chosen to distinguish between viable and dead cells. The camera was set to 
monochrome instead to colour mode, as just the wavelength of either fluorescein or 
propidium iodide (PI) was intended to be captured after passing the corresponding filter. 
No signal was detected for samples of exclusively viable cells when the red filter was 
used nor for exclusively dead cells when the green filter was used. Brightness was 
selected to assess the intensity of both fluorescein and PI. Criteria of size, shape and 
density were not adequate for cell spheroids as these characteristics are subject to 
change during cell growth. The lowest magnification (4x) was selected to obtain the 
highest possible number of AELC per image to obtain a representative number of cells.  
The method was based on the assumption that the fluorescence sum intensity of either 
PI or fluorescein would result in a linear response to an increasing cell number given, 
providing under and overexposure was avoided. The increase in sum intensity would 
therefore simply be given by the multiplication of pixel number and pixel intensity 
(given as a grey scale level from 0-255). The FDA exposure time was chosen regarding 
the following considerations. First, the conclusion was drawn that, regardless of AELC 
cell density, only one exposure time for FDA and one for PI should be used in order to 
minimize potential errors for users. Lowest fluorescence was observed directly after the 
encapsulation process, which is a stressful insult to the cells that leads to reduced cell 
activity. Consequently, AELC on the day of encapsulation were used to define the FDA 
exposure time. The shortest exposure at which cells could easily be identified by visual 
inspection ranged from 150ms to 200ms. A low exposure time had to be chosen to 
avoid overexposure and signal bleeding when images of beads of much higher cell 
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density are taken. Overexposure is indicated by white pixels and was never observed in 
the data presented in this thesis when the established exposure times were used. The 
signal-to-noise (S/N) ratio calculated for a small range of slightly lower and higher 
exposure times, indicated that an exposure time of 150ms was most suitable. PI 
exposure was defined according to the FDA signal, with the best S/N result for 1000ms. 
It became evident that cell density was relevant for viability measurements. The higher 
the cell density, the higher the lower threshold had to be set in order to separate the 
background from the signal. The reason for this can be explained with the 3D format of 
AELC. Pixel intensity increases as more cells lie behind each other in the 3-dimensional 
matrix, adding to the total signal. An increment in cell density also increases the total 
amount of light scattering, which consequently results in a higher background signal, 
exceeding the lower threshold value of low cell density beads. Light scattering can be 
assumed to increase the background in a likewise manner for FDA and PI and therefore 
if the lower threshold for PI and FDA is equally increased, viability should remain 
unaffected. However, the FDA/PI ratio increased with cell density, which means that 
the sum intensity for FDA incremented more than the PI signal over the period of cell 
growth. This can be explained with the observation that HepG2 cells are more 
metabolically active when grown in a 3D format than monolayer or single cells (Selden 
et al., 1999). PI intercalates into DNA and is not subject to this deviation. In this respect 
PI might be more accurate when testing AELC of different cell densities when the same 
threshold settings are being used. However, this would be essentially more time 
consuming as two sample have to be tested, of which one has to be treated with a toxic 
reagent to kill all cells. Values that were obtained for the lower threshold when AELC 
images were taken one day after the encapsulation process were highly consistent 
including samples from four distinct encapsulation processes. This was similar for 
densities above 20 million cells/ml beads, although showed less consistency for the 
lower PI threshold. These findings suggest that the method is reliable for beads of 
similar cell density. The average lower threshold value was equivalent for FDA and PI, 
which means that the exposure times had been selected accurately to equalize the 
difference in FDA and PI fluorescent intensity. Calculations demonstrate that deviations 
from the true viability value will be strongest for viabilities close to 50% and negligible 
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for viabilities close to 100% and 0%. It was also estimated that the deviation to true 
value is less than the expected intra-sample deviation. 
Image analysis to measure AELC viability is a simple tool that holds several 
advantages. First of all AELC viability can be assessed without the need to disrupt 
either the alginate matrix nor cell spheroids. These procedures are time consuming and 
also have the potential to alter the final viability result. The process is rapid; one sample 
can be stained, images taken (5-6 images/sample) and analysed within seven minutes, 
which means that results are available almost immediately. This capacity makes it 
especially interesting for quality control purposes but also in general when fast 
decisions are needed. Furthermore, the method is very economical (100 samples can be 
tested for less than £1) and is therefore ideal for high through-put testing. Additionally, 
there is little scope for variability between operators when using the established 
protocol and exposure times. When taking TIF images, the exposure time is recorded, 
and established threshold settings mean that fluorescent intensity is objectively 
quantified, and the translation of the threshold settings into a macro prevents the 
operator from changing the settings. This is in strong contrast to the trypan blue 
exclusion test, when a dead/viable cell count is highly subjective and dependent on the 
operator’s interpretation.  
AELC were stained simultaneously with FDA and PI. This is advantageous because the 
quantity of beads used per image is irrelevant, as the same sample is used to calculate 
the sum intensity of PI and FDA. In contrast, when only one dye is used, images of two 
samples have to be taken. Consequently an unequal number of beads would have a 
strong impact on fluorescence sum intensity, and therefore on the viability value 
generated. The fact that the number of beads is irrelevant allows calculating the viability 
of a single bead. In summary it can be stated that fluorescent microscope image analysis 
is a highly controllable and, apart from the simple staining process, an operator 
independent tool to measure cell viability. Good controllability is an important aspect 
for quality control.  
There have been some discussions about the use of membrane integrity tests to measure 
the success of cryopreservation, as viability might not reflect whether cells are 
optimally functional (Pegg, 2010a). For this reason image analysis results were 
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compared to cell counts, enzyme-linked immunosorbent assay (ELISA) and 
methylthiazol tetrazolium (MTT) data. Samples of different viability levels (high-
middle-low) followed the same ranking for cell counts, ELISA and MTT, however 
deviations from the positive result varied strongly between test systems. For example: 
the percentage of the positive control reached for alpha-fetoprotein (AFP), Anti-Trypsin 
and albumin production was comparable to the viability data but strongly differed to 
fibrinogen and alpha acid glycoprotein (AGP) production. This might be accounted for 
by the different pathways that were affected after the stressful insult, but also 
demonstrates that none of the test systems, nor a combination, is able to describe cell 
viability (vitality) fully. 
The plate reader set-up followed the same principle as the microscope set-up with the 
same advantage of being simple, fast and economical. Again FDA and PI signal had to 
be equalized.  This was done by measuring the same sample with different gains for 
FDA and PI and by selecting the optimal combination. The gain, which intensifies the 
signal, was chosen according to the dynamic range of the instrument. In this respect a 
gain of 1200 for FDA was too high and a gain of 300 for PI was too low, as no linear 
correlation was given for those gain values. An equalization factor X was calculated to 
further equalize the FDA and PI signal. At each test day different ratios of beads with 
exclusively dead and viable cells were prepared to obtain viabilities between 5% and 
95%. Cells were stained and fluorescence was measured. Measured RLU levels were 
subsequently plotted against the target viability value. A similar approach has been 
patented for the viability determination of parasitic and non-parasitic worms (Peak, 
2012). The gradient and the y-intercept of the linear regression of four experiments 
performed on the same day were determined and the average calculated, instead of 
calculating the mean of each viability level (n=4) and subsequently plotting the 
averaged RLU value against the target viability. This had the advantage that outliers 
were easily identified and high R-values were reached. Outliers were assumed to have 
occurred from pipetting errors, when different ratios of viable and dead beads were 
prepared. As for image analysis, the aim was to identify settings that could be used over 
the whole range of cell densities seen during the preparation of cells for use within the 
bioartifical liver assist device (BAL). For this reason an independent equalization factor 
was determined for AELC one, five 10 and 16 days after encapsulation. The PI/FDA 
Chapter 3: Image analysis validation for cell viability quantification 
94 
 
gain combination of 1200/600 and 900/600 gave the lowest viability deviation between 
samples measured with the same gain combination but calculated with the equalization 
factors established for the four cell densities. This was because of the low equalization 
factor deviation between cell densities, and because equalization factors were close to 
one, therefore having less impact on the final PI sum intensity. It was estimated that the 
intra-sample deviation is closely similar to the error that can be expected when the same 
equalization factor is used for varying cell densities with a deviation of less than 1% for 
viabilities exceeding 80%, and a deviation of 2% for samples of viabilities below 80%. 
The main disadvantage of the plate reader set up is that fluorescein “leaching” will not 
be recognized. Fluorescein leaks or “leaches” out of cells with damaged cell membranes 
which are still enzymatically active. “Leaching” leads to falsely high FDA readings and 
has especially been noticed for samples with viabilities lower than 40% that were 
measured within the first hours after the exposure to a harming insult such as freezing or 
solution toxicity. This intermediate state is followed by progressive loss of cell viability 
with lowest viability after 24 hours, as described for AELC cryopreserved by slow 
cooling (Massie et al., 2011). Progressive cell death after cryopreservation has also been 
observed in kidney cells and has been termed cryopreservation-induced-delayed-onset-
cell-death (CIDOCD). Additionally, a process of repair has been described in AELC 
and rat hepatocytes during which sub-lethally damaged cells regain their membrane 
integrity approximately between 24 and 48 hours post-warming (Massie et al., 2011; 
Watts & Grant, 1996). The best time to test AELC viability was therefore assumed to be 
24 hours post-stress when fluorescein leaching is strongly reduced as damaged cells 
either have stopped enzymatic activity or undergone repair. Also, differences between 
conditions were expected to be most pronounced after CIDOCD and before the 
beginning of cell recovery and cell growth. 
Chapter 3: Image analysis validation for cell viability quantification 
95 
 
3.6 Conclusion 
In the process of this thesis about 20000 images were taken, corresponding to about 
3300 measured samples. This demonstrates the necessity for a fast and inexpensive test 
method, given by both approaches; image analysis and plate reader analysis. To 
describe the culture process of a bioartifical liver (BAL)  assist device it is reasonable to 
measure several parameters, especially as the final protein production is crucial for the 
effectiveness of the BAL application. However, as setting up a complicated method, 
such as the Liquidus Tracking (LT) cryopreservation process implies inevitably many 
technical improvements, it was considered that viability measurements were sufficiently 
powerful to describe post-stress viability in a way to allow comparison of experimental 
conditions. This assumption was reinforced by enzyme-linked immunosorbent assay 
(ELISA), cell count and methylthiazol tetrazolium (MTT) measurements, which 
followed the same order as the viability data, measured by using the image analysis 
system. Alginate encapsulated liver cells (AELC) for LT were always taken from the 
same starting material, and therefore deviations regarding the cell number were not 
expected. Based on the observation of fluorescein cell leaching, and the general 
advantage of visual inspection, the microscope set up was used for viability 
measurements throughout the work of this thesis. Therefore samples were tested 24 
hours post-stress when fluorescein leaching was reduced and differences between 
conditions were expected to be most pronounced.  
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4 CHAPTER 4 
Manual Liquidus Tracking 
4.1 Introduction 
The fundamental basis of the Liquidus Tracking (LT) theory encompasses the concept 
that cryoprotectant agent (CPA) toxicity can be reduced if the temperature is decreased, 
such that concentrations high enough to lead to vitrification can be achieved step-by-
step at lower temperatures. Reduced toxicity and decreased drug efficiency can be 
explained by decreased enzyme activity which for mammalian cells is highest at ~37°C, 
but is also a result of decreased reaction kinetics in general, which includes reduced 
chemical and/or osmotic stresses. Slower molecular motion also increases the time a 
substance needs to penetrate the cell, which delays its potential effect. Reduced toxicity 
at lower temperatures has been shown in previous work by Matheny in 1968 (Matheny 
et al., 1969), who incubated rabbit atria in different dimethyl sulfoxide (Me2SO) 
concentrations at increasing temperatures. The effect is also reflected by reduced drug 
efficiency at lower body temperature, which has been widely studied by Weihe in 1973 
(Weihe, 1973). 
4.1.1 Manual Liquidus Tracking 
Manual Liquidus Tracking holds some logistical advantages since it does not require 
complex equipment. It can allow small batch vitrification for samples of moderate 
volumes (in the region of 2 – 10ml), and can help in testing various LT conditions in 
parallel within one experiment (e.g. buffers, antioxidants, CPAs). This was necessary to 
optimize the automatic LT procedure, which is a time and material consuming process. 
In general three test set-ups have been defined which can be used to perform manual 
LT. Set-up 1 corresponds to the manual LT approach used by Farrant (Farrant, 1965b) 
and Pegg (Pegg et al., 2006). The sample to be vitrified is transferred from one sample 
container to the next, each with a higher CPA concentration whilst the temperature is 
decreased. Set-up 2 reflects the dual solution mode that can be used with the automatic 
Planer Liquidus Tracker. The sample remains within the same sample container 
throughout the vitrification procedure and the CPA concentration is increased by the 
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addition of a slightly higher concentrated CPA solution (e.g. 20% for manual LT). After 
mixing, the sample volume has to be reduced as a result of limited container volume 
and to minimize the amount of CPA needed to increase the CPA concentration in the 
next step. Set-up 3 reflects the Liquidus Tracker single solution mode as it uses highly 
concentrated CPA solutions (60-80%) to increase the CPA concentration within the 
sample. In contrast to the automatic approach, it is unnecessary to reduce the sample 
volume of the manual set-up before the next CPA addition. In general a final volume of 
5ml was reached for which 15ml centrifuge tubes could be used. 
4.1.2 Improved laboratory translation for manual Liquidus Tracking 
Maintaining the sample temperature close to its equilibrium melting point during CPA 
changes, providing effective mixing and reaching the target CPA concentration is 
problematic for manual LT for several reasons. As the temperature gets colder over the 
LT process, the CPA solution becomes more viscous with the consequence that 
homogenisation will take more time. Thus, the freezer lid has to be open for longer and 
more heat fluctuation occurs. Also the addition and reduction of CPA becomes more 
inaccurate due to increased viscosity. 
4.1.3 The Refractive Index 
One of the most important measurements to control the LT procedure is to determine 
the CPA concentration after its increase or decrease. This information is needed to 
establish an effective pipetting and mixing process and to estimate the expected error, 
which is especially important to prevent the sample from freezing in case insufficient 
CPA was added. If the concentration is known during the process necessary adjustments 
can be carried out. A simple way to determine the CPA concentration is by measuring 
the refractive index of a respective solution (Umlas & O’Neill, 1980). The refractive 
index describes how light propagates through an optical medium and is defined as the 
ratio of the speed of light in a vacuum and the speed of light in a substance. To 
determine the refractive index a refractometer can be used, which measures the degree 
to which the light changes direction (angle of refraction) when crossing the interface 
between two media and correlates it to the refractive index of the sample. This is 
normally based on Snell’s law with: n1*sinØ1 =n2*sinØ2, where Ø1and Ø2 are the 
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angles of incidence and refraction, and n1 and n2 are the refractive indices of the prism 
material and the sample. As the refractive index of the refractometer’s prism material 
and the angle of incidence are known, the refractive index of the sample can be 
calculated. The main factors that affect refractive index measurements are concentration 
of the dissolved substance and the temperature of the solution. 
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4.2 Aims 
The first aim of this chapter was to prove the principles of Liquidus Tracking (LT) by 
showing that Cryoprotectant agent (CPA) toxicity is reduced at lower temperatures. To 
estimate the impact of temperature on CPA toxicty, alginate encapsulated liver cells 
(AELC) were incubated in different dimethyl sulfoxide (Me2SO) concentrations at 
different temperatures, including low subzero temperatures. Secondly, different 
methods to carry out small scale manual liquidus tracking were tested and evaluated 
with respect to practicablity. The most practical method was improved in terms of 
sample homogenisation and heat fluctuation to maintain the sample close its melting 
point. Parameters that could affect automatic LT approach were also investigated. To 
distinguish between osmotic injury and cytotoxicity the impact of osmotic pressure on 
cell viability was assessed.  
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4.3 Methods and Materials 
Materials 
Me2SO (Sigma, Cat. No.154938) 
1xPBS with Mg
2+
 and Ca
2+
 (Sigma, Cat. No. D8662) 
Controlled Rate Freezer (Planer, Kryo 10, Series II) 
Alginate encapsulated liver cells  
4.3.1 Dimethyl sulfoxide toxicity at different temperatures and concentrations 
Method 
PBS was used as a cryoprotectant agent (CPA) carrier solution with a concentration of 
1x for all dimethyl sulfoxide (Me2SO) solutions. Samples were incubated at 37°C 
(incubator) and 4°C (fridge) at increasing concentrations of Me2SO (10-70% (v/v)). 
Unless noted differently alginate encapsulated liver cells (AELC) cultured for 8-11 days 
were used. After the incubation beads were washed with an excess of ice cold PBS. 
Then after being incubated for 24 hours in complete media to allow full expression of 
any damage, beads were stained with FDA/PI and viability was measured. Each test day 
the viability of an unfrozen sample was measured as a positive control. 
4.3.1.1 Dimethyl sulfoxide toxicity at temperatures below zero 
AELC, cultured for 4-5 days were incubated at 37°C (incubator), 20°C (room 
temperature), 4°C (fridge) and -10°C, -20°C, -30°C, -40°C, -50°C (Planer Kryo 10 
freezer) for 40 minutes in increasing concentrations of Me2SO (20% to 60% (v/v)). 
Beads incubated at subzero temperatures were pre-incubated in the following solutions 
for one minute at 0.5°C (ice-water) to prevent immediate freezing before the addition to 
the final Me2SO solution:  
- beads incubated at  -10°C: 20% (v/v) Me2SO  
- beads incubated at  -20°C: 30% (v/v) Me2SO  
- beads incubated at  -30°C: 40% (v/v) Me2SO 
- beads incubated at  -40°C: 50% (v/v) Me2SO  
- beads incubated at  -50°C: 60% (v/v) Me2SO  
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Then after being incubated for 24 hours in complete media, beads were stained with 
FDA/PI and viability measured. Each test day the viability of an unfrozen sample was 
measured as a positive control. 
4.3.2 Determination of osmotic effects 
AELC were incubated at 0.5°C for five minutes in 20% (v/v) Me2SO and were then 
transferred to 40% (v/v) Me2SO for 15 and 40 minutes at 0.5°C (tubes on ice). Beads 
from the same flask were immediately incubated in 40% (v/v) Me2SO for 15 and 40 
minutes (Figure 4.1). The experiment was repeated at 37°C. Pre-incubation at 20% (v/v) 
Me2SO at 37°C was reduced to two minutes as Me2SO diffusion is increased at higher 
temperatures. After the incubation half the volume was removed and replaced with 
PBS. After two minutes half the volume was removed once again and replaced with 
PBS. After two further minutes all supernatant was removed and beads were washed 
twice with 1ml PBS. Then after being incubated for 24 hours in complete media to 
allow full expression of any damage, beads were stained with FDA/PI and viability was 
measured. 
 
 
 
 
 
 
Figure 4.1 Osmotic stress 
AELC were pre-incubated in 20% (v/v) Me2SO at 0.5°C (37°C) before adding AELC to the final 
Me2SO solution of 40% (v/v) Me2SO at 0.5°C (37°C). Simultaneously AELC were incubated 
directly in the final 40% (v/v) Me2SO solution at 0.5°C (37°C). AELC viability was assessed 24 
hours after the incubation in complete media at 37˚C. 
4.3.3 Manual Liquidus Tracking 
Materials 
Me2SO (Sigma, Cat. No154938) 
 
20%  
Me2SO 
 
 
40% 
Me2SO 
 
 
0%  
Me2SO 
 
40%  
Me2SO 
 
with pre-incubation without pre-incubation 
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1xPBS with Mg
2+
 and Ca
2+
 (Sigma, Cat. No. D8662) 
6-well plate 
100 um cell strainers (BD Bioscience, Cat. No. 352360) 
Controlled Rate Freezer (Planer, Kryo 10, Series II) 
Method 
AELC (0.25ml of settled beads, 9-11 days after encapsulation; unless otherwise noted) 
were added to A: cell strainer (set-up 1), B: 2ml microfuge tube (set-up 2) or C: 15ml 
centrifuge tube (set-up 3). Beads within the freezing solutions were maintained for 
approximately 30 minutes before use at 0.5°C and all further preparation was 
undertaken on ice. Prior to cooling, the Planer freezer was pre-cooled to 0°C. All 
solutions needed to increase the Me2SO concentration were placed into the freezer at the 
beginning of the run. That way the sample temperature and the temperature of the new 
solution were kept approximately the same. The temperature was monitored by 
anchoring a thermocouple submerged in liquid inside. As a positive control the viability 
of unprocessed AELC was measured on the same day as the cooling procedure was 
carried out. After the warming procedure (4.3.3.4), AELC were transferred to a new 
6-well plate with fresh medium and were maintained at 37°C for 24 hours before 
viability was measured. For all cryopreservation experiments, a programmed cooling 
rate of -2°C/minute was used. 
4.3.3.1 Manual Liquidus Tracking set-up 1 
LT experiments were carried out as follows: AELC were added to a cell strainer as 
described and were then placed in a 6-well plate containing 8ml of freezing solution per 
well. All plates were placed into the freezer at the beginning of the run into the pre-
cooled freezer. At fixed temperatures, the cooling chamber was opened quickly and cell 
strainers transferred from one 6-well plate to the next, each subsequent one with a 
higher Me2SO concentration (Figure 4.2). Melting point of the Me2SO solutions were 
determined using the release of latent heat (Massie et al., 2011a) and were then 
compared with the literature values (Elford, 1970; Farrant, 1965b). Temperatures at 
which the Me2SO change can be carried out was -5°C (from 20% to 30% 
Me2SO), -10°C (from 30% to 40% Me2SO), -20°C (from 40% to 50% Me2SO), -30°C 
(from 50% to 60% Me2SO), -40°C (from 60% to 70% Me2SO) (Table 4.1). The transfer 
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temperature included an offset of approximately +30% from the equilibrium melting 
point of the sample to avoid any sample freezing. The lowest temperature that could be 
chosen for the transfer was determined by the CPA concentration of the starting plate as 
it contained the lower CPA concentration. The freezer temperature was set 10°C below 
the transfer temperature to provide sufficient cooling (8ml per well for a 6-well plate) 
with a holding time of 10 minutes and a freezer cooling rate of -2°C/minute). Transfer 
temperatures for solutions containing 50-70% (v/v) CPA were determined empirically, 
as viscosities at lower temperatures were too high to allow effective mixing. 
 
 
Figure 4.2 A schematic of manual LT set-up 1. 
A schematic showing samples (in cell strainers) being transferred between 6-well plates with 
increasing CPA concentration (e.g. 20% 30%, 40%, 50%, 60% and 70% CPA) as the cooling 
proceeds. All plates were placed into the freezer at the beginning of the run. Temperatures at which 
the CPA transfer was carried out when Me2SO was used were: -5°C (from 20% to 30% 
Me2SO), -10°C (from 30% to 40% Me2SO), -20°C (from 40% to 50% Me2SO), -30°C (from 50% to 
60% Me2SO) and -40°C (from 60% to 70% Me2SO). 
Table 4.1 LT transfer temperatures for Me2SO 
*transfer temperatures were determined empirically, as viscosities at colder temperatures were difficult to 
handle. N/A, non-applicable. 
 
% (v/v) Me2SO from: transfer at: 
melting point of Me2SO 
at: 
freezer holding 
temperature 
20 to 30   -5°C 20%:  -8°C -15°C 
30 to 40 -10°C 30%: -15°C -20°C 
40 to 50 -20°C 40%: -30°C -30°C 
50 to 60   -30°C* 50%: -50°C -40°C 
60 to 70   -40°C* N/A -50°C 
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4.3.3.2 Manual Liquidus Tracking set-up 2 
In this set-up 2ml microfuge tubes with a starting volume of 1.5ml were used (Figure 
4.3). At each Me2SO change 750µl of Me2SO solution was taken out and 750µl of a 
20% higher Me2SO concentration was added, then the solution was mixed with a 
pasteur pipette. This procedure allowed an increase of 10% Me2SO at each step. As 2ml 
microfuge tubes have a different heat transfer rate to 6-well plates, the freezer holding 
time and temperature had to be modified to achieve a 20 minute incubation time 
between each Me2SO change. Therefore the holding time was first set to 15 minutes at 
the median temperature between the starting temperature and the next transfer 
temperature. Then the holding temperature was set 5˚C below the transfer temperature 
until the required temperature was reached. As for set-up 1 a cooling rate 
of -2°C/minute was chosen and the same transfer temperatures were used. At the 
beginning of the run enough CPA solution of e.g. 40% 50%, 60%, 70% and 80% 
Me2SO was stored in the freezer to be cooled. To assure corresponding cooling rates, 
the volume of each solution was similar to the sample volume of 1-2ml.  
 
Figure 4.3 A schematic of manual LT set-up 2. 
When using set-up 2 the sample remained in the same sample container throughout the vitrification 
procedure. To increase the CPA concentration by increments of 10% an equal amount of a 20% 
higher concentrated CPA solution was added. Samples were mixed pippeting up and down for at 
least five times before the volume was reduced. The same transfer temperatures as for set-up 1 
(Table 4.1) were used. 
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4.3.3.3 Manual Liquidus Tracking set-up 3 
In this test set-up 15ml centrifuge tubes were used. The Me2SO concentration was 
increased by adding small amounts of highly concentrated Me2SO (Table 4.2). The 
volume was not reduced during the cooling procedure, as in general a starting volume of 
750µl was used, resulting in a final volume of 4.5ml (Figure 4.4).The cooling protocol 
was kept as for LT set-up 2.  
 
Figure 4.4 A schematic of manual LT set-up 3.  
For set-up 3 two highly concentrated CPA solutions 60% and 80% were used to increase the CPA 
concentration of the sample. Smaller volumes were necessary to increase the sample CPA 
concentration so that the sample volume did not have to be reduced after each addition as for 
set-up 2. 
 
Table 4.2 Amount of CPA to be added to increase sample CPA concentration by increments of 10% 
Initial CPA (%) 
Initial 
Vol. (µl) 
Vol. (µl) of 60% (80%)* 
CPA to add 
Target 
CPA (%) 
20 750 200 30 
30 900 400 40 
40 1125 400* 50 
50 1500 800* 60 
60 2250 2400* 70 
final vol. 4500   
Formula to determine the amount of 60% (80%) CPA to be added: B=(A*c-A*a)/(b-c) with B=volume of 
80% CPA to add, A=start vol., c= final CPA concentration, a=start CPA concentration, b=80% CPA 
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4.3.3.4 Manaual Liquidus Tracking warming procedure  
To avoid osmotic injury the Me2SO decrease per step was reduced to 20% (v/v), except 
for step one, which decreased from 70% to 40% (v/v) Me2SO. Temperatures were 
chosen according to freezers that were available in the laboratory. A -80°C and -20°C 
freezer were required as some samples were warmed at the same time others were 
cooled with the controlled rate freezer, of which only one was available. Samples with a 
Me2SO concentration of 20-30% (v/v) were placed directly (A) into ice-cold PBS for 10 
minutes, then washed several times with an excess of PBS and were then transferred to 
complete media and incubated at 37°C for 24 hours. Samples containing 40-50% (v/v) 
Me2SO were placed into (B) ice-cold 20% (v/v) Me2SO for 10 minutes and were then 
processed as described for A. Samples at 60% (v/v) Me2SO and samples at 70% (w/w) 
Me2SO at -60°C were placed into (C) 40% (v/v) Me2SO at -20°C for 15 minutes and 
then processed following step B and A. Vitrified samples were kept at -80°C for 20 
minutes and then processed following step C, B and A (Figure 4.5). 
 
Figure 4.5 LT warming-step by step. 
Samples were kept in a -80˚C freezer for 20 minutes, then CPA concentration was reduced to 40% 
(v/v) and samples were incubated in a -20˚C freezer for 15 minutes. CPA concentration was 
reduced to 20% and then 0% (v/v). In both concentrations AELC were incubated for 10 minutes 
while being kept on ice (0.5˚C). 
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4.3.4 Manual Liquidus Tracking step by step 
For each experiment seven samples were used. One sample was taken out of the Planer 
freezer before the Me2SO concentration was increased and temperature further reduced 
for the remaining samples. Beads incubated in 70% (v/v) Me2SO were cooled either 
down to -60°C and warmed directly or cooled to -160°C (vitrified) and stored for 3-7 
days in liquid nitrogen until use (Figure 4.6). For the complete LT pathway, the time 
taken to achieve the vitrified state was about 10 minutes.  
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Figure 4.6 Step-by-step manual LT 
One sample was taken out of the freezer before the Me2SO concentration was increased and 
temperature reduced. Samples were processed following a warming protocol (4.3.3.4). AELC were 
cultured for 24 hours in complete media at 37˚C before measuring viability. 
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4.3.5 Temperature recordings  
Sample temperatures were measured using a Type K thermocouple which was either 
placed in the bottom of a 6-well plate or in the conical part of a microfuge or centrifuge 
tube. The temperature was then recorded by a Picotech TC-08 datalogger.  
4.3.6 Thermocouple defined approximate freezing point (TdAFP) detection for 
dimethyl sulfoxide 
Materials 
Me2SO (Sigma, Cat. No154938) 
1xPBS with Mg
2+
 and Ca
2+
 (Sigma, Cat. No. D8662) 
Controlled Rate Freezer (Planer, Kryo 10, Series II) 
Picotech TC-08 datalogger 
Method 
The thermocouple defined approximate freezing point (TdAFP) is an approximation of 
the equilibrium melting point of a sample. The TdAFP was detected by measuring the 
release of latent heat. For samples that supercool, the release of latent heat can be seen 
as a peak on the time/temperature curve. In an ideal set-up, the release of latent heat will 
increase the sample temperature up to the equilibrium melting point of that solution 
(Figure 4.7). For more accurate measurements differential scanning calorimetry has to 
be used to measure the equilibrium melting point. The TdAFP was measured by adding 
1.5ml of each solution (10%, 20%, 30%, 40%, 50%, 60% and 70% (v/v) Me2SO) to a 
microfuge tube. A thermocouple was inserted into each tube to record the ice nucleation 
point. Cooling was performed using the Planer Kryo 10 machine at a cooling rate 
of -2°C/minute. PBS was used as a cryoprotectant carrier solution. Any inadvertent ice 
nucleation by cooling to below the melting (freezing) point of a given mixture in a LT 
set-up had to be avoided at all times. Therefore, the temperature at which the Me2SO 
concentration had to be increased was determined as follows: for each condition the 
average temperature was calculated and an offset of +30% of the average temperature 
was introduced to compensate for any deviation between the actual temperature to the 
theoretical melting point and to ensure that the Me2SO increase can be carried out 
before any nucleation occurs. The Liquidus Tracker can only be programmed with 
whole numbers and therefore results were rounded.  
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Figure 4.7 Supercooling and release of latent heat 
This schematic shows the temperature curve of a supercooled sample and the temperature increase 
of the sample during the release of latent heat (solid line). The equilibrium melting point of the 
sample is also shown (dashed line). Upon the release of latent heat the sample temperature is 
increased approximately to its equilibrium melting point. The actual temperature reached was 
defined as thermocouple defined approximate freezing point (TdAFP). 
4.3.7 Refractive index of dimethyl sulfoxide 
Materials 
Cole-Pamer Digital Refractometer, Brix, 45.0 to 95.0%, EW-02941-33 
Method 
To measure the refractive index of a sample, at least 0.4ml of that solution had to be 
placed on the prism surface of the Cole-Pamer refractometer. The refractometer 
contains an automatic temperature compensation tool which allows measurements 
between 0 - 40°C. Samples taken during the LT process were warmed up to at least 0˚C 
before measurement. Distilled water was used for calibration. A standard curve to 
determine the Me2SO concentration of an aqueous solution was established by 
measuring the refractive index of increasing Me2SO concentrations at room 
temperature. The equations for the trendlines were: y = -0.0029x
2
 + 1.0412x + 0.631(R² 
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= 0.9995) for volume/volume, y = -0.0023x
2
 + 0.9839x + 0.5218 (R² = 0.9993) for 
weight/weight and y = -0.0027x
2
 + 0.9754x + 0.5082 (R² = 0.9992) for weight/volume, 
with y = % Me2SO and x= refractive index (Figure 4.8). 
 
 
Figure 4.8 Refractive index of Me2SO 
The concentration of an aqueous Me2SO solution (Me2SO in 1x PBS at 20°C) as a function of the 
refractive index. By using the standard curve the CPA concentration of a sample can be 
determined. 
4.3.7.1 Improved manual Liquidus Tracking  
Manual LT set-up number 3 has here shown to be the most practical. For a more 
reliable process the set-up was improved by using a ‘thermal buffer - TB’ - insulating 
each 15ml centrifuge tube within a 70% ethanol solution held in a 50ml centrifuge tube. 
A hole with a diameter of a 15ml centrifuge tube was cut in the 50ml centrifuge tube 
lid, to keep the 15ml tube fixed in the middle of the 50ml tube. A special stirrer was 
made by using a 2ml Pasteur pipette which was cut in a specific shape that allowed 
pressure and suction by up and down movement to provide effective mixing of viscous 
solutions (Figure 4.9). 
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Figure 4.9 Improved manual LT 
A.:The insolation system of 70% (v/v) ethanol helped to maintain the sample temperature during 
the CPA change when the freezer lid is opened. B: A special stirrer made to deal with highly 
viscous solutions of a 2ml Pasteur pipette; top cut to a length of 1 cm, border cut with a upper 
diameter of 0.3cm and a lower diameter of 1.2cm. The opening was closed with blue tack. Pressure 
and suction by up and down movement provided effective and fast mixing even for viscous 
solutions. 
 
A. B. 
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4.4 Results 
4.4.1 Can CPA toxicity be reduced by decreasing the temperature?  
Alginate encapsulated liver cells (AELC) were incubated at different temperatures in 
increasing concentrations of dimethyl sulfoxide (Me2SO) to observe the effect of 
temperature on Cryoprotectant agent (CPA) toxicity. 
4.4.1.1  Me2SO toxicity at different temperatures and incubation times 
AELC were incubated at 37°C in increasing concentrations of Me2SO (10-70% (v/v)). 
A sudden viability drop was observed at 40% (v/v) for samples incubated at 37°C, but 
was delayed to 50% (v/v) Me2SO when the incubation temperature was set to 4°C. This 
was independent of whether AELC were incubated for a period of 40 minutes or 6 
hours. Recovery of AELC incubated for 6 hours was approximatly 20-30% lower than 
the recovery of AELC that were incubated for 40 minutes. When exposed to low 
concentrations of Me2SO (10-30% (v/v)) viabilities as high as 80% were maintained as 
long as high incubation temperature (37°C) and long exposure time (6 hours) were not 
combined. In this case viability decreased to 60% before dropping to 0% at 40% (v/v) 
Me2SO. The viability of untreated samples was > 99% (Figure 4.10). 
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Figure 4.10 AELC viability at increasing Me2SO concentrations, incubation temperatures and time 
Viabilities remained approximately constant until they suddenly dropped to nearly zero percent 
when reaching a concentration of either 40% or 50% (v/v) Me2SO at an incubation temperature of 
37°C or 4°C, respectively. This was independent of whether the incubation time was set to 40 
minutes or 6 hours. AELC were cultured for 24 hours in complete media at 37˚C before viability 
was assessed by FDA/PI staining. 
4.4.1.2 Me2SO toxicity at different temperatures below zero 
To verify the results of the previous experiment and to investigate the Me2SO toxicity at 
subzero temperatures, AELC were incubated at temperatures between 37°C and -50°C. 
AELC 2-5 days after encapsulation were used as the purpose was to investigate Me2SO 
toxicity. These beads contain less cells and no spheroids and therefore ice formation 
may have less impact on viability. Moreover lower cell density increases Me2SO 
diffusion which is necessary to effectively prevent ice formation inside the cell. The 
viability of unfrozen samples measured each day was > 97%. Me2SO toxicity was 
clearly decreased when exposure temperature was reduced. For example up to 50% 
(v/v) Me2SO was well tolerated when alginate encapsulated HepG2 cells were 
incubated at -20°C but decreased to 0% for all temperatures between -10°C and +37°C. 
Temperatures lower than -20°C did not prevent further cell death. Some of the samples 
were frozen after the incubation process as the Me2SO concentration was too low to 
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avoid ice formation. These samples showed lower viabilities than unfrozen samples of  
higher CPA concentration that were incubated at the same temperature (Figure 4.11).  
 
Figure 4.11 Temperature impact on Me2SO toxicity 
AELC were incubated at increasing Me2SO concentrations at decreasing temperatures for 40 
minutes. From 37˚C to -20˚C viability increased, below -20˚C viability decreased. AELC were 
cultured for 24 hours in complete media at 37˚C before viability was assessed by FDA/PI staining.  
* frozen samples 
4.4.1.3 Dimethyl sulfoxide toxicity over time 
To estimate the impact of exposure time on Me2SO toxicity, AELC were incubated for 
1, 5, 15 and 40 minutes in 30% to 70% (v/v) Me2SO at 4°C. Solutions with 10-20% 
(v/v) Me2SO were not further investigated as they had shown little effect on cell 
viability for temperatures lower than 20°C (Figure 4.11). After 1 minute, AELC 
incubated in 30%, 40% and 50% (v/v) Me2SO still showed high viabilities of  >90%. 
Instead, recovery of cells incubated in 60% and 70% (v/v) Me2SO decreased to about 
50% after 1 minute. After five minutes most of these cells incubated in 70% (v/v) 
Me2SO had died whereas those exposed to 60% (v/v) Me2SO still showed a recovery of 
44%. Less toxic were solutions of 30-50% (v/v) Me2SO with AELC still showing 
viabilities of approximately 83%. After 15 minutes the difference between the 
conditions became more evident showing a modest decline to 80% for 30% (v/v) 
Me2SO and to 70% for 40% (v/v) Me2SO. A stronger reduction was seen for 50% and 
60% (v/v) Me2SO with viabilities being reduced to 50% and 14%, respectively. Finally 
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after 40 minutes, viability of cells incubated in 60% (v/v) Me2SO was reduced to 0%. 
AELC exposed to 50% and 40% (v/v) Me2SO still reached a viability of 12%, and 23% 
respectively. The exposure to 30% (v/v) Me2SO showed little additional effect with 
viabilities still reaching 77%. For 60% and 70% (v/v) Me2SO viability decreased 
strongest during the first minute, for 30% and 40% (v/v) Me2SO during the first five 
minutes and for 50% during the first 15 minutes (Figure 4.12).  
 
Figure 4.12 Me2SO toxicity over time at 4˚C 
The figure shows Me2SO toxicity at 4˚C over time. AELC were incubated in 1x PBS solutions 
containing 10-70% (v/v) Me2SO. AELC viability slightly decreased over time when exposed to 30% 
(v/v) Me2SO, but strongly decreased when 40% and 50% (v/v) Me2SO was used. Exposure to 60% 
Me2SO (v/v) resulted in complete cell death after 40 minutes, whereas AELC incubated in 70% 
Me2SO already showed very low recovery after five minutes. AELC were cultured for 24 hours in 
complete media at 37˚C before viability was assessed by FDA/PI staining. 
4.4.2 Determination of osmotic effects 
AELC pre-incubated in 20% (v/v) Me2SO before being incubated in 40% (v/v) Me2SO 
showed no significant difference in recovery to those directly exposed to 40% (v/v) 
Me2SO when the incubation temperature was set to 0.5°C. This changed when the 
incubation temperature was set to 37°C. At this temperature the pre-incubation step 
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significantly reduced cell death and improved recovery from 21% +/- 7% to 45% +/- 
7% (n=5) for an incubation period of 15 minutes and from 3 +/- 2% to 36 +/- 2% (n=5) 
when AELC were incubated for 40 minutes (Figure 4.13).  
 
Figure 4.13 Effect of temperature on osmotic injury 
Columns in black: with pre-incubation - AELC first incubated for 2 minutes in 20% (v/v) Me2SO, 
then in 40% (v/v) Me2SO for 15 or 40 minutes. Columns in white: without pre-incubation - AELC 
directly incubated in 40% (v/v) Me2SO for 15 or 40 minutes. A: There was no significant difference 
between the two conditions, (pre-incubation and without pre-incubation), when the incubation was 
carried out at 0.5°C. B: Viability was significantly higher for pre-incubated AELC when the 
incubation temperature was set to 37°C, with ** p<0.01, (n=5 +/-SD). AELC were cultured for 24 
hours in complete media at 37˚C before viability was assessed by FDA/PI staining. 
4.4.3 Thermocouple defined approximate freezing point (TdAFP) for dimethyl 
sulfoxide 
Latent heat release was only observed for solutions of 10%, 20% 30% and 40% (v/v) 
Me2SO, but not for solutions of 50%, 60% or 70% (v/v) Me2SO (Figure 4.14). 
Measured equilibrium melting points were -3.5°C +/- 0.23, -9.2°C +/-0.94, -19.8°C +/-
0.77 and -38.8°C +/-1.85 for 10, 20, 30 and 40% (v/v) Me2SO, respectively. The 
equilibrium melting points for 10% and 20% (v/v) Me2SO were in agreement with those 
known from literature (10% (-3°C), 20% (-9°C)), whereas 30% and 40% (v/v) Me2SO 
were lower (literature: 30% (-16°C), 40% (-30°C)). The equilibrium melting point of a 
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given concentration was determined by calculating the average of five individual 
measurements (Figure 4.15). 
 
 
Figure 4.14 Equilibrium melting point detection for increasing concentrations of Me2SO 
The equilibrium melting point for 10, 20, 30, 40, 50, 60 and 70% (v/v) Me2SO was determined by 
cooling 1.5ml of each sample at -2˚C/minute in a controlled rate freezer. Thermocouples within the 
solution measured the temperature during the crystallisation process. Latent heat release was only 
observed for solutions containing 10%, 20% 30% and 40% (v/v) Me2SO. Higher concentrated 
solutions did not show any peak (release of latent heat) in their cooling profile.  
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Figure 4.15 Me2SO Liquidus curve: TdAFP vs. literature data 
Thermocouple defined approximate freezing points for 10% and 20% (v/v) Me2SO were in 
agreement with the equilibrium melting point for 10% and 20% (v/v) Me2SO found in literature 
((Elford, 1970; Farrant, 1965b), whereas measured values for 30% and 40% (v/v) Me2SO were 
lower. 
4.4.4 Liquidus Tracking step-by-step (set-up 1) 
In order to determine at which step viability is decreased, one sample was taken out of 
the Planer freezer just before the Me2SO concentration was increased and temperature 
further reduced for the remaining samples. Viability remained constant until a 
concentration of 30% (v/v) Me2SO, before starting to reduce. An exception to this was 
LT run five, for which viability was already decreased at 30% (v/v) Me2SO. Between 
30% and 60% (v/v) Me2SO the strongest viability loss was observed. Recovery 
remained constant between 60% and 70% (v/v) Me2SO. There was no notable 
difference between samples with a final concentration of 70% (v/v) Me2SO that were 
cooled to -60°C and directly rewarmed, and those cooled to -160°C and rewarmed after 
vitrification. An exception was LT run 4, for which viability decreased from 60% to 
13% after vitrification. The average viability after vitrification was 23 +/- 16%. The 
highest value was reached for LT run 1 with a remaining viability of 46% (Figure 4.16).  
-60
-50
-40
-30
-20
-10
0
0 10 20 30 40 50 60
T
em
p
er
at
u
re
 (
C
˚)
  
Me₂SO concentration (%, v/v) 
measured
literature
Chapter 4: Manual Liquidus Tracking 
120 
 
 
Figure 4.16 LT step-by-step (set-up 1) 
The scheme shows how viability decreased during the LT process after each Me2SO addition step. 
The figure shows four different runs. Experiment 3 was excluded from evaluation due to strong ice 
formation. Between 30% and 60% Me2SO most of the viablity was lost, but remained constant 
between 60% and 70% (v/v) Me2SO. Apart from LT run 4, full progress to vitrification did not 
have an effect on viability. The average viability after vitrification was 23 +/- 16% (n=4). The 
highest value was reached for LT run 1 with a remaining viability of 46%. AELC were cultured for 
24 hours in complete media at 37˚C before viability was assessed by FDA/PI staining. 
4.4.5 Liquidus Tracking step-by-step (set-up 1, 2 and 3) 
Set-up 2 and 3 were compared to results of set-up 1. As for the previous experiments, 
viability of set-up 2 remained constant until a concentration of 30% (v/v) Me2SO before 
starting to drop. For set-up 3 viability decreased continuously until a concentration of 
60% (v/v) Me2SO. For both set-ups (2 and 3) recovery remained constant between 60% 
and 70% (v/v) Me2SO and no additional decrease was recorded after vitrification. 
Viability after vitrification for set-up 2 and 3 was 44% and 23%, respectively (Figure 
4.17). 
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Figure 4.17 LT step-by-step set-up 1, 2 and 3 
The Figure shows the data of one run of set-up 2 and 3, the average of set-up 1 (n=4, +/- SD), and 
the overall average of all runs (solid line). Considerable variability was seen between runs; 
nevertheless viability dropped mostly between 30% and 60% Me2SO (v/v). Viability after warming 
for samples exposed to the final Me2SO concentration of 70% (v/v) was approximately 30% 
regardless of whether samples were cooled to -60°C or cooled and stored at -160°C. AELC were 
cultured for 24 hours in complete media at 37˚C before viability was assessed by FDA/PI staining. 
4.4.6 Liquidus Tracking step-by-step at 0.5°C. 
In this experiment LT was performed on ice (0.5°C) using LT set-up 2. Between each 
increase, samples were kept on ice for 15 minutes so that the incubation time in CPA 
would be comparable to LT set-up 2. Warming was performed in the same step wise 
manner described in section 4.3.3.4, but was carried out at 0.5°C. The experiment was 
intended to determine whether CPA toxicity decreased due to its stepwise addition of 
Me2SO (prevention of osmotic injury) or due to the temperature decrease. As seen 
before, recovery strongly reduced when the Me2SO concentration was increased to 40% 
(v/v). Contrary to manual LT performed at decreasing temperatures (4.4.5), at 50% (v/v) 
Me2SO most cells had died and there was no viability observed for cells that reached a 
final concentration of 60% and 70% (v/v) Me2SO (Figure 4.18).  
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Figure 4.18 LT step-by-step at 0.5°C 
The Figure shows data from 5 runs of set-up 2 carried out at 0.5˚C. Viability decreased to 4% +/- 3 
when AELC were incubated in 50% (v/v) Me2SO. No viability was detected for AELC incubated in 
60% and 70% (v/v) Me2SO. 
4.4.7 Liquidus Tracking temperature profile 
For each manual LT experiment (set-up 1, 2 and 3) the temperature curve was recorded 
using the Pico Logger software (Figure 4.19, Figure 4.20). A temperature increase of 
approximately +2°C was measured when cell strainers were transferred between 6-well 
plates (8ml PBS-Me2SO per well) while the freezer lid was held open (set-up 1). The 
temperature was increased by approximately +20°C when 2ml microfuge tubes with a 
volume of 1.5ml PBS- Me2SO solution were used. The average cooling rate until the 
starting temperature was reached was 7.51°C/minute (set-up 2). Set-up 3 showed an 
average temperature increase of 11.1°C. The average cooling rate until the starting 
temperature was reached was -2.94°C/minute. 
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Figure 4.19 LT temperature profile set-up 1 
The figure shows the recorded temperature increase during cell strainer transfer. Initial 
temperature indicates the sample temperature before cell strainers were transferred. Final 
temperature indicates the temperature of the solution into which cell strainers were placed 
(temperature was measured after transfer). The temperature difference between initial and final 
temperature was approximately +2°C. 
 
 
Figure 4.20 LT temperature profile set-up 2 and 3 
The figure shows the temperature increase during Me2SO addition for set-up 2 and 3. The 
temperature was increased by approximately 20°C when 2ml microfuge tubes with a volume of 
1.5ml PBS-Me2SO solution were used. The average cooling rate until the starting temperature was 
reached was -7.51°C/minute. Set-up 3 showed an average temperature increase of 11.1°C. The 
average cooling rate until the starting temperature was reached was -2.94°C/minute. 
-50
-30
-10
10
10 30 50 70 90
T
em
p
er
at
u
re
 (
°C
) 
Time (minutes) 
20% (v/v) Me₂SO 30% (v/v) Me₂SO 
40% (v/v) Me₂SO 50% (v/v) Me₂SO 
60% (v/v) Me₂SO 70% (v/v) Me₂SO 
30% (v/v) Me2SO 
initial temperature 
40% (v/v) Me2SO 
final temperature 
-50
-30
-10
10
0 20 40 60 80 100
T
em
p
er
at
u
re
 (
˚C
) 
Time (minutes) 
set-up 2
set-up 3
CPA increase -  
temperature increase 
Chapter 4: Manual Liquidus Tracking 
124 
 
4.4.8 Improved manual Liquidus Tracking 
We determined that manual LT set-up 3 was most practical. Nevertheless temperatures 
increased by up to 11°C during the addition of Me2SO. Applying an insolation system 
helped to decrease temperature variations. When Me2SO addition was carried out at 
2.5°C, -3.5°C and -13°C, the temperature increase was reduced by approximately 3°C, 
5°C and 6°C, respectively. At -25°C and -35°C the temperature increase was reduced by 
10°C and 13°C, respectively (Figure 4.21). By using the new stirrer made of a Pasteur 
pipette that uses pressure and suction by up and down movement, the mixing time for 
viscous solutions was reduced. This was tested by mixing 4ml of uncoloured and 1ml of 
coloured glycerol. Glycerol has a similar viscosity to Me2SO at -40°C. Mixing by 
conventional pipetting took 30 seconds to completely homogenize the sample, when 
using the new stirrer mixing was completed within 15 seconds. The sample CPA 
concentration reached with the new mixing technique, determined by refractometry, 
were 24.7% +/-1.0, 32.7% +/-1.7, 43.5% +/-0.4, 51.1% +/-0.8 and 62.3% +/-0.6 (n=6) 
and therefore within a range of +/- 4% of the target concentration of 25%, 35%, 45%, 
55% and 65% (Figure 4.22). 
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Figure 4.21 LT insolation system 
By insolating the sample tube with 70% (v/v) ethanol (TB insolation), the temperature increase 
during each CPA addition step was reduced. The grey dashed line demonstrates the freezer 
temperature curve, the red line the temperature curve of samples without TB insolation and the 
blue line the temperature curve of a sample with insolation system. Each condition was tested in 
triplicate. This figure shows as an example the temperature curve of one sample. The temperature 
increase was reduced from a: 7.1°C to 4.5°C, b: 7.9°C to 3.2°C, c: 7.7°C to 2.1°C, d: 14.5°C to 4.4°C 
and e: 17.8°C to 5.2°C.  
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Figure 4.22 Manual LT stirring device.  
By using the newly-developed  stirrer that uses pressure and suction by up and down movement the 
sample CPA concentration reached was within +/-4% of the target concentration of 25%, 35%, 
45%, 55% and 65% CPA (n=6, +/- SD). The concentration was measured by determining the 
refractive index. 
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4.5 Discussion 
The first aim of this chapter was to prove the Liquidus Tracking (LT) theory that 
cryoprotectant agent (CPA) toxicity can be reduced by lowering the temperature. At 
lower temperatures molecules move slower and therefore less collisions between 
molecules decrease the possibility of any chemical or biochemical reaction. It has been 
predicted that by every one degree Celsius drop in human body temperature, cellular 
metabolism slows by 5% (Erecinska et al., 2003)  and it was shown that for hibernating 
animals for which minimal body temperature can fall as low as -2.9˚C, the metabolism 
can be reduced to 1% of the euthermic rates (Carey et al., 2003). 
To determine the influence of the CPA exposure temperature on our cell system, 
alginate encapsulated liver cells (AELC) were incubated at increasing dimethyl 
sulfoxide (Me2SO) concentrations at decreasing temperatures. When exposed to 40% 
(v/v) Me2SO, viability dropped to almost 0% when the incubation was carried out at 
37°C, whereas recovery remained above 60% for samples that were kept at 4°C, but 
then dropped abruptly when the Me2SO concentration was increased to 50% (v/v). This 
was independent of time whether AELC were incubated for a period of 40 minutes or 6 
hours. The viability drop was further delayed by setting the incubation temperature 
to -10°C and -20°C. Up to 55% (v/v) Me2SO was well tolerated when AELC were 
incubated at -20°C. Apart from the mentioned reasons for reduced CPA toxicity in 
general, there might be further explanations for Me2SO in particular. Me2SO is known 
to easily permeate cell membranes (Anchordoguy et al., 1992) and it is strongly 
believed that Me2SO has the ability to replace water and solvate lipid headgroups 
(Gordeliy et al., 1998; Tristram-Nagle et al., 1998). A decrease in Me2SO concentration 
in the bilayer at lower temperatures has been observed and it has been suggested that 
Me2SO is more hydrophilic at lower temperatures. As a consequence less membrane 
dehydration might account for reduced Me2SO toxicity at lower temperatures (Sum & 
de Pablo, 2003). Me2SO can dissolve DNA at high concentrations and temperatures 
above 20ºC (Bonner & Klibanov, 2000) and oxidizes sulfhydryl groups (Snow et al., 
1975). Those effects can also be expected to reduce when temperature decreases.  
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Nevertheless reduced toxicity at lower temperatures does not assure effective 
vitrification, since sufficient CPA has to penetrate the cells to avoid ice nucleation 
before the temperature is further decreased. It is possible that in these experiments cells 
incubated at -10°C or -20°C did not reach the same intra-cellular Me2SO concentration 
as cells incubated at higher temperatures. For an optimized LT procedure it is therefore 
necessary to compromise between longer exposure time and higher exposure 
temperature to achieve sufficient CPA penetration, and a shorter exposure time at lower 
temperatures for minimum toxicity. 
Decreasing the incubation temperature further to -30°C, -40°C or -50°C was 
unfavourable with a lower recovery than at -20°C. An explanation could be the initial 
pre-incubation step at which cells were directly incubated in high concentrations of 
Me2SO (40-60 w/v %) for one minute at 0.5°C, to achieve some CPA pre-loading to 
avoid immediate freezing of AELC at the moment they were added to the pre-cooled 
Me2SO solutions (-30°C to -50°C). The exposure to high Me2SO concentrations, 
although only for one minute, possibly caused cell death by osmotic or chemical 
toxicity. When AELC were incubated in increasing  Me2SO concentrations at 0.5˚C 
over time, it was shown that one minute was sufficient to strongly exhibit Me2SO 
toxicity (AELC viability reduced by 45%) when the concentrations was 60% (v/v). 
However, concentrations up to 50% (v/v)  were well tolerated for one minute. Lower 
viability of AELC pre-incubated in 40% and 50% (v/v) Me2SO which were then added 
to more concentrated Me2SO solutions at temperatures below -20˚C could have been 
caused by insufficient  Me2SO penetration during the pre-incubation step. As a 
consequence, introducing the AELC bead solution to temperatures < -30°C would have 
initialized instant intracellular ice formation.  
Interestingly viability did not decrease slowly while the Me2SO concentration was 
increased, but usually dropped precipitously when a certain Me2SO concentration at a 
given temperature was reached. This would suggest a strong influence of osmotic 
pressure, which will be increased by both higher temperature and Me2SO concentration. 
The observation that the viability drop was independent of the exposure time if this was 
over 40 minutes, suggests a strong instant effect rather than progressive chemical or 
biochemical toxicity. Similar observations were made by Fahy (Fahy, 1982). In his 
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studies on rabbit renal cortex 40% Me2SO was toxic whereas 30% w/v Me2SO was 
completely nontoxic. 
To investigate the impact of osmotic stress a two-step Me2SO addition protocol was 
compared to a one step addition protocol. Upon addition of CPA, cells initially shrink as 
water leaves the cell by osmosis. Following this, cells swell as CPA crosses the cell 
membrane to enter the cell. This shrink and swell response occurs as cells possess 
increased permeability to water than solutes (Meryman, 2007; Paynter et al., 2005). The 
faster water is drawn out of the cell and the slower CPAs enter the cell, the more the cell 
will shrink. Currently several different theories of how osmotic injuries occur have been 
proposed. The minimum volume hypothesis suggests that upon shrinkage in hyper-
osmotic condition cytoskeleton components and the shrunken cell membrane 
irreversibly interact. This compromises cell integrity upon rehydration (Meryman, 
2007). The maximum cell surface hypothesis proposes that cell shrinkage induces 
irreversible membrane fusion and hence reduces the effective area of the cell 
membrane. When the cells are returned to isotonic condition, the cells lyse before the 
initial volume is regained as a result of the reduced membrane area (Steponkus & Wiest, 
1978). Stepwise CPA addition decreases the difference in solute concentration inside 
and outside the cell. As a consequence cells do not shrink or swell beyond their osmotic 
tolerance (Si et al., 2006) and hyperosmotic stress is decreased. Step-wise addition and 
removal of CPAs have been shown to significantly improve survival of various cell 
types including oocytes (Isachenko et al., 2004; Wang et al., 2010) and islets (de Freitas 
et al., 1998). 
When AELC were pre-incubated in 20% (v/v) Me2SO before adding them to 40% (v/v) 
Me2SO at 37°C recovery was significantly increased from approximately 21% to 45% 
for an incubation period of 15 minutes and from approximately 3% to 36% when 
exposure lasted for 40 minutes. Cells, which underwent the pre-incubation step, were 
exposed for five minutes longer to toxic Me2SO. However, these cells showed better 
recovery which can therefore be explained by decreased osmotic stress as a result of the 
stepwise increase of Me2SO. Contrary to this, no significant difference in recovery was 
observed between the two conditions when the incubation was carried out at 0.5°C, 
which would strongly suggest that osmotic stress for AELC is reduced at lower 
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temperature. This might come as a surprise since studies on oocytes have shown more 
shrink response and therefore higher osmotic damage at lower temperatures (Paynter et 
al., 2005). However, it has been reported that the conductivity of water and CPA is cell-
type and species specific (Si et al., 2006) and is likely to be different for tissue-like 
material. For example it has been reported that for lung fibroblasts (Rule et al., 1980) 
and human spermatozoa (Gilmore et al., 1995; Phelps et al., 1999) conductivity in the 
presence of Me2SO was half the value of cells in saline. However, in oocytes little or no 
difference was observed (Benson & Critser, 1994; Paynter et al., 1999; Paynter et al., 
1997). 
Another theory to explain the process of osmotic stress proposes that the extent of 
solution influx and efflux in the cell plays a major role. The rate of flux is directly 
dependent on the temperature of a given solution and has been approximated by the 
following equation: v = Lp ART(p), where Lp is the hydraulic conductivity, A the 
membrane surface area, R the gas constant, T the absolute temperature and p the 
difference in intra and extracellular osmolality. At lower temperatures the water flux 
rate will therefore be reduced which could reduce cell membrane damage caused by 
osmotic poration. This theory has been proposed by Muldrew and McGann in 1994, and 
states that strong water flux and frictional forces between water and potential membrane 
pores might damage the cell membrane (Muldrew & McGann, 1994). Although their 
idea was that the formation of pores is damaging as they allow ice crystals to grow 
inside the cell, the mechanism is often cited for osmotic injury in general. Another 
theory proposes that, as a result of hyperosmotic stress an influx of non-permeating 
solutes occurs. This leads the cells to swell beyond their normal isotonic volume and to 
lyse once they are returned to isosmotic conditions (Mazur et al., 1972). An influx of 
non-permeating solutes might be further enhanced by pores formed by osmostic 
poration. At lower temperatures, but also when CPAs are increased in a step-wise 
procedure, osmotic pressure and consequently the influx rate will be decreased. Thus, 
an influx of non-permeating solutes should be reduced. Work by Guan (Guan et al., 
2013) on precision-cut liver slices showed no effect when a gradient instead of a step-
wise loading/unloading protocol was used. Despite the reduction of osmotic stress, the 
viability of slices did not improve. Liver slices in their study and hepatocyte spheroids 
at low temperature in my experiments were not sensitive to osmotic changes. On the 
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other hand the time factor for AELC had a lower impact on viability than the final CPA 
concentration, possibly suggesting the level of dehydration as the main factor for CPA 
toxicity. It was noticed that cell viability after incubation in equal concentrations of 
CPA for the same length of time varied between experiments that were carried out on 
different days. AELC were used between 9-11 days of growths after encapsulation. 
Variations in average cell density and bead size might be responsible for varying CPA 
diffusion rates and thus for CPA toxicity. 
The second aim of this chapter was to investigate the practical challenges of manual LT 
and to establish an optimized and reliable manual protocol. The chosen CPA was 
Me2SO as it has been the CPA of choice for other recent LT studies (Pegg et al., 2006; 
Wang et al., 2007). Three test set-ups were tested and compared. To run a LT 
experiment the liquidus curve of the CPA solution has to be known. In this chapter the 
Me2SO liquidus curve was established by measuring the thermocouple defined 
approximate freezing point (TdAFP). Temperature values were equal to differential 
scanning calorimetry (DSC) measurements found in the literature for concentrations up 
to 20% (v/v) Me2SO (Elford, 1970; Farrant, 1965b). However, the sample temperature 
did not return the true equilibrium melting point when the concentration was increased 
to 30% and 40% (v/v) Me2SO. This can be explained by the chamber temperature, 
which will be lower than the sample temperature, and thus will cool the sample 
temperature below the equilibrium melting temperature. No peak of release of latent 
heat was detected for concentrations of 50% (v/v) Me2SO and above. Those samples 
contained low concentrations of water which meant that only small amounts of heat 
were released - too small to be detectable as samples were simultaneously cooled by 
low subzero freezer temperatures.  
DSC measurements use the melting curve to measure the equilibrium melting point and 
are more accurate. Therefore literature values were used to define the CPA transfer 
temperatures. Those were set 5˚C above the equilibrium melting point to avoid any 
freezing. The transfer temperature of solutions containing 40% (v/v) and more Me2SO 
were set +10˚C above the equilibrium melting point as they became otherwise too 
viscous for pipetting and mixing. Using the refractive index to measure the 
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concentration of Me2SO of a sample proved to be efficient and reliable. The coefficient 
of determination R
2
of the standard curve, fitted by linear regression, was >0.999.  
For set-up 1, AELC to be vitrified were transferred in a cell strainer from one well 
containing 8ml of CPA solution to the next, each with a higher CPA concentration at a 
lower temperature. A disadvantage of this set-up is that it is only suitable for tissue 
pieces, which can be transferred by using forceps or encapsulated cells of a unit size 
allowing them to be trapped by a suitable cell strainer in which the sample can be 
transferred. The first observation made was, that the cooling rate of the sample (as 
opposed to the chamber (-2°C/minute) became very low when the sample temperature 
approached  the next transfer temperature, which was caused by the thermal mass 
provided by the plastic of the 6-well plates and the CPA volume of 8ml. This was 
overcome by setting the temperature of the freezer -10°C below the sample temperature 
to be reached which led to a measured sample cooling rate of 
approximately -0.75°C/minute. However, to avoid any ice formation close observation 
of the sample temperature during cooling had to be maintained throughout the 
experiment which was done by recording temperatures from the thermocouples in 
dummy wells. A freezer holding time of 10 minutes at -10°C below the transfer 
temperature allowed enough time for the sample to reach the transfer temperature and to 
place all six cell strainers into the next plate. Cooling and holding time approximated 30 
minutes between each stepwise CPA increase. The length of the total incubation time 
was chosen on the basis of Pegg’s work on articular cartilage (Pegg et al., 2006). Cell 
densities of alginate encapsulated HepG2 liver cells are lower than those for articular 
cartilage and therefore it was assumed that sufficient time for CPA penetration was 
given.  
During first experiments random ice formation in some samples was visually noted, 
possibly caused by a carry-over effect each time the samples were transferred in cell 
strainers to the next higher CPA concentration. Surface adherence of lower concentrated 
CPA solution on the cell strainer will result in uncontrolled and successively increasing 
dilution of the CPA, which at worst might lead to ice formation as lower temperatures 
are reached. Ice formation could also have been caused from inhomogeneous heat 
transfer between wells as higher cooling rates were measured for those samples that 
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were positioned closer to the freezer ventilator. Mixing was not carried out for set-up 1 
because this would have taken too long (8ml/well) with a higher risk of sample 
warming as this step has to be done by opening the lid of the Planer freezer. As a 
consequence, inhomogeneous CPA distribution could also explain why some of the 
wells became partially frozen. In order to avoid any ice formation during the LT 
procedure, the transfer temperature was set 30% above the sample melting point, instead 
the initial offset of 20%. Reasons given for ice formation can also be listed as potential 
causes for sample to sample variability. Additionally, inadvertent and variable sample 
warming, when cell strainers are taken out of solution and placed in the next well can 
cause sample variability, depending on how fast the samples are transferred. 
Nevertheless, one can speculate that the sample temperature increase was low, as the 
transfer per cell strainer took less than five seconds, and the temperature of the solution 
the cell strainer was placed into only increased by approximately 2°C. 
For set-up 2, the CPA increase was achieved by adding a 20% more concentrated 
Me2SO solution to the sample. To maintain a constant volume, half of the solution was 
taken off after mixing was completed. As the volume had to be reduced, this set-up was 
only feasible for sample material that would accumulate at the bottom of the tube by 
gravity (in the time given until the next CPA addition step). The sample cooling rate 
was similar to the cooling rate of the freezer chamber when microfuge tubes and 
volumes below 1.5ml were used. To allow a diffusion period of approximately 30 
minutes, and, to provide a similar cooling profile as set-up 1, the freezer temperature 
was set on hold for 15 minutes once the average temperature between the starting and 
the transfer temperature was reached. Then an additional holding step was set at -5˚C 
below the transfer temperature, for seven minutes to reach the required temperature and 
to process the samples. As for set-up 1 a freezer cooling rate of -2°C/minute was chosen 
and the same transfer temperatures were used. The main advantage of set-up 2 was that 
samples were mixed during each step, which was important to provide homogenous 
CPA distribution. Another advantage of set-up 2 was that the sample remained within 
the same solution holder during the whole LT process which made it possible to record 
the temperature throughout the process. The main disadvantage of set-up 2 became 
evident: as the freezer chamber was opened to allow manual access whilst CPA 
concentration was changed, the temperature inside the freezer deviated rapidly, 
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affecting the temperature of the solutions kept inside the freezer. Extracting and adding 
half of the sample volume and the mixing process took time and therefore had a 
considerably impact on the sample temperature. During the CPA addition processes a 
temperature increase up to +20°C was measured by thermocouples placed inside the 
sample tubes.  
Set-up 3 is a variant of LT set-up 2 whereby only one highly concentrated CPA solution 
was used to make the stepwise required CPA concentration. However, since the final 
steps of LT require solutions in the range of 60% CPA, an extremely concentrated CPA 
(80% v/v) had to be added. The sample remained within the sample container 
throughout the process and the solution was mixed after each step as for set-up 2. One 
advantage of set-up 3 is that smaller volumes need to be added at each step, avoiding 
the problem of accumulating supernatant volumes, therefore the sample volume does 
not have to be reduced each time as for set-up 2. Several other advantages can be 
outlined for this approach: - as only one solution has to be added the accuracy of 
achieving the target CPA improves: there is no loss of cell material and the process is 
faster which means less sample-to-sample variability due to potential temperature 
variation. Sample volume (0.75ml to 4.5ml) and the property of the tube (15ml 
centrifuge tube) provided more thermal buffering against transient temperature 
fluctuation than set-up 2. This and the faster process explain why the average 
temperature increase during each CPA addition and mixing step was lower than for set-
up 2, at approximately +11°C. Using only one (two) solutions to increase the CPA 
concentration also simplified the process when different conditions within one run were 
being compared. A potential disadvantage of this approach is that highly concentrated 
CPA is added to the sample at relatively high temperatures which could be a problem 
for cells that are especially prone to osmotic stress and CPA toxicity, if the mixing is 
not processed quickly enough. As a compromise two different highly concentrated 
solutions were used; 60% for the first step and 80% for the final increase.  
In order to investigate at which step viability was mostly decreased during the LT 
procedure, step-by-step LT experiments were carried out. All three set-ups; 1, 2 and 3 
were tested.  Some samples were removed at each stage just before the next addition of 
Me2SO, and rewarmed for viability measurements, whilst the remaining cohort stayed 
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in the controlled rate freezer as the LT run progressed further. In the final step, the two 
remaining samples were slowly cooled down to -60°C. One sample was warmed up 
immediately; the other one was directly added to the vapour phase of liquid nitrogen 
and rewarmed after 3-7 days. A simplified reversal of the LT protocol was used to warm 
samples after cooling. The Me2SO was reduced from 70% to 50% at -20°C in a first 
step and was limited to a 20% concentration reduction for all subsequent steps. This 
seemed a reasonable approach, based on the observation that osmotic injury was 
strongly reduced at 0.5°C, although reverse osmotic stress could be more damaging as 
membranes change and become more brittle when they are exposed to low 
temperatures. 
Manual step-by-step experiments showed that viability was decreased after each LT 
step, and thus the results did not indicate a specific concentration at which viability was 
primarily reduced. Still, the data suggests that viability is mainly reduced between 30% 
and 60% (v/v) Me2SO but is kept constant between 60% and 70% (v/v) Me2SO, 
regardless of whether samples are cooled down to -60°C and immediately re-warmed or 
stored at -160°C and subsequently rewarmed. The experiments showed that cell 
viabilities can be ~30% after achieving the vitrified state and reversal via LT. 
Concentrations of 60% and 70% (v/v) Me2SO were reached at very low temperatures  
(< -25°C) and it could be hypothesized that at these low temperatures, the Me2SO influx 
is limited which means that full intracellular Me2SO concentrations of 60-70% (v/v) 
might not have been achieved (which could explain higher consistency between these 
steps). In this respect, cells that survived the LT process until the final increase to 70% 
(v/v) Me2SO seem to have achieved sufficient Me2SO penetration to be vitrified. This 
could of course also be brought about by the high viscosities of the Me2SO mixture 
acting to kinetically inhibit ice crystal formation, and the parallel extreme osmotic 
dehydration of the cells which also prevented organisation of any residual water 
molecules into ice nuclei. High variability between experiments can be partially 
explained by temperature profile variations and CPA concentration differences between 
samples resulting from the different manual approaches to achieving LT and handling 
variability. Divergent CPA concentrations across the LT steps could have resulted from 
pipetting difficulties with the highly viscous higher CPA solutions, and ‘carry over’ 
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effects in those experiments where samples were physically moved between different 
Me2SO mixtures.  
Manual LT set-up 3 was performed on ice (0.5°C) to determine whether the LT protocol 
decreased CPA toxicity due to its stepwise addition of Me2SO (prevention of osmotic 
injury) or due to the temperature decrease. Viabilities after “manual LT” at 0.5°C were 
similar to those seen in previous experiments, when AELC were directly incubated in 
increasing concentrations of Me2SO for 40 minutes at 4˚C. Recovery was strongly 
reduced at 40% and 50% (v/v) Me2SO and no viability was observed when cells were 
incubated in 60% and 70% (v/v) Me2SO. Contrary, AELC exposed to 70% (v/v) Me2SO 
and vitrified following manual LT at decreasing temperatures reached viabilities of 
approximately 30%. This suggests that stepwise CPA addition to reduce osmotic stress 
during LT has only a minor influence on CPA toxicity. Instead, CPA exposure at low 
temperatures might reduce intracellular Me2SO concentration or/and dehydration and 
therefore increase cell recovery.  
Manual LT set-up 3 was most practical. Nevertheless heat fluctuation during the CPA 
addition process was observed. The increase in sample temperature was especially 
strong at lower temperatures. This was mainly caused by a prolonged mixing procedure 
due to increasing sample viscosity and the larger volumes that had to be mixed. To 
provide a more reliable process each LT container (15ml centrifuge tube) was externally 
suspended within a 70% ethanol solution held in a 50ml centrifuge tube. By using the 
described ‘thermal buffer- jacket - TB’ for insolation, the temperature fluctuation during 
CPA change was reduced from a maximum of +18°C (CPA addition at -35°C) to less 
than + 5°C. When first developing the insolation system the following was considered: 
the solution used for TB should not freeze during the cooling process as this would 
affect the cooling rate of the LT sample itself due to altered heat capacities. Also the TB 
solution should remain liquid so that the LT sample tube could be taken out from the 
TB at the end of the run and stored in liquid nitrogen. Additionally, the TB system 
should be as symmetrical as possible to allow a homogenous cooling profile throughout 
the entire volume. The TB carrier solution should be as low toxic as possible for 
handling purposes, and the TB system had to be of a size that could fit within a 
controlled Planer Kryo -10 freezer. It was important that the sample cooling rate during 
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CPA addition or reduction was affected as little as possible, while the TB insolation 
should maintain the same temperature for several minutes in an altered environment 
until the CPA change has been processed. Other combinations of TB carrier solutions 
and tubes with better thermal buffering abilities might be used. Nevertheless this could 
lead to lower sample cooling rates causing longer runs and therefore longer exposure 
times to CPAs and cold temperatures. Using a Pasteur pipette to mix the samples after 
each addition step became especially complicated at low temperatures due to the 
increase in CPA viscosity.  To overcome this problem a stirrer was designed that uses 
suction and pressure by up and down movement. For this a Pasteur pipette was used as 
the material of the Pasteur pipette is inert to most reagents. This was important to assure 
that as little as possible of the sample solution would stick to the stirrer after mixing to 
avoid any loss of material as this would change the target CPA concentration. The 
diameter of the top part of a Pasteur pipette is just slightly smaller than the diameter of a 
15ml centrifuge tube. By cutting the top and the border a device was made that could be 
introduced into a 15ml centrifuge tube. The small space between tube and stirrer border 
and the up and down movement of the stirrer enabled mixing by pressure and suction. 
To maximize the mixing effectiveness several different designs were created by cutting 
more or less of the top and the border of the Pasteur pipette. For example, if the border 
remains uncut, the pressure is too high and it becomes very difficult to move the stirrer. 
By using the new stirrer the time needed to mix viscous solutions was reduced, an 
important measure to maintain the sample temperature during CPA concentration 
change. Also when mixing is carried out by pipetting, there is a risk that sample solution 
remains in the top of the Pasteur pipette. Although a small amount of sample solution 
sticks to the stirrer, the impact was acceptable as the CPA concentration after mixing 
was in a range of +/- 4% of the target concentration. 
Additionally, handling variability can be compensated for by testing a higher number of 
samples. However, the maximum number of samples that can be processed during one 
LT run has to be limited to maintain similar sample warming and incubation times for 
all the processed samples.  Thus, in the present manual LT feasibility study, it was 
found that a maximum of eight samples per experiment, which can all be housed in the 
chamber of a Kryo 10 cooler and processed within two minutes, including CPA 
addition and mixing, should not be exceeded. 
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4.6 Conclusion 
In summary experiments proved the Liquidus Tracking (LT) principle that 
cryoprotectant agent (CPA) toxicity can be reduced by decreasing the temperature. 
Further experiments led to the assumption that chemical toxicity has a higher impact on 
cell viability than osmotic pressure. 
 LT by manual protocols has been shown to be a complex and lengthy procedure. Some 
of the complications that were observed for manual LT may not apply for an optimized 
automatic approach, which would minimize inhomogeneous dimethyl sulfoxide 
(Me2SO) concentrations and temperature fluctuations during Me2SO changes. 
Moreover the Me2SO concentration will potentially be increased in smaller steps and 
therefore toxicity should be further reduced. In addition, by its nature, manual LT is 
complicated and can result in high variability. Nevertheless, this approach offers the 
possibility of testing several conditions at the same time and can therefore be used to 
pre-test different LT factors before being taken forward to automatic LT. Improvements 
made for manual set-up 3 may further increase post-warming cell recoveries. 
The possibility to further reduce CPA toxicity by using combination of penetrating and 
non-penetrating CPAs instead of Me2SO as a sole reagent will be explored in the next 
chapter.
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5 CHAPTER 5 
Cryoprotectant agent development 
5.1 Introduction 
Manual Liquidus Tracking (LT) experiments (Chapter 4) have shown that high 
concentrations of dimethyl sulfoxide (Me2SO) are highly toxic for alginate encapsulated 
liver cells (AELC) even at low temperature. As it was conceivable that high Me2SO 
toxicity would also occur in an optimized automatic LT process, additional possibilities 
of cryoprotectant agent (CPA) reduction had to be identified. 
5.1.1 Cryoprotectant agent (CPA) toxicity 
Several other methods are known for reducing CPA toxicity; for example by decreasing 
the final CPA concentration and the exposure time to toxic CPAs. However, lower 
concentrations of CPAs bear a higher risk of ice nucleation before reaching the glass 
transition range. Effective vitrification is normally achieved once the homogeneous 
nucleation temperature (Th) falls below the glass transition temperature (Tg). Ice 
nucleation can be prevented to some extent and on a kinetic basis by either applying 
high hydrostatic pressure (Fahy et al., 1984) or by increasing the cooling rate. Both 
methods decrease the homogenous nucleation temperature, which means that nucleation 
is more likely to occur at a lower temperature. In order to increase the cooling rate, 
which consequently also decreases the exposure time to toxic CPAs, normally the 
sample volume has to be decreased since the minimum temperature that can be reached 
in a standard laboratory is that of liquid nitrogen (-196˚C). To decrease the sample 
volume and to increase the heat transfer, thin straws have been used (Jondet, 1965). 
More recently, promising results have been gained by adding small drops of sample 
directly to liquid nitrogen (Leunufna & Keller, 2003) or using holders such as cryo-
loops (Mavrides & Morroll, 2002). However, both high hydrostatic pressure and high 
cooling rates are inapplicable for an open, high volume system, such as LT. 
A more feasible way to reduce CPA toxicity for our purpose is by using CPAs other 
than Me2SO or by using combinations of various CPAs. Combinations of CPAs have 
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proven to be less toxic than the use of a single CPA (Jomha et al., 2010). It has even 
been shown that the toxicity of formamide can be reduced by the addition of Me2SO 
(Fahy, 2010) and that Me2SO toxicity can be reduced by the addition of sugars (Clark et 
al., 1984). 
Secondly, toxicity of the vitrification solution can be reduced by partially replacing 
penetrating CPAs with non-penetrating CPAs. This procedure is limited for use with 
mammalian cells, as some penetrating CPAs are essential in any vitrification protocol. 
The combination of 40-50% (w/v) penetrating and up to 10% (w/v) non-penetrating 
CPA has shown effective vitrification properties and decreased toxicity (Fahy et al., 
1984; Kuleshova et al., 1999). Also, evidence exists that CPA toxicity can be decreased 
by using a different vehicle solution, for example by replacing sodium with choline 
(Wusteman et al., 2008). 
5.1.2 Viscosity; the limiting factor for a CPA solution for Liquidus Tracking  
Viscosity is the first limiting factor for the development of a new LT CPA solution 
because highly viscous material cannot be pipetted or mixed effectively which is 
important for accurate manual LT. On the other hands, Liquidus Tracker pumps are 
unable to operate at viscosities much higher than 934mPa*s. This is the viscosity of 
glycerol at room temperature and is comparable to 70% (w/v) Me2SO at -40˚C, which is 
the concentration and the temperature the automatic Liquidus Tracker stops pumping 
and stirring (S. Butler, personal communication Planer). It was essential for the 
development of the stirring and pump system of the Liquidus Tracker that experiments 
were carried out at room temperature and therefore, due to its similar viscosity to 
Me2SO at -40˚C, glycerol was used.  
5.1.3 CPA concentration for Liquidus Tracking 
Combinations of 40-50% (w/v) penetrating CPAs with 10-20% (w/v) non-penetrating 
CPAs have been largely successful for small volumes when rapid vitrification (by 
plunging into LN) and fast warming (RT) rates could be applied. Nevertheless, for 
bulky samples, a final CPA concentration of 50-60% (w/v) used in these protocols 
(Table 5.4) could be too low to prevent the formation of “double stable glasses” and re-
crystallisation during the warming process (Angell, 1981; Boutron & Kaufmann, 1979). 
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Therefore, it was concluded that LT CPA development should be based on 60-70% 
(w/v) total CPA concentration with the option to reduce the final CPA concentration if 
vitrification properties remained unaffected. 
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5.2 Aims 
The aim of Chapter 5 was to develop a CPA solution that has low toxicity for AELC but 
is also of relatively low viscosity at low temperatures so that it can be used in a liquidus 
tracking procedure. It was also important to test the vitrification properties of the new 
CPA solution to estimate whether the vitrified state can be reached within a reasonable 
concentration of approximately 65% (w/v). Finally, the liquidus curve of the new CPA 
solutions had to be determined.  
 
Chapter 5: Cryoprotectant agent development 
143 
 
5.3 Methods and Materials 
5.3.1 CPA toxicity test 
Materials 
1xPBS with Mg
2+
 and Ca
2+
 (Sigma, Cat. No. D8662) 
Me2SO (Sigma, Cat. No. 154938) 
D+ Trehalose (Sigma, Cat. No. T95531) 
D+ Raffinose (Sigma, Cat. No. 83400) 
D+ glucose (Sigma, Cat. No. 66152) 
D- Fructose (Sigma, Cat. No. F3510) 
Sucrose (BDH, Cat. No. 102745C) 
Ethanol (Fisher Chemicals, Cat. No. E/650DF/17) 
Methanol (AnalaR Normapur, Cat. No. 2084730) 
Propylene Glycol (Sigma, Cat. No. 134368) 
Ethylene Glycol (Sigma, Cat. No. 293237) 
Alginate encapsulated liver cells (8-11 days after encapsulation) 
Method 
To evaluate the toxicity of a CPA solution a two-step protocol was used to reduce 
potential osmotic injury. A volume of 0.25ml settled beads (AELC), were incubated in a 
30% (w/v) CPA solution first for five minutes at room temperature and then for an 
additional five minutes at 0.5°C (tubes in ice-water). The concentration was increased to 
60% (w/v) CPA using a 70% (w/v) pre-cooled (at 0.5°C) CPA solution (Table 5.1). 
Beads were incubated for 20 minutes at 0.5°C. By adding 1xPBS the CPA concentration 
was reduced to 30% (w/v). Samples were left on ice for five minutes. Thereafter 
samples were washed twice with 4ml of 1xPBS. Finally AELC were incubated in 
complete media for 24 hours before viability was measured. 
Table 5.1: CPA toxicity pipetting scheme 
 total volume (ml) to come up with 
70%(w/v) 
CPA to be added (ml) 
 1.30 30% (w/v) CPA   1 
extract 1.3ml 1.00 60% (w/v) CPA 3 
final volume 4.00   
Chapter 5: Cryoprotectant agent development 
144 
 
5.3.2 Viscosity rating of new CPA solutions 
Materials 
as in section 5.3.1 
Controlled Rate Freezer (Planer, Kryo 10, Series II) 
Method 
CPA solutions with a final CPA concentration of 70% (w/v) were prepared using Sigma 
1xPBS (+Mg
2+
, Ca
2+
) as a carrier solution. Solutions were cooled to -40°C and viscosity 
was mechanically tested by pipetting solutions up and down using a 1ml pipette. This 
allowed a ranking based on applying a standardised suction and pressure (delivered by 
the barrel of the pipette) to raise the solution to a standard height (defined by the 
geometry of the pipette tip). As a reference solution 70% (w/v) Me2SO was used, as this 
was the standard solution for developing the automatic Liquidus Tracker. A viscosity 
rating was assigned as follows: 1 = similar to the reference condition (70% (w/v) 
Me2SO), easy to pipette; 2 = pipetting not possible but can be easily stirred; 3 = very 
viscous, pipetting and stirring very difficult; 4 = pipetting and stirring not possible, 
almost solid. 
5.3.3 Viscosity measurement  
Materials 
as in section 5.3.1 
Control Bohlin CVO automated shear rheometer  
Method 
The viscosities were determined using a Bohlin CVO automated shear rheometer. This 
type of rheometer measures the friction resistance caused by a liquid placed between a 
horizontal plate and a graduated cone spinning plate. For more viscous material more 
force is needed to reach the programmed rotational speed (rpm) of the spinning plate. 
Experiments were conducted at room temperature and the shear stress (s
-1
) was 
increased by 10 rpm every 10 seconds, from 10 to 250 rpm. The viscosity of each 
sample was obtained by calculating the average viscosity for shear rates between 10 and 
250 rpm. Two independent samples of each solution were tested.  
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5.3.4 Standard vitrification protocol 
Materials 
as in section 5.3.1 
Controlled Rate Freezer (Planer, Kryo 10, Series II) 
Method 
To evaluate the vitrification properties of a CPA solution a two-step protocol was used 
in order to reduce potential osmotic injury. Therefore 0.25ml settled beads (unless 
otherwise stated: 8-11 days after encapsulation) were incubated in a 31.5% (w/v) CPA 
solution first for five minutes at room temperature and then for an additional five 
minutes at 0.5°C (tubes in ice-water). The CPA concentration was increased to 63% 
(w/v) using a 70% (w/v) pre-cooled CPA solution (at 0.5°C). Samples were left on ice 
for five minutes and then plunged into liquid nitrogen. Samples were warmed for 
approximately eight minutes until they reached a liquid state. By adding ice cold 1xPBS 
(+Mg
2+
, Ca
2+
) the CPA concentration was reduced to 31.5% (w/v). Samples were left on 
ice for five minutes before washing twice with 4ml 1xPBS (+Mg
2+
, Ca
2+
). Finally, 
AELC were incubated in complete media for 24 hours before measuring viability. 
5.3.5 Equilibrium melting point measurements by Differential Scanning 
Calorimetry 
Materials 
as in section 5.3.1  
Q2000 Calorimeter (TA Instruments) 
High volume stainless steel pans 
Universal Analysis software (TA Instruments) 
Crimper 
Method 
Differential Scanning Calorimetry (DSC) is used to measure the energy flow to and 
from a sample during a temperature controlled program. In this way exo- or 
endothermic reactions, such as glass transitions, melting and nucleation events can be 
identified. A sample of known mass is added to a sealed capsule, the pan. Another pan, 
the reference pan, remains empty. Both pans are subjected to a cooling and heating 
cycle over the temperature range of interest whilst the temperature of both pans is 
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recorded. The energy required to keep both sample and control at the same temperature 
is plotted on a DSC trace against the temperature (°C) of the program, allowing thermal 
properties to be observed. For this study, modulated DSC (mDSC) was used, which is a 
technique whereby a sine wave modulation is introduced on top of a linear heating rate. 
By applying this, small thermal events can be identified even at relatively rapid heating 
rates.  
Each sample pan was loaded with 80µl of CPA solution. Before the addition each pan 
was weighed. Pans were then crimped, reweighed, sample mass calculated and the 
values entered into the software. The reference pan and sample pans were loaded onto 
the calorimeter in an auto-sampler. Analysis was carried out at 5°C/minute with a 
modulation of 1°C/minute. Data was analysed using the TA Universal Analysis 
software. Solutions were prepared in triplicate of which each was measured in duplicate. 
5.3.6 Improved manual LiquidusTracking 
The CPA concentration was increased by adding small amounts of highly concentrated 
CPA to 15ml centrifuge tubes containing AELC as given in Table 5.2. The cooling 
protocol is shown in Table 5.3. For both CPA solutions, Me2SO and No.18, the same 
protocol was followed and both solutions were tested within the same run. The 
improved manual LT system described in Chapter 4 was followed, with some 
modifications in order to simplify the procedure, and were as follows. The first increase 
to 25% (w/v) CPA was carried out on ice by adding 1ml of 50% (w/v) CPA solution to 
1ml of settled beads. The volume was decreased to 1.2ml before adding sample to a 
precooled chamber (at -3.5˚C).  
Table 5.2 Amount of 80% CPA required to increase the sample CPA concentration by increments 
of 10% 
Initial CPA (%) 
Initial 
Vol. (µl) 
Vol. (µl) of 80% CPA to 
add 
Target 
CPA (%) 
25 1200 267 35 
35 1467 419 45 
45 1886 754 55 
55 2640 1485 64 
final vol. 3925   
formula to determine the amount of 50% (80%) CPA to be added: B=(A*c-A*a)/(b-c) with B=volume of 
80% CPA to add, A=start vol., c= final CPA concentration, a=start CPA concentration, b=80% CPA 
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Table 5.3 Me2SO  and mixed CPA transfer temperatures 
*transfer temperatures were determined empirically, as viscosities at colder temperatures have been 
shown to be too difficult to handle. 
5.3.7 Most commonly used CPAs for vitrification 
In PubMed 41 review papers about vitrification were studied of which eight included 
technical information and references of further technical papers. The most commonly 
and successfully used penetrating CPAs mentioned in these papers were dimethyl 
sulfoxide (Me2SO), glycerol, ethylene glycol (EG), propylene glycol (PG) and 
formamide. In most protocols the disaccharide, sucrose, was used as a non-penetrating 
CPA. For the vitrification of hepatocytes the combination of 40% (v/v) EG and 0.6M 
sucrose has been shown to be especially successful (Kuleshova et al., 2004; Magalhães 
et al., 2009). Vitrification protocols including CPAs, cooling and warming protocols 
and cell type are summarized in Table 5.4. 
 
% (w/v) CPA from: Transfer temperature Freezer holding temperature 
25 to 35 -3.5°C -8.5°C 
35 to 45 -13°C -18°C 
45 to 55 -25°C* -30°C 
55 to 64 -30°C* -35°C 
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Table 5.4 Summary of vitrification protocols 
CPA Cell type Cooling, Warming Viability Article 
Me2SO, Propylene 
Glycol, Glycerol (Li 
et al., 1990) Sucrose, 
Ficoll  
Human 
blastocytes  
cooling: to LN                         
warming at 37°C  
Depending on 
blastocyte type and 
protocol  
(Kader et al., 
2009)  
40% (v/v) Ethylene 
Glycol, 0.6M Sucrose  
Mouse 
NSCs  
cooling: to LN  >99%  (Kuleshova et 
al., 2009) 
2M Me2SO, 1M 
Acetamide, 3M 
Propylene Glycol  
Human 
ESCs  
cooling: to LN                       
warming at 37°C                
Container volume 200µl  
12.2% normal 
morphology and 
karyotype  
(Fujioka et al., 
2004) 
3.1M Me2SO, 3.2M 
Formamide, 2.21M 
Propylene Glycol in 
EuroCollins solution  
Rabbit 
cartilage  
 six sequential 15 min 
steps of CPA addition, 
then fast cooling (-
43°C/min) to -100°C, 
then slow cooling to 
3°C/min to -135°C. 
Warming: slow 
(30°C/min) to -100°C 
then fast 225°C/min)    
Container volume : 2ml  
No significant 
difference in the 
performance of 
fresh and 
cryopreserved 
cartilage, 
successful 
transplantation, no 
immune reaction  
(Song et al., 
2004) 
40% (v/v) Ethylene 
Glycol,  0.6 M 
Sucrose  
Hepatocytes  Gradual increase of 15% 
CPA cooling: 
400°C/min, warming: 
650°C/min  
Almost 100% 
retention of cell 
function  
(Kuleshova et 
al., 2004) 
CPA screen: best 
CPA combination: 
20% EG, 20% Me2SO 
10% 1,3-butanediol 
(v/v)  
Mouse 
blastocytes  
Equilibrated for 3 min at 
RT in 25% CPA conc. 
then directly to LN. 
Warming in a water bath 
at 20°C (in straws)  
96.2% 
developmental rate 
after 24 hours  
(Valdez et al., 
1992) 
VS1: 40% EG (v/v), 
0.6M Sucrose)                       
VS2: same as VS1 + 
9% (w/v) Ficoll: 
shown that 
1,2Propanediol is not 
better than EG  
Rat 
Hepatocytes  
Pre-equilibration in 10%,  
25% EG (each 3min) 
before exposure to VS1 
or VS2-then to LN, 
warming at 38°C  
N/A  (Magalhães et 
al., 2009) 
14% Me2SO, 14% 
Formamide, 17% 
Propylene Glycol, 
10% colloid (w/v)  
Rabbit 
kidney  
Vitrification with cooling 
rate<10°C/min  
50% of rabbit 
kidneys tolerate 
perfusion at -25°C 
with VS4A1  
(Arnaud et al., 
2003)  
72% Me2SO (w/v)  Articular 
cartilage 
(lambs)  
Liquidus Tracking  Functionality 60%  (Wang et al., 
2007)  
20% Me2SO, 20% 
EG, 0.5M Sucrose  
Human 
embryonic 
stem cells  
In a straw to LN 
warming at 37°C  
All clumps 
revcovered  
(Reubinoff et 
al., 2001)  
5.3.8 Viscosity of commonly used Cryoprotectant agents 
Viscosity data of some known penetrating CPAs and sugars at different concentrations 
and temperatures were compared (Table 5.5 and Table 5.6) in order to develop a CPA 
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solution with a comparable viscosity to 70% (w/v) Me2SO. Table 5.5 informs about 
molecular structure, weight, and specific density. 
Table 5.5 Specifications of penetrating CPAs 
Name 
Mol. 
Formula 
Structure 
Mol. 
Weight 
Specific 
Density 
Viscosity 
(mPa*s) 
Methanol CH4O 
 
32.04 0.787 0.54 
N,N-
Dimethyl-
formamide 
(DMF) 
C3H7NO 
 
73.09 0.945 0.79 
Water H2O 
 
18.02 0.999 0.89 
Ethanol C2H6O 
 
46.07 0.787 1.07 
Dimethyl 
sulfoxide 
(Me2SO) 
C2H6OS 
 
78.13 1.095 1.99 
Formamide CH3NO 
 
45.04 1.129 3.34 
Ethylene 
glycol 
C2H6O2 
 
62.07 1.111 16.1 
1,2-
Propanediol 
(propylene 
glycol) 
C3H8O2 
 
76.1 1.033 40.4 
1,3-
Butanediol 
C4H10O2 
 
90.12 1.002 98.3 
Glycerol C3H8O3 
 
92.09 1.257 934 
Data from Thermophysical Properties of Chemicals and Hydrocarbons, Carl L. Yaw, William Andrew, 
Norwich, NY, 2008 
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Table 5.6 Viscosity of sugars at different concentrations and temperatures  
Data from Migliori et al.2007, *Curme and Johnston 1952 
5.3.9 CPAs for Liquidus Tracking 
Formamide is highly corrosive and can be deadly if ingested. Dimethyl formamide is a 
possible carcinogen, and has been associated with birth defects. Both reagents are 
categorized as toxic by the European Dangerous Substances Directive and therefore 
were regarded as too hazardous for the cryopreservation of a biomass to be used in a 
bioartificial liver device that will be connected to a patient. The CPAs 1,3-Butandiol 
and glycerol are already highly viscous at room temperature and would become too 
viscous at low subzero temperature to be used in a LT procedure. Propylene glycol (1,2-
Butandiol) was chosen, despite its high viscosity, due to its very good vitrification and 
stabilization properties (Boutron & Kaufmann, 1979). High molecular weight non-
penetrating CPAs like dextran, polyethylene glycol and ficoll were rejected due to their 
high viscosities and were also deemed unnecessary since sugars have been shown to be 
successful non-penetrating cryoprotectants. Sugars are well tolerated even at high 
concentrations and can be used to partially replace penetrating CPAs without 
substantially modifying the vitrification properties of the solution (Kuleshova et al., 
1999). Methanol and ethanol were tested because of their low viscosity despite the fact 
that only few papers refer to them as useful CPAs. 
Sugar/water (w/w) Viscosity (mPa*s) 
10% Fructose at 20°C 1.43 
10% Fructose at 0°C 2.89 
20% Fructose at 20°C 2.09 
30% Fructose at 20°C 3.07 
10% Glucose at 20°C 1.58 
10% Glucose at 0°C 2.78 
20% Glucose at 20°C 2.13 
30% Glucose at 20°C 3.46 
10% Sucrose at 20°C 1.48 
10% Sucrose at 0°C 2.98 
20% Sucrose at 20°C 2.38 
30% Sucrose at 20°C 3.46 
30% Propylene glycol at 20°C 2.7* 
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5.4 Results 
5.4.1  Methanol vs. ethanol as penetrating low viscosity CPAs 
High concentrations of dimethyl sulfoxide, ethylene glycol, propylene glycol and sugars 
at low sub-zero temperatures can become too viscous to be used for LT. Methanol and 
ethanol are both of much lower viscosity and could therefore offer a means to reduce 
the viscosity by partially replacing high viscous CPAs. Significantly higher viability 
was obtained when methanol was used instead of ethanol in a mixture of 
Me2SO/glucose/ethanol or methanol in a ratio of 5/1/1, regardless of whether the final 
concentration was 60% or 70% (w/v). Hence, methanol was used to reduce viscosity of 
potential CPA mixtures in further experiments (Figure 5.1).  
 
 
 
 
 
 
 
 
 
Figure 5.1 Toxicity test methanol vs. ethanol 
AELC were incubated for 20 minutes at 0.5°C in 60% (w/v) and 70% (w/v) final CPA 
concentration using a step-wise CPA addition and reduction process (5.3). AELC were cultured for 
24 hours in complete media at 37˚C before measuring viability by FDA/PI staining. The 
combination of Me2SO/glucose/ethanol (ratio 5/1/1) showed significantly higher toxicity than the 
same combination with methanol. Data are n=5 +/- SD. **p<0.01, *<0.05. 
5.4.2 Testing different sugars and sugar combinations 
The addition of 10% (w/v) sugar (glucose, fructose, raffinose, sucrose, trehalose) to 
50% (w/v) Me2SO had a strong impact on cell viability when AELC were incubated for 
20 minutes on ice in different CPA mixtures. The viability of AELC incubated in 50% 
(w/v) Me2SO without sugar decreased from 90% +/- 2.15 (n=3), untreated AELC to 
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4.9% +/-3.56 (n=3). The addition of 10% (w/v) of any sugar to 50% (w/v) Me2SO 
increased cell viability markedly by up to 50% although the final CPA concentration 
was increased to 60% (w/v). Results suggest that the combination of two sugars 
(average viability of 60% +/-4.36 (n=10)) was more beneficial than the use of a single 
sugar (average viability of 51% +/-3.15 (n=5)). Otherwise, viability within the two 
groups was comparable. The highest average viability for the group of individual sugars 
was reached with glucose, yielding 58% +/- 6.1 (n=3). In the group of two sugars the 
highest viability value was reached with the combination of sucrose and fructose 
reaching 66% +/-9 (n=3). However, in both cases the difference within the group was 
not significant (Figure 5.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 Sugars and sugar combination as non-penetrating CPA 
AELC were incubated in 50% (w/v) Me2SO (white) or 50% (w/v) Me2SO plus 10% (w/v) sugar, 
either of one single sugar (grey) or two different sugars (black). AELC were incubated for 20 
minutes at 0.5˚C, using a step-wise CPA addition and reduction procedure (5.3). AELC were 
cultured for 24 hours in complete media at 37˚C before measuring viability by FDA/PI staining. 
Data were n=3 +/- SD. Viability obtained with 50% (w/v) Me2SO (n=3 +/- SD) was significantly 
lower than with solutions containing one sugar (grey dotted, average of single sugar solutions, n=5 
+/-SD) or two sugars (black dotted, average of two sugar solutions n=10 +/-SD). One sugar (grey 
dotted) resulted in significantly lower viability than solutions with two sugars (black dotted) 
***p<0.001, **p<0.01.  
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5.4.3 Viscosity rating of candidate CPA combinations 
The viscosities of 21 combinations of penetrating CPAs (Me2SO, EG, PG) with the non-
penetrating CPA glucose were compared to the reference solution of 70% (w/v) Me2SO 
(Table 5.7). Viscosity comparison was carried out by using a simple mechanical 
procedure described in section 5.3.2. It was predicted that at least 40% (w/v) penetrating 
CPAs and a maximum total concentration of 70% (w/v) CPA should be used to obtain 
sufficient vitrification for large volumes and slow cooling rates (>10˚C/min) as 
explained in section 5.1.3. Glucose was chosen as the non-penetrating CPA as it gave 
the highest viability within the group of individual sugars. Only the condition with 60% 
(w/v) Me2SO and 10% (w/v) glucose showed a similar viscosity to 70% (w/v) Me2SO 
and was rated with “1” (easy to pipette at -40˚C). Combinations with high amounts of 
glucose and PG were more viscous than those which contained mainly EG and Me2SO. 
Out of the 20 solutions tested, eight were rated with “2” (difficult to pipette at -40˚C), 
11 were rated with “3” (difficult to stir at -40˚C), and one was rated with “4” (not 
possible to stir). The last contained the highest amount of PG which is of much higher 
viscosity than Me2SO and EG (Table 5.5) and comparable to the viscosity of glucose 
(Table 5.6).  
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Table 5.7 Viscosity rating part 1: The viscosity of 21 combinations of penetrating and non-
penetrating CPAs tested at -40°C 
Penetrating CPA (single) Non-penetrating CPA Viscosity rating 
40% CPA 30% Glucose   
40% Me2SO 30% Glucose 2 
40% EG 30% Glucose 3 
40% PG 30% Glucose 3 
50% CPA 20% Glucose   
50% Me2SO 20% Glucose 2 
50% EG 20% Glucose 2 
50% PG 20% Glucose 3 
60% CPA 10% Glucose   
60% Me2SO 10% Glucose 1* 
60% EG 10% Glucose 2 
60% PG 10% Glucose 4 
70% CPA 0% Glucose   
70% Me2SO 0% Glucose 1* 
Penetrating CPA (combination) Non-penetrating CPA Viscosity rating 
40% CPA 30% Glucose   
20% Me2SO, 20% EG 30% Glucose 3 
20% Me2SO, 20% PG 30% Glucose 3 
20% EG, 20% PG 30% Glucose 3 
13.3% Me2SO, 13.3% EG, 13.3% PG 30% Glucose 3 
50% CPA 20% Glucose   
25% Me2SO, 25% EG 20% Glucose 2 
25% Me2SO, 25% PG 20% Glucose 3 
25% EG, 25% PG 20% Glucose 3 
16.7% Me2SO, 16.7% EG, 16.7% PG 20% Glucose 3 
60% CPA 10% Glucose   
30% Me2SO, 30% EG 10% Glucose 2 
30% Me2SO, 30% PG 10% Glucose 3 
30% EG, 30% PG 10% Glucose 2 
20% Me2SO, 20% EG, 20% PG 10% Glucose 2 
Solutions were compared to the reference solution (70% (w/v) Me2SO). Viscosity was assessed by trying 
to pipette or stir the solution at -40˚C.Viscosity was rated 1-4 (1=similar to 70% (w/v) Me2SO, easy to 
pipette; 2= pipetting not possible but can be easily stirred, 3 = very viscous, stirring very difficult, 4 = 
stirring not possible, almost a solid). Highlighted data indicates a group of CPA combinations with the 
same concentration (w/v) of penetrating and non-penetrating CPAs. Optimal mixes*  
5.4.4 CPA mixtures of low viscosity 
The eight solutions with a viscosity rating of “2” identified in the previous experiment 
(5.4.3) were modified by replacing highly viscous CPAs with less viscous CPAs. In 
most cases 10% (w/v) glucose or PG was replaced with either EG, Me2SO or methanol. 
EG was replaced with Me2SO or methanol, and Me2SO replaced with methanol. Thus, 
in a range of 10% (w/v) all possible combinations were tested and the viscosity of all 
but two solutions (No.3, No.17) was sufficiently reduced for LT, resulting in a viscosity 
rating of “1” or “1-2” (Table 5.8). 
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Table 5.8 Viscosity rating part 2: solutions of reduced viscosity 
Solution 
No. 
Me2SO, EG, PG Methanol Glucose Viscosity rating 
  0% Me2SO       
1 25% EG, 25% PG 10% Methanol 10% Glucose 1-2 
2 30% EG, 30% PG 10% Methanol - 1-2 
3 50% EG 10% Methanol  10% Glucose 2 
4 60% EG 10% Methanol  - 1 
  20% Me2SO       
5 
20% Me2SO, 20% EG, 10% 
PG 10% Methanol 10% Glucose 1-2 
6 20% Me2SO, 30% EG 10% Methanol  10% Glucose 1-2 
  30% Me2SO       
7 30% Me2SO, 20% EG 10% Methanol 10% Glucose 1 
8 30% Me2SO, 20% PG 10% Methanol 10% Glucose 1 
9 
30% Me2SO, 10% EG, 
10%PG 10% Methanol 10% Glucose 1-2 
  40% Me2SO       
10 40% Me2SO 10% Methanol 20% Glucose 1 
11 40% Me2SO, 10% EG 10% Methanol 10% Glucose 1 
12 40% Me2SO, 10% PG 10% Methanol 10% Glucose 1-2 
13 40% Me2SO, 20% EG 10% Methanol - 1 
14 40% Me2SO, 20% PG 10% Methanol - 1 
15 
40% Me2SO, 10% EG, 
10%PG 10% Methanol - 1 
16 
40% Me2SO, 10% EG, 
10%PG   5% Methanol  5% Glucose 1-2 
17 
40% Me2SO, 20%EG, 
10%PG - - 2 
18 40% Me2SO, 20%EG - 10% Glucose 1-2 
  50% Me2SO       
19 50% Me2SO 10% Methanol 10% Glucose 1 
20 50% Me2SO 10% EG 10% Methanol - 1 
21 50% Me2SO 10% PG 10% Methanol - 1 
22 50% Me2SO, 10% EG - 10% Glucose 1-2 
23 50% Me2SO, 10% PG - 10% Glucose 1-2 
24 50% Me2SO, 20% EG - - 1 
25 50% Me2SO, 20% PG - - 1-2 
26 
50% Me2SO, 10% EG, 
10%PG - - 1-2 
  60% Me2SO       
27 60% Me2SO  - 10% Glucose 1 
28 60% Me2SO   5% Methanol 5% Glucose 1 
29 60% Me2SO 5%PG - 5% Glucose 1-2 
30 60% Me2SO 5%EG - 5% Glucose 1-2 
Viscosity of solutions rated with 2 from Table 5.7was reduced by partially replacing highly viscous CPAs 
(e.g. PG) with less viscous CPAs (e.g. methanol). Solutions were compared to the reference solution 
(70% (w/v) Me2SO) at -70°C. Viscosity was rated 1-3 ((1=similar to 70% (w/v) Me2SO, 2= pipetting not 
possible but can be easily stirred, 3 = very viscous). In bold: indicates a group of CPA combinations with 
the same concentration of Me2SO. 
5.4.5 Toxicity test of low viscous CPA solutions 
The toxicity of CPA solutions with a viscosity rating of “1” and “1-2” was assessed by 
comparing AELC recovery after incubation in 60% (w/v) CPA. A 70% (w/v) starting 
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solution (Table 5.8) was used to make up the final concentration of 60% (w/v) CPA. 
Starting solutions were used in the following assessments for comparisons in order to be 
in line with the concentrations used for the viscosity studies (Table 5.8). A 
Me2SO/sugar ratio of 6:1 as for solution No.27 had previously proven to be 
substantially lower in toxicity than Me2SO alone (Figure 5.2). Hence, the aim was to 
find a solution of even lower toxicity. Solutions listed in Table 5.8 were too numerous 
to be tested in duplicate within one experiment. For this reason solutions were separated 
in two groups; those containing more and those containing less penetrating CPAs than 
solution No.27. 
5.4.5.1 Solutions with higher predicted toxicity than reference solution No.27 
As expected, most solutions with higher concentrations of penetrating CPAs than 
solution No.27 showed higher toxicity to AELC. Exceptions to this were solutions with 
65% (w/v) penetrating CPAs and only 5% (w/v) glucose (No.16, No.29, No.30). After 
being incubated in these solutions, AELC exhibited similar (No.29, No.30) or better 
recovery (No16) than solution No.27, suggesting that 5% (w/v) glucose is sufficient to 
markedly improve viability. Incubating AELC in solutions without glucose led to a 
decrease in viability from 99.8% to 22.3% or less. In contrast, the lowest viability 
attained for a solution containing glucose was 59.9% (No.30). The highest viability was 
obtained with solution No.16, which contained only 5% glucose but less Me2SO than 
the reference solution. AELC incubated in solution No.13, No.20 and No.24 showed 
higher viabilities (17.2%, 4.26% and 22.3%) than AELC incubated in solution No.14, 
No.21 and No.25 (2.3%, 0.7% and 8.8%). For the latter, EG had completely or partially 
been replaced with PG (Table 5.9). 
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Table 5.9 Solutions predicted to have higher toxicity effects than reference solution No.27 
Solution No. Me2SO, EG, PG Methanol Glucose 
% Viability 
(n=2) 
+ control untreated untreated untreated 99.8 
2 30% EG, 30% PG 10% Methanol - 2.1 
13 40% Me2SO, 20% EG 10% Methanol - 17.2 
14 40% Me2SO, 20% PG 10% Methanol - 2.3 
15 40% Me2SO, 10% EG, 10%PG 10% Methanol - 7.5 
16 
40% Me2SO, 10% EG, 
10%PG 
5% Methanol 5% Glucose 83.7 
20 50% Me2SO 10% EG 10% Methanol - 4.3 
21 50% Me2SO 10% PG 10% Methanol - 0.7 
24 50% Me2SO, 20% EG - - 22.23 
25 50% Me2SO, 20% PG - - 8.8 
26 50% Me2SO, 10% EG, 10%PG - - 10.4 
27 60% Me2SO - 
10% 
Glucose 
63.0 
29 60% Me2SO 5%PG - 5% Glucose 61.1 
30 60% Me2SO 5%EG - 5% Glucose 59.8 
Toxicity of CPA solutions with a viscosity rating of 1 and 1-2 which were predicted to be more toxic than 
solution No 27. A 70% (w/v) CPA starting solution was used to increase the sample CPA concentration to 
30% and then to 60% (w/v). AELC were incubated for 20 minutes at 0.5°C before the concentration was 
reduced in a two-step procedure (5.3). AELC were cultured for 24 hours in complete media at 37˚C before 
measuring viability by FDA/PI staining. In bold: solutions of low toxicity (addition of glucose). 
5.4.5.2 Solutions with lower predicted toxicity than reference solution No.27 
In this group of solutions (Table 5.10) all but one (No.10 with 20% w/v glucose) 
contained the same amount of glucose (10% w/v). Seven of the 12 solutions were 
equally or less toxic than the reference solution and five were substantially more toxic. 
Of these five all contained the same amount of methanol (10% w/v) and high 
concentrations of Me2SO (>= 40% w/v) or Me2SO and PG (>=50% w/v). Methanol was 
only well tolerated when the Me2SO concentration was equal or less than 30% (w/v) 
and with at least 10% (w/v) EG. An exception was solution No.10 that contained 10% 
(w/v) more glucose than all other solution and for which 40% Me2SO was well tolerated 
by AELC exhibiting a viability of 86.0%. Solutions without methanol all maintained 
high viabilities. As in the previous experiment, solutions containing PG (No.8, No.12 
and No.23) were more toxic to cells than solutions where PG had been replaced with 
ethylene glycol (No.7, No.11 and No.22). Recoveries given in per cent viability for 
AELC incubated in PG-containing CPA solutions were: 53.8%, 48.6% and 78.7%. For 
the same CPA solution but with EG recoveries were 90.3%, 66.3% and 92.8%. EG also 
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seemed to exhibit lower toxicity to AELC than Me2SO, as solution No19 (viability: 
42.1%) showed less viability than solution No11 (viability: 66.3%), which in turn 
showed lower viability than solution No7 (viability: 90.3%). In each case 10% (w/v) 
Me2SO was replaced with 10% (w/v) EG (Table 5.10). 
Table 5.10 Solutions with lower or similar toxicity than reference solution No.27 
Solution 
No. 
Me2SO, EG, PG Methanol Glucose % Viability 
(n=2) 
1 25% EG, 25% PG 10% Methanol  10% Glucose 57.7 
5 20% Me2SO, 20% EG, 10% 
PG 
10% Methanol  10% Glucose 97.9 
7 30% Me2SO, 20% EG 10% Methanol 10% Glucose 90.3 
8 30% Me2SO, 20% PG 10% Methanol 10% Glucose 53.8 
9 30% Me2SO, 10% EG, 
10%PG 
10% Methanol 10% Glucose 89.7 
10 40% Me2SO 10% Methanol 20% Glucose 86.1 
11 40% Me2SO, 10% EG 10% Methanol 10% Glucose 66.3 
12 40% Me2SO, 10% PG 10% Methanol  10% Glucose 48.6 
18 40% Me2SO, 20% EG - 10% Glucose 97.2 
19 50% Me2SO 10% Methanol  10% Glucose 42.5 
22 50% Me2SO, 10% EG - 10% Glucose 92.8 
23 50% Me2SO, 10% PG - 10% Glucose 78.7 
27 60% Me2SO - 10% Glucose 80.5 
Toxicity of CPA solutions with a viscosity rating of 1 and 1-2. showed lower or similar levels of toxicity 
than the reference solution No.27. EG was the least toxic penetrating CPA in this set-up. By adding EG 
the Me2SO concentration was reduced to 20-30%. Methanol was only well tolerated in combination with 
EG and Me2SO. AELC were cultured for 24 hours in complete media at 37˚C before measuring viability 
by FDA/PI staining. Bold type denotes solutions with low toxicity. 
5.4.6 Optimal CPA solutions 
Solutions of lower toxicity than reference solution No.27 were tested again using the 
same protocol as before to define the solution of lowest toxicity. A new solution (No.6: 
20% Me2SO + 30% EG + 10% methanol +10% glucose (w/v)) with a viscosity rating of 
“1-2” was included. A total of nine solutions were tested with the same batch of AELC 
on day 8, 9 (cell density: 10
6
cell/ml beads), and 13 (cell density 14
6
cell/ml beads) after 
encapsulation. Values gained from day 8 and 9 were comparable and therefore an 
average was calculated (n=3). Recovery was higher and differences between solutions 
were less pronounced at day 13 after encapsulation than on the days before and 
therefore data was evaluated separately (n=2). Solution No.18 and No.6 showed 
markedly better performance than the reference solution No.27 with viabilities of up to 
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80%. AELC recovery was also higher for solution No.22, No.5 and No.7, although to a 
lesser extent (Figure 5.3, Figure 5.4). 
 
Figure 5.3 Toxicity comparison of low toxic CPA solutions 
All solutions with lower toxicity than solution No 27 were tested, with the same batch of AELC on 
day 8-9 (black, n=3 +/- SD) and 13 (grey n=2 +/- SD) after encapsulation. Cell density was lower on 
day 8 and 9 (cell density: 10
6
cell/ml beads) than on day 13 (cell density: 14
6
cell/ml beads).AELC 
were incubated in 60% (w/v) CPA solution for 20 minutes at 0.5˚C; a step-wise CPA addition and 
reduction procedure was used (5.3). Solutions No.6 and No.18 were the least toxic, with viability 
levels of up to 90%, followed by solutions No22, No5 and No7. AELC were cultured for 24 hours in 
complete media at 37˚C before measuring viability by FDA/PI staining. 
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Figure 5.4 Fluorescent microscope images of CPA solutions exhibiting lowest toxicity to AELC 
Viability was assessed using FDA (green/live) and PI (red/dead) stains. Images are representative of 
four further repeats. Original magnification 40x. Solution No.6 and No.18 show highest viability. 
 
PI (dead) PI (dead) FDA (live) FDA (live) 
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5.4.7 Viscosity of optimal CPA solutions 
The viscosity of the CPA solutions (concentration 70% (w/v) tested in 5.4.9 was 
measured using a Bohlin® CVO automated shear rheometer. The viscosity of reference 
solution (70% (w/v) Me2SO) was the lowest among the CPA solutions. Nevertheless, 
differences between sample conditions were less than 3mPa*s (Table 5.5). 
 
Figure 5.5 Viscosity of the nine best CPA solutions 
Viscosity of water (standard), CPA solutions and Me2SO was measured at 20˚C using a Bohlin 
CVO automated shear rheometer. Data was n=2. The viscosity of low toxic CPA solutions at a 
concentration of 70% (w/v) was comparable to the viscosity of Me2SO.  
5.4.8 Toxicity of dimethyl sulfoxide and ethylene glycol 
One possibility to permit the use of more viscous CPAs is by running the LT 
experiment at a higher temperature. However, this will compromise the effect of low 
temperatures to decrease CPA toxicity and is only useful if the new CPA solution is of 
significantly lower toxicity. Ethylene glycol seemed to be less toxic than all other tested 
penetrating CPAs (Table 5.9 and Table 5.10). For this reason EG as a sole agent and in 
combination with Me2SO and glucose with a final concentration of 40% (w/v) and 60% 
(w/v) was tested. As seen in Figure 5.6, recovery of AELC when both EG and Me2SO 
were used as a sole agent, was very low, with viabilities of less than 3%. AELC 
incubation in EG with glucose in a ratio of 6/1 resulted in significantly higher viabilities 
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than Me2SO and glucose with a ratio of 6/1. Both solutions were more toxic to AELC 
than the combination of Me2SO/EG with glucose in a ratio of 4/2/1 as used for CPA 
solution No.18. 
A. 
 
B. 
 
Figure 5.6 CPA toxicity Me2SO versus EG 
AELC were incubated at 0.5⁰C in A: 40% and B: 60% (w/v) CPA solution for 1 hour, and 20 
minutes, respectively. A step-wise addition and reduction procedure was used. AELC were cultured 
for 24 hours in complete media at 37˚C before measuring viability by FDA/PI staining. In both 
experiments AELC recovery for Me2SO/EG/glucose vs. Me2SO/glucose or EG/glucose was 
significantly higher, ** p<0.01, (n=5 +/-SD). Toxicity of EG plus glucose was significantly higher 
than Me2SO and glucose, ** p<0.01, (n=5 +/-SD). 
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5.4.9 Vitrification properties of low toxic CPA solutions 
Solutions No.5, No.6, No.7, No.18 and No.22 were chosen for further studies as they 
were the least toxic to AELC (5.4.6). AELC were vitrified in the new CPA mixtures in 
order to estimate their vitrification properties. As observed in the toxicity studies, 
solution No.18 exhibited the best results with an average viability of 53% +/-9, followed 
by solution No.6 (43% +/-8), No.22 (31% +/-12), No.5 (23% +/-5) and No.7 (16% +/-
5). Lowest viability was reached with Me2SO (1% +/-3) (Figure 5.7). 
 
 
Figure 5.7 CPA solutions of low toxicity used to vitrify AELC 
AELC were vitrified in CPA solutions of lowest toxicity (5.4.8). A step-wise CPA addition and 
reduction procedure was used (5.3.4). The final CPA concentration was 63% (w/v). AELC were 
cultured for 24 hours in complete media at 37˚C before measuring viability by FDA/PI staining. 
Solution No.6 and No.18 showed best performance, followed by solution No.22, No.5 and No.7 (n=5 
+/-SD). 
5.4.10 Vitrification and devitrification properties of low toxic CPA solutions 
The vitrification properties of solutions No.5, No.6, No.7, No.18 and No.20 were 
visually compared to Me2SO by cooling 4ml of each solution in a 6-well plate 
at -10⁰C/min to -160⁰C. All solutions vitrified at a concentration of 70% (w/v), but only 
solution No.22 and Me2SO vitrified at 60% (w/v). Unlike Me2SO and solution No.22, 
all other solutions contained 20% (w/v) or more EG. During the warming process, the 
rate of ice disappearance for the 60% (w/v) solutions was, in descending order: No.5, 
0
20
40
60
80
100
positive
control
No5 No6 No7 No18 No22 Me2SO
V
ia
b
il
it
y
 (
%
) 
Chapter 5: Cryoprotectant agent development 
164 
 
No.7, No.6 and No.18. Solution No.18 was the only one of the four that did not contain 
10% (w/v) methanol (Figure 5.8). 
 
 
 
Figure 5.8 Vitrification properties of low toxic CPA solutions 
A volume of 4ml of each solution was vitrified in a 12-well plate. A: solutions after being cooled 
at -10˚C/min to -160˚C. All solutions vitrified when at a concentration of 70% (w/v), but only 
solution No.22 and Me2SO vitrified at 60% (w/v). B: solutions after 10 minutes at room 
temperature, showing a different velocity at which any nucleated ice melted during warming. Ice of 
solution No.7 and No.5 melted faster than ice of No.6 and No.18. Images are representative of four 
further repeats. 
5.4.11 Liquidus curve of optimized CPA solution No.18 
The liquidus curve of solution No.18 had to be established in order to use the new 
solution for LT. The fastest method to establish the working definition for the liquidus 
A 
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curve of a new solution was by measuring the release of latent heat (4.3.6) to determine 
the thermocouple defined approximate freezing point (TdAFP) of increasing CPA 
concentrations. The melting point of 12.5% (w/v) and 37.5% (w/v) CPA No.18 was 
compared to data gained from differential diffraction scanning calorimetry (DSC). DSC 
was used as an alternative and more accurate method for determining the equilibrium 
melting point (Figure 5.9). This method could not be used at all times as the equipment 
required was not available in-house. Data was therefore compared to the TdAFP to 
estimate the accuracy of this method. The temperature difference between the two 
methods was 0.19˚C for 12.5% (w/v) and 0.93˚C for 37.5% (w/v) (n=3) (Figure 5.10). 
No peaks as a result of release of latent heat or during the endothermic reaction as ice 
melts (DSC) were obtained for 50% (w/v) CPA. 
 
  
  
Figure 5.9 Determination of equilibrium melting point using differential scanning calorimetry 
(DSC).   
The equilibrium melting point was determined from the melt curve and was defined as the 
temperature at which the trough was greatest. Figure A is an example of a thermogram of 12.5% 
(w/v) CPA and figure B is an example of a thermogram of the 37.5% (w/v) CPA solution. The y-axis 
shows the release of heat and the x-axis the temperature from -100˚C to +40˚C.  
A B 
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Figure 5.10 TdAFP and equilibrium melting point determination using “release of latent heat” and 
“DSC”.  
Each solution was prepared in triplicate, and was tested in duplicate for DSC and five times for 
“release of latent heat” measurements. The temperature difference between the averages of the two 
methods was 0.19˚C for 12.5% (w/v) and 0.93˚C for 37.5% (w/v). Data were n=3 +/- SD. 
5.4.12 Liquidus curve of CPA solution No.18 in comparison to dimethyl sulfoxide 
The data obtained from DSC and release of latent heat measurements were used to set 
up the liqidus curve for CPA solution No.18. No peaks as a result of release of latent 
heat or during the endothermic reaction as ice melts (DSC) were obtained for 50% (w/v) 
CPA. Nevertheless, from optical investigation it was observed that a 50% (w/v) CPA 
solution froze at approximately -30˚C. This was in accordance with the trendline value 
of solution No.18 (Figure 5.11). The melting points of 12.5% and 25% (w/v) CPA 
No.18 were comparable to those of Me2SO. For higher concentrations the melting curve 
of Me2SO runs below that of No.18. 
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Figure 5.11 Liquidus curve of CPA No.18 in comparison to the liquidus curve of Me2SO 
At low CPA concentrations (<=25% (w/v) the melting point of CPA No.18 are comparable to those 
of Me2SO (Chapter 4). For lower concentrations the predicted melting curve of No.18 runs above 
that of Me2SO. 
5.4.13 Manual Liquidus Tracking with CPA solution No.18 and dimethyl sulfoxide 
The CPA solutions No.18 and Me2SO were compared using the modified manual LT 
protocol as described in section 5.3.6. Viability, cell number, methylthiazol tetrazolium 
(MTT) and alpha-fetoprotein (AFP) production were measured 24 and 48 hours after 
rewarming from -160˚C. The following values, expressed as percentage of the positive 
control (un-treated), were obtained: AELC viability 24 hours post-warming was 74% 
+/-3 for solution No.18 and 29% +/-6 for Me2SO. After 48 hours viability increased to 
76% +/- 5 for solution No.18 and decreased to 23% +/-5 for Me2SO. Cell numbers 24 
hours after vitrification was 79% +/- 2 for No.18 and 51% +/- 7 for Me2SO. The cell 
number increased to 85% +/- 8 for No.18 and 59% +/- 6.3 for Me2SO after 48 hours. 
MTT values of 68% +/-13 and 45% +/-9 after 24 hours and 68% +/-12 and 45% +/-9 
after 48 hours were reached for solution No.18 and Me2SO respectively. AFP 
production was 34% +/- 1.6 for No.18 and 21% +/- 3 for Me2SO after 24 hours and 
increased to 78% +/- 9.5 and 48% +/- 4.3 after 48 hours (Figure 5.12). 
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Figure 5.12 Manual LT with CPA solution No.18 vs. Me2SO 
CPA solutions No.18 and Me2SO were compared using the modified manual LT protocol as 
described in section 5.3.6. Viability, cell number, MTT and AFP production were significantly 
higher for CPA solution No.18 than for Me2SO. Data are n=5 +/- SD **p<0.01 and *p<0.05. 
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5.5 Discussion  
The purpose of this chapter was to develop a new CPA solution with optimized 
properties for Liquidus Tracking (LT). An iterative series of experiments were designed 
to investigate the practicalities of using different CPA solution within the LT principle, 
to be balanced by differential toxicities seen at high concentrations. As a result of the 
time-consuming stepwise CPA addition and reduction process and the high 
concentrations that are needed to vitrify bulky materials, it was important to develop a 
CPA solution with minimal toxicity. However, the first limiting factor for the new CPA 
solution was viscosity, as the pumps and stirrer of the automatic Liquidus Tracker (see 
later work in Chapter 6 and 7) do not work when a viscosity of approximately 900 
mPa*s is surpassed. Also, highly viscous material cannot be pipetted or mixed 
accurately when using the manual LT approach. A good CPA solution was considered 
to be of low viscosity, low toxicity and of good vitrifying capability. After a literature 
search to identify commonly used CPAs and by comparing the viscosity of these CPAs 
with Me2SO, three penetrating CPAs including dimethyl sulfoxide (Me2SO), ethylene 
glycol (EG), propylene glycol (PG) and sugars as non-penetrating CPA were chosen as 
promising CPAs for further studies. 
In regard to toxicity the addition of sugars displayed an overwhelming protective effect 
by increasing viabilities to up to 60%. When AELC were incubated in 50% (w/v) 
Me2SO for 20 minutes on ice, viability dropped to less than 5%, but remained high 
when 10% sugar was added. One main reason sugars are used in vitrification protocols 
is to decrease the amount of penetrating CPAs while keeping similar final CPA 
concentrations and vitrification properties. Here, Me2SO was not replaced, but instead 
10% w/v sugar was additionally included. Comparable to reduced toxicity of formamide 
through the addition of Me2SO (Fahy et al., 1995) this is an actual account of toxicity 
neutralisation. It is possible that the protective effect is caused by osmotically reducing 
the cell volume, and therefore triggering reduced uptake of penetrating CPA, which 
leads to less intracellular dehydration through CPAs and also reduced osmotic stress 
when CPAs are washed out. The type of sugar used appeared to be irrelevant; however 
the combination of two sugars seemed to be slightly more effective than the use of one 
single sugar. Sugars were selected based on different positive effects. Fructose and 
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Raffinose have shown to minimize the amount of reactive oxygen species (ROS) 
(Nishizawa et al., 1997). ROS are known to increase substantially during environmental 
stress, potentially causing significant damage to the cell (Devasagayam et al., 2004). 
Trehalose and sucrose are thought to stabilize cell membranes by interacting with polar 
head groups of phospholipids during dehydration (Rudolph & Crowe, 1985). Glucose 
has been reported to prevent irreversible binding of Me2SO to proteins (Clark et al., 
1984). The fact that no significant difference between sugars was detected might hint at 
a more general influence of the non-penetrating CPA, such as less CPA influx and 
reduced osmotic stress. More specific actions, as described above, might play a minor 
role and might therefore be more detectable when the effects of two sugars are 
combined. 
In order to simplify the procedure, glucose was chosen as the non-penetrating CPA for 
further studies. Reasons for this were several: as a single sugar glucose showed the 
highest average viability for AELC, although the difference to that of other sugars was 
not significantly relevant. Large CPA volumes are needed for automatic LT and glucose 
is inexpensive in comparison to raffinose and trehalose and is also cheaper than sucrose 
and fructose. Moreover, the use of raffinose and trehalose in concentrations exceeding 
0.5M and 1M respectively has been advised against, because the sugars precipitate 
(Kuleshova et al., 1999). Glucose has been successfully used in several vitrification 
protocols (Dhali et al., 2000; Fan et al., 2009). Produced by the liver, glucose is a 
natural cryoprotectant in wood frogs (Conlon et al., 1998). The addition of natural 
levels of glucose to the incubation media prevented freezing damage of wood frog 
hepatocytes at -4˚C. In addition, glucose might serve to a certain degree as a penetrating 
CPA, as it has been demonstrated that liver cells have glucose channels (Sugimachi et 
al., 2006). Conversely, being a reducing sugar, glucose could have adverse effects. 
Reducing sugars can unfold proteins via Maillard reaction between the carbonyl group 
of the reducing sugar and primary amines of aminoacids. Irreversible protein unfolding 
can have a negative impact on cell viability (Carpenter et al., 1988).  
The evaluation of different sugars was stopped at that point due to the high costs for 
trehalose and raffinose, and because results between sugars had shown to be 
comparable. Instead, combinations of commonly used penetrating CPAs (Me2SO, EG, 
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PG) with increasing concentrations of glucose to a final concentration of 70% (w/v) 
were tested on viscosity. The studies accessibility to a viscometer or rheometer was 
limited and no means were available to measure viscosities either in large numbers of 
samples at the same time or at low subzero temperatures. Nevertheless, the mechanical 
evaluation by standardised pipetting and stirring these mixtures at -40˚C and comparing 
them to Me2SO provided a simple way to quickly test a high number of solutions at low 
subzero temperatures. The reliability of the mechanical test was verified by 
rheologically measuring the viscosity of the nine least toxic CPA solutions. On the basis 
of the mechanical test these solutions had been considered to be fairly similar in 
viscosity to Me2SO, which was confirmed by the rheological measurements. Although 
Me2SO proved to be the least viscous, the difference to the most viscous solution 
(No.12) was less than 3mPa*s. 
When testing the first set of CPA solutions it became obvious that all but one mixture 
containing more than 10% (w/v) glucose were substantially more viscous than Me2SO 
and only one mixture (60% (w/v) Me2SO + 10% (w/v) glucose) of the 21 combinations 
was of similar viscosity. To obtain more solutions of low viscosity, 10% of a more 
viscous CPA was systematically replaced with 10% of a less viscous CPA. Both PG and 
EG as well as glucose exhibit high viscosities in comparison to Me2SO. Therefore 
methanol was selected as a low viscosity CPA as a means to reduce the overall viscosity 
of the CPA mixture. Ethanol is less viscous than methanol but proved to be more toxic 
to AELC. Monovalent alcohols like methanol and ethanol are not commonly used in 
cryopreservation protocols, mostly due to their known high toxic effects on many 
biological systems. However, methanol has shown to be effective for non-mammalian 
cells such as protozoa (Kirsop & Henry, 1984; Polge & Soltys, 1960) yeast (Kirsop & 
Snell, 1984). cyanobacteria and algae (Bodas et al., 1995; Konev et al., 1975). It has 
also been used successfully in fish semen and embryo preservation (Lahnsteiner, 2008; 
Lahnsteiner et al., 2002; Seki et al., 2011). In these applications, the concentration used 
was 10% or less, which justified the concentration used for new LT CPA solutions. 
Ethanol in comparison to methanol has only been used in very few cryopreservation 
protocols (Lewis et al., 1993) due to its higher toxicity, which corresponds to the data 
found in this chapter. By replacing more viscous CPAs with less viscous CPAs, 
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including methanol, the viscosity of all but two solutions was reduced, resulting in 28 
different CPA solutions with a similar viscosity to Me2SO. 
When testing the toxicity of these solutions it was shown that, as expected, higher 
concentrations of penetrating CPAs resulted in lower AELC viability. Interestingly the 
addition of just 5% (w/v) glucose was sufficient to substantially increase viability, 
whereas the increase from 10% to 20% (w/v) glucose did not show much further 
improvement. Results also suggest that for AELC, EG is less toxic than Me2SO or PG. 
This observation corresponds to previous findings from other authors in chondrocytes 
and alginate encapsulated HepG2 and β-TC-cells (Jomha et al., 2010; Lawson et al., 
2011; Valdez et al., 1992). As stated by Fahy, the non-specific toxicity of a given 
solution is dependent on the strength of hydrogen bonding between water and the polar 
groups of the permeating cryoprotectants (Fahy, 2010). According to this theory, 
viability increases when the average polar group of a CPA is interacting less strongly 
with water which in general means that weaker glass formers favour higher viability. 
Group polarity of CPAs is as follows: propylene glycol > Me2SO> ethylene glycol > 
amides. This seems to correlate with the toxicity results and vitrification properties of 
the newly developed CPA solutions for AELC. Replacing PG with Me2SO did not make 
much difference in AELC viability, but EG seemed to be superior to PG and Me2SO. As 
discussed later in more detail, Me2SO vitrified best among six selected CPA solutions, 
but was more toxic. In contrast CPA solutions No.18 and No.6 were the least toxic, but 
seemed to be the least effective for vitrification.  
The combination of Me2SO with EG (No.18) has shown to be less toxic than other 
combinations. EG has been stated to be the least toxic CPA for hepatocyte virtification 
(Kuleshova et al., 2004; Magalhães et al., 2008) but for AELC, the combination of 
Me2SO and EG resulted in significantly higher viability than either of the CPAs on its 
own. This combination has also shown good results for the vitrification of cumulus cells 
using 22% EG and 18% Me2SO (Saeed et al., 2000) and in equine embryos with a 
concentration of 17.5% for both EG and Me2SO (Oberstein et al., 2001). There has been 
no explication so far about the interaction between EG and Me2SO, but both solutions 
are also main components of the well-known and commercially available vitrification 
solutions VS55 and M22 (Fahy et al., 1995; Fahy et al., 2004). These solutions 
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additionally contain non-penetrating CPAs and also formamide, which was regarded as 
too toxic for our purpose, and ice-blockers which are deemed too expensive for the 
development of a large scale preservation method. Although of general high toxicity, 
methanol was well tolerated when in combination with EG and low amounts (>=30% 
w/v) of Me2SO. Solution No.6 containing 10% (w/v) methanol was the second least 
toxic after solution No.18. Methanol has a very high rate of permeability, exceeding that 
of Me2SO as demonstrated in algal cells (Brand & Diller, 2004) which might explain to 
some extent its high toxicity. Nevertheless, high penetration rates and low viscosity 
might be necessary for some vitrifiction protocols, and for those protocols methanol 
might be a considerably useful CPA. 
When developing new CPA solutions it is necessary to assess toxicity of 
cryoprotectants at the concentrations needed to vitrify. CPA concentrations in the 
literature are given in different units such as volume per volume (v/v), weight per 
weight (w/w), weight per volume (w/v) or moles per volume. In respect to laboratory 
practicability, the use of weight/volume is preferable, which is why it has been used in 
this work. However, in regard to vitrification properties, it might be more meaningful to 
use weight/weight as the amount of water in comparison to CPAs is kept constant. 
Important work regarding the vitrification properties of CPAs has been done by Boutron 
and others (Baudot & Boutron, 1998; Baudot et al., 2000; Boutron, 1986; Wowk et al., 
1999; Wowk et al., 2000) who used weight/weight for their comparability studies. Fahy, 
who has mainly concentrated on the toxicity of CPA mixtures, normally used 
weight/volume (Fahy et al., 2004). He determined the minimum concentration needed 
to vitrify a solution at a given volume at maximum cooling rates and then used the 
minimum concentration to compare the toxicity of different CPA mixtures. Others have 
used molarities (Fujioka et al., 2004; Kuleshova et al., 2004), which can be helpful to 
predict osmotic pressure. If little is known about the toxicity of a potential CPA 
solution, it might be more efficient to first test the toxicity of different mixtures at the 
same concentration in order to make a pre-selection before testing a variety of 
concentrations. This strategy was pursued in this work on the grounds that exact final 
CPA concentrations for LT are of less importance than for conventional vitrification, as 
final concentrations are reached at very low temperatures (<-30˚C), at which CPA 
penetration and toxicity are suspected to be strongly reduced. Furthermore, exact final 
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concentrations are difficult to achieve as the procedure itself, manually as well as 
automatically, implies pipetting and pumping inaccuracies. It was, nonetheless, 
important to get an estimation of the vitrification properties of the potential CPA 
solutions. Me2SO and the five CPA solutions of lowest toxicity to AELC were therefore 
vitrified and compared. Whilst all solutions vitrified at 70% (w/v), only Me2SO and the 
mixture of Me2SO/EG/glucose with a ratio of 5:1:1 vitrified at 60% (w/v). One reason 
why the other four solutions did not vitrify is probably the higher concentration of EG 
and methanol. EG has been described as a less effective vitrifier than Me2SO and PG 
(Baudot et al., 2000) and methanol only vitrifies on its own under high pressure 
(Brugmans & Vos, 1995). However, CPA solutions No.5 and No.9, and to a smaller 
extent No.6, melted faster than solution No.18, which did not contain methanol. This 
might suggest a positive effect of methanol during the warming phase by increasing the 
velocity at which ice melts, and thus decreasing the amount of potential devitrification. 
As a next step in the investigation the CPA solutions were used to vitrify AELC. The 
same order in viability as previously seen for toxicity studies, with highest viabilities 
gained from solution No.18, was observed. Reduced incubation time before plunging 
AELC into liquid nitrogen could be beneficial for solutions with higher concentrations 
of fast penetrating CPAs (Me2SO, methanol), and some of the solutions might vitrify 
also at lower concentrations which would reduce CPA toxicity and increase viability. 
However, for the chosen set-up solution No.18 was superior to the other solutions and 
proved to be an efficient vitrifier. Vitrification experiments can only give an indication 
whether a CPA solution is suitable for LT. Ultimately only the LT procedure itself can 
be used to determine the best CPA solution. However testing all CPA solutions in a LT 
set up would have been too time-consuming. Automatic LT only allows testing of one 
CPA solution per experiment, and even the manual LT set up is very limited in sample 
number (maximum 10). Due to the long LT process and consequently long exposure 
times to toxic concentrations of CPA, it was concluded that the CPA solution of lowest 
toxicity (No.18) would be more beneficial to cryopreserve AELC using LT than the best 
vitrifier (No.22 or Me2SO). Also CPA concentrations for LT can be adjusted to a level 
that allows vitrification at very low subzero temperatures (<-30˚C) at which CPA 
toxicity might be completely reversed. 
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The next challenge was to determine the liquidus curve for solution No.18. 
Unfortunately, it was not always possible to conduct DSC measurements. For this 
reason, using the release of latent heat was established as an alternative method. The 
equilibrium melting point of 12.5% and 37.5% (w/v) were determined using both 
methods; DSC and the release of latent heat. The temperature difference between the 
two methods was less than 1˚C. This seemed to be acceptable considering that the 
temperature for each LT CPA increase was set +5˚C above the equilibrium melting 
point to account for pipetting and pumping deviations. When using release of latent heat 
to measure the equilibrium melting temperature of high concentrations of Me2SO 
(Chapter 4), values were lower than the literature DSC values. Conversely, 
measurements for 37.5% (w/v) of CPA solution No.18 were comparable between 
methods. Two reasons would explain this observation. First, the sample temperature 
does not return to the true equilibrium melting point since the chamber temperature 
cools the sample temperature during the warming process. The longer the warming 
process and the colder the chamber temperature, the stronger this effect will be. 
Concentration above 25% (w/v) of Me2SO freeze at lower temperatures than the same 
concentration of solution No.18. This means that the freezer will be at a lower 
temperature for Me2SO than for solution No.18. Contrary to Me2SO, CPA solution 
No.18 contains high concentrations of sugars, which might act as nucleation points 
when supersaturated (for example at low temperatures), reducing the amount of 
supercooling. Both a shorter warming process (less supercooling) and a higher chamber 
temperature at the time of nucleation (higher melting point) will reduce the amount of 
heat loss and result in more comparable values between the true equilibrium melting 
point, given by DSC measurements - a precise method to measure the equilibrium 
melting point - and measured values by release of latent heat.  
Finally, manual LT was used to compare CPA solution No.18 with Me2SO. After 
vitrification, cell number, AFP and MTT production was significantly higher for 
solution No.18 than for Me2SO, showing that No.18 is the better CPA solution for the 
LT approach. 
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5.6 Conclusion 
By using viscosity as a limiting factor the immense number of possible CPA 
combinations was reduced to a reasonable number of 28. By systematically replacing 
highly viscous CPAs with less viscous CPAs, all combinations in a range of 10% (w/v) 
were tested. Toxicity studies identified nine particularly useful CPA solutions of low 
toxicity of which five were further investigated regarding their vitrification properties. 
CPA solution No.18, a mixture of Me2SO, EG and glucose in a ratio of 4/2/1 was 
predicted to be the most suitable for LT due to its low toxicity, although it was less 
efficient as a vitrifier than other solutions. It can be assumed that, with respect to the 
main components, there is little possibility to develop a better CPA solution for 
Liquidus Tracking. Although solutions were developed to be first of low viscosity and 
second of low toxicity, solution No 18 resembled those vitrification solutions that are 
commercially sold. Using a manual LT system clearly demonstrated that CPA solution 
No.18 is superior to Me2SO as a sole agent. 
The final CPA concentration that is required to obtain a stable glass and to avoid 
devitrification for volumes up to 400ml for automatic LT still has to be determined.
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6 CHAPTER 6 
The automatic Liquidus Tracker 
6.1 Introduction 
Automatic Liquidus Tracking (LT) is the up-scaled and automated version of the 
manual LT approach described in Chapter 4. The Liquidus Tracker is an almost 
completely automated vitrification machine that has been developed by Planer plc in 
cooperation with David Pegg as a means of cryopreserving biological samples that are 
not suitable for conventional slow-rate freezing or for ultra-fast vitrification such as 
organs and tissues or large volumes. The Liquidus Tracker prototype used for the work 
of this chapter was developed for use with articular cartilage connected to parts of knee-
bone. This is reflected in the design of the stirrer, the inlet and outlet system and the 
volume of the sample container. The inlet and outlet system can be operated by two 
different methods - the dual solution mode which is similar to the manual LT set-up 2, 
and the single solution mode which is similar to the manual LT set-up 3 (Chapter 4). 
For the work of this chapter the single solution mode was used which has the advantage 
of being less complex in terms of the inlet pump system and more cost effective as less 
reagents are needed to increase the cryoprotectant agent (CPA) concentration of the 
sample (Figure 6.1, Figure 6.2). New approaches needed to be developed to enable 
automatic LT to be used with AELC, and these are described. 
6.1.1 The dual solution mode 
The dual solution mode works with three peristaltic pumps, of which two operate the 
inlet and one the outlet. A highly concentrated CPA solution and a buffer are mixed by 
pumping the two inlet solutions into a combined inlet tube to obtain a solution that is 
slightly more concentrated than the solution within the sample container. The sample 
container is completely filled with the inlet solution before the volume is reduced. High 
amounts of CPA and buffer solutions are needed to increase the sample CPA 
concentration (Figure 6.1). 
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Figure 6.1 The dual solution mode 
High concentrated CPA (1) is pumped by a peristaltic inlet pump (2) towards the sample carrier. 
Before passing the sample carrier inlet port, the CPA solution is mixed and diluted with a buffer 
solution (3) being pumped (4) from a separate container to the combined inlet tube. The new 
solution (5) which is slightly more concentrated than the sample itself, is added to the sample 
carrier (6) to increase the CPA concentration before the sample reaches its melting point. After the 
mixing process, sample is extracted by the outlet pump (7) and led to the waist container (8). 
6.1.2 The single solution mode 
The single solution mode only uses one highly concentrated CPA solution to increase 
the CPA concentration within the sample. Therefore only two peristaltic pumps are 
needed, one for the inlet and one for the outlet. The outlet volume is determined by the 
volume of the next infusion so that sufficient CPA can be added to increase the sample 
CPA concentration. Both, inlet and outlet volume increase after each step as more CPA 
has to be added when targeting the same percentage increase during each step. The 
stirrer operates throughout the entire process (Figure 6.2). 
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6.1.3 The cooling system 
 
 
 
 
Figure 6.2 The single solution mode 
High concentrated CPA (1) is pumped by a peristaltic inlet pump (2) into the sample carrier (3) to 
increase the CPA concentration before the temperature is reduced. After mixing the sample, some 
of the solution is extracted by the outlet pump (4) and lead to the waist container (5). 
6.1.3 The Liquidus Tracker 
The Liquidus Tracker (single solution mode) consists of one inlet and one outlet pump, 
a magnetic stirrer, a controlled rate freezer and a personal computer. All of these units 
are connected to the controller. The LT device is controlled by the computer software 
CfgPid and Delta T. The temperature-CPA-profile, which determines the CPA 
concentration that has to be reached at a certain temperature to prevent freezing, is 
entered into the CfgPid table. Commands are sent to the controller which in turn 
operates the peristaltic pumps. High concentrated CPA solution is pumped into the 
sample carrier to increase the CPA concentration. After mixing, solution is extracted by 
the outlet pump and is led to the waist container. The system stirs continuously through 
all three phases: injection, hold phase and extraction until the final target CPA 
concentration is reached. Commands to operate the stirrer are sent from the CfgPid 
software to the controller and from the controller to the stirrer. For the stirring process 
the sample carrier has to be maintained in a fixed position – this is provided by the 
sample holder. Information about start temperature and cooling rates are managed by 
the DeltaT software. Once the controller obtains the information from the computer, 
they are sent to the controlled rate freezer. Before being added to the sample, the inlet 
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1. CPA solution (high (%)) 
2. Peristaltic inlet pump 1 
3. Sample carrier 
4. Peristaltic outlet pump 2 
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CPA solution has to be cooled down. This is achieved by keeping the inlet tube, 
wounded around the sample holder, within the freezer. The longer the inlet tube and the 
slower the cooling rate, the closer is the inlet temperature to the freezer temperature. 
The LT system also includes two measures of security, a pressure relief valve for the 
event of inlet solution freezing while pumping and an overflow port inside the sample 
carrier that is connected to an outlet tube. This prevents pressure build up inside the 
container and CPA solution to leak into the freezer. The temperature of the inlet and the 
outlet solution, as well as the temperature of the solution inside the sample carrier are 
measured via thermocouples which are connected to a Pico Logger (Figure 6.3). 
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Figure 6.3 The Liquidus Tracker 
The graph shows the automatic LT device displaying the one solution mode. Watson-Marlow 
pumps, Planer stirrer and Planer freezer (Kryo10, series II) are operated by the controller which 
gets its commands from the computer software CfgPid and DeltaT. The sample carrier has to be 
inserted in the sample holder which is placed inside the Planer freezer. The inlet tube goes from a 
highly concentrated CPA solution into the pump and to the sample container. The outlet tubes goes 
directly to the pump and from there into a waste bottle. The CPA concentration of the sample is 
increased by pumping high concentrated CPA solution into the sample carrier. The stirrer consists 
of a plastic part that turns around within the sample container and a magnetic part which is 
powered by a motor. A pressure relief valve is added between the inlet pump and the freezer as a 
measure of security. The temperature of inlet, outlet and sample are measured by the Pico Logger. 
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6.1.4 The stirrer 
To fully mix large volumes, mechanical stirring is required to ensure that the solution is 
thoroughly mixed. A stirrer for cryopreservation purposes has to withstand (to -160˚C) 
and work (to -40˚C) at very low subzero temperatures, which is normally not provided 
by any electrical application. This is overcome by placing the motor outside the freezer 
and by magnetically coupling the motor to a stirring system held inside the freezer. The 
motor rotates a metal plate inside the freezer, which in turn magnetically drives the 
stirrer inside the sample carrier. The stirrer is made of a bottom part and an upper part. 
The bottom part of the stirrer contains three holes through which the inlet, outlet and 
overflow ports are introduced and which hold this part of the stirrer in static position. 
The upper part is made of a disc which holds several small magnets and four paddles 
which rotate between the sample carrier wall and the static paddles. This way the 
solution is being mixed, while tissues and organs can be placed in the centre of the 
sample carrier. To increase the mixing effect, the rotation direction is constantly 
changed (Figure 6.4).  
Figure 6.4 Sample holder and stirrer 
Figure A: demonstrates the sample carrier holder, the sample carrier and part of the motor which 
rotates the metal disc inside the freezer. The metal disc and the motor are separated by the freezer 
lid. Figure B: shows the stirrer inside the sample carrier. The paddles of the upper stirrer move 
between the sample carrier wall and the paddles of the bottom stirrer part.  
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6.1.5 Heat transfer 
Heat or thermal energy is the motion of atoms or molecules (kinetic energy) that can be 
transmitted to another system. The amount of thermal energy depends on how fast the 
molecules move, on the specific heat capacity and on the mass of an object. The specific 
heat capacity is defined as the amount of energy that is required to increase the 
temperature of one kg of that substance by one degree. The temperature is the average 
value of energy for all the atoms and molecules in a given system and is independent of 
the amount of matter. Heat always flows from the body of higher temperature to the 
body of lower temperature. This continues until the temperatures equalize each other. 
Heat can be transferred in three ways: conduction, convection and radiation. Both 
conduction and convection require matter to transfer heat. Instead, radiation does not 
rely upon any contact between the heat source and the heated object. Heat is transferred 
by means of electromagnetic waves such as the sun light. Conduction is the transfer of 
energy that occurs when two particles collide with each other. The particle of higher 
kinetic energy transfers some of its kinetic energy to the particle of lower kinetic 
energy. This is how heat energy is transferred from the sample solution, to the sample 
carrier and finally to the controlled rate freezer. An increase of the freezer temperature 
is prevented by controlled addition of vaporous nitrogen that has just been released from 
liquid nitrogen. Convection is a way of energy transfer that occurs when warmer areas 
of a liquid or gas rise to cooler areas in the liquid or gas, whereby both mix with each 
other. Heat transfer by convection is provided by the stirring process of the LT device. 
Heat transfer is an important aspect of cooling and warming of larger volumes. Slow 
cooling and warming rates are easy to achieve but there are limitations for high cooling 
and warming rates. Normally higher rates can be achieved by increasing the temperature 
difference between sample and freezer, between sample and inlet solution and by 
increasing the amount of inlet solution. Regardless the stirring process, heat gradients 
may still exist within samples, making devitrification and/or ice recrystallization more 
likely. 
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6.2 Aims 
The aim of this chapter was to set-up the Liquids Tracker and to run the standard single 
solution mode cooling profile with dimethyl-sulfoxide (Me2SO) as developed by Planer. 
Following this, the Liquidus Tracking system was adapted to the use of alginate 
encapsulated liver cell (AELC). This included the development of a filter system and a 
new protocol to increase in the sample cooling rate. Finally the newly developed 
cryoprotectant agent solution (CPA No18 – Chapter 5) was compared to Me2SO. 
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6.3 Methods and Materials 
6.3.1 Liquidus Tracker set-up 
Materials 
Controlled Rate Freezer (Planer, Kryo 10, Series II) 
Watson Marlow pumps 520Du 
Inlet tube: Plat Silicon tube; bore 4.8mm, wall.2.4 mm, 
 (Watson Marlow, Cat. No. 913.AJ48.024) 
Outlet tube (outside pump): Plat Silicon tube; bore 4mm, wall 1.6mm, 
(Watson Marlow, Cat. No. 913.A048.016 
Oulet tube (inside pump): Santropene tube, bore 6.3mm, wall 2.4mm, 
(Altec, Cat. No. 01992042) 
Pressure relieve valve (Smart products, Cat. No. 303303PS-1700S020-2368) 
Ten barbed Tee tubing connectors for bore size 4.95mm (Altec, Cat. No. 05-405123) 
Barbed straight tube connectors for bores size 6.3mm and 4.3mm 
(Altec Cat. No. 05-42-5355) 
Method 
The Liquidus Tracker was set up following the operator’s manual if not otherwise 
noted. The inlet pump was equipped with an inlet tube of three meter length, which was 
wrapped five times around the sample holder before being connected to the sample 
container. The pressure relief valve was installed between the tube that goes into and 
out of the inlet pump. For the loop the same tube type as for the inlet was used. Tubes 
were connected with barbed striped tube connectors. For the outlet two different tube 
types were used. Inside the Waston Marlow pump a certain tube thickness had to be 
reached to allow perelistic pumping. For that reason a tube with a larger bore size of 
6.3mm and a wall thickness of 2.4mm from Altec Santroprene was used inside the 
pump which was connected to a silicon tube of 4mm bore size and a wall thickness of 
1.6mm. For the connections barbed straight tube connector from Altec were used. 
6.3.1.1 The CfgPid profile 
The following data was added to the CfgPid software: Kstart - the CPA concentration of 
the starting solution, F1 and F2, the pump calibration factors, the 
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temperature/concentration values, the start volume (Ksol1), (same for each new cycle) 
and the temperature at which the stirrer was supposed to stop (Off1). The single solution 
mode was selected. The CfgPid software uses the temperature/concentration table to 
calculate the amount of CPA that is needed for the next inlet. The points (T1, K1) to 
(T10, K10) define points on the curve and linear interpolation is used by the software to 
determine the concentration between these points (Figure 6.5).  
 
 
Figure 6.5 The CfgPid software 
Data added in the CfgPid table were needed to operate the perelistic pumps and the stirrer. The 
temperature/concentration table described the sample temperature that was supposed to be 
reached at a certain CPA concentration. The start volume (Ksol1) and a start concentration 
(Kstart) had to be defined. Pump calibration factors (F1 and F2) described the flow throughput for 
a given set-up.  
6.3.1.2 Delta T 
Freezer information such as start temperature and the cooling rate were added to the 
Delta T software, which provided a PC interface to the Planer controlled rate freezers.  
6.3.1.3 Pump calibration 
Pumps were calibrated with the final LT set-up in respect to tube type, lengths and 
geometry (wounded around the sample holder). The inlet and outlet tube volume was 
determined by pumping a sequence of normal water and coloured water into a 
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volumetric flask. Once either, the normal or coloured water had finished, the time was 
stopped and the volume was measured. Calibration values F (flow factors in ml/minute) 
were entered into the CfgPid software, to determine the pump speed needed to obtain 
the necessary amount of inlet and outlet during the LT process.  
6.3.1.4 Freezer connection 
The data cable 12-pin connector of the Kryo10 series II freezer was exchanged with a 
new 10-pin connector to be compatible with the Planer controller. 
6.3.1.5 Filling the sample carrier 
The sample carrier has a volume of 500ml and was filled manually for each run with the 
starting solution. Then the upper part of the stirrer was placed on top. The container was 
closed tightly with an inner and an outer lid. Before filling, the inlet, outlet and 
overflow ports were connected to the tubes to prevent the solution to leaking out (Figure 
6.6). 
 
 
 
 
Figure 6.6 Filling the sample carrier 
The Figure describes how the sample was added to the sample container and how the stirrer was 
put together before being placed into the sample holder. 
6.3.1.6 The CPA concentration/temperature curve 
To evaluate the outcome of each LT run, the temperature/concentration curve was 
determined. Therefore a sample of extracted solution was taken at the end of each 
extraction cycle and the CPA concentration was determined by measuring the refraction 
index. This value was correlated to the temperature of the sample inside the sample 
carrier at the beginning of the inlet cycle. The length of a complete cycle was seven 
minutes and followed the subsequent sequence: inlet over one minute - mixing for three 
empty sample 
carrier- sample 
volume 500ml 
 
starting solution 
filled up to the 
outlet port level 
 
magnetic 
stirrer placed 
above static 
part of the 
stirrer 
internal plastic 
lid for 
protection 
placed above 
the stirrer 
  
closed tightly 
with cover lid 
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minutes-outlet over three minutes. Consequently the temperature at the beginning of the 
inlet cycle when new CPA solution was pumped in was higher than at the end of the 
outlet cycle. To obtain the lowest temperature reached for a given CPA concentration 
the temperature had to be recorded at the end of the extraction cycle. The temperature-
concentration curve for each run was then compared to the liquidus curve of the CPA 
solution and the CfgPid profile used in the experiment. 
6.3.2 Changes made to the original Liquidus Tracker set-up 
6.3.2.1 Temperature measurement 
Materials 
Type K thermocouple (Pico Technology, Cat. No. SE027) 
TC-08 data logger (Pico Technology) 
PicoLog recorder software (Pico Technology) 
Method 
To measure the temperature of the inlet solution a thermocouple was inserted into the 
inlet tube just a few centimetres before the inlet port, to measure the temperature just 
before being pumped into the sample carrier. The temperature inside the sample carrier 
was measured by introducing a thermocouple through the overflow tube and port. The 
thermocouple was fixed one centimetre from the bottom and on to the overflow port to 
prevent the thermocouple to interfere with the stirring system. The outlet solution was 
measured by a thermocouple inside the outlet tube just after the outlet port exit (Figure 
6.7). 
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Figure 6.7 Monitoring inlet, outlet and sample temperature 
The graph demonstrates where thermocouples (in red) were placed to measure the temperature of 
inlet, outlet and sample solution. To measure the inlet and outlet temperature, thermocuples were 
inserted into the tubes (in black) just before the ports (in blue). The thermocouple to measure the 
sample temperature was introduced through the overflow port.  
6.3.2.2 Outlet filter system  
Materials 
plastic tube: length 3cm, diameter 3cm 
mesh: 200µm Nylon mesh 
Method 
Unlike larger constructs, alginate encapsulated liver cells (AELC) do not remain 
statically on the bottom of the sample carrier while being stirred. Therefore a mesh 
system was needed to keep the beads inside the sample carrier. The first filter system for 
AELC was made out of a piece of mesh which was directly attached to the outlet port 
opening. However within the first few extraction cycles the filter would block despite 
occasional starting a short reversed flow to unblock the filter. A new filter system of 
increased filter area was designed. The filter area was increased from 0.20cm
2
 to 
9.82cm
2
 by using a plastic tube which was covered from both ends with a mesh. The 
outlet port was introduced through the mesh at the outer edge to maintain most of the 
mesh closer to the inner part of the sample carrier so that the filter system would not 
interfere with the stirrer. By increasing the filter area and by keeping the filter away 
from the opening of the port where the suction force was highest, filter blockage was 
avoided (Figure 6.8). 
  
 Thermocouple 
introduced through 
a hole of the outlet 
tube 
 
 
 
Thermocouple added through the 
overflow port allows measuring 
the temperature within the sample 
carrier without interfering with the 
stirrer system 
Thermocouple 
introduced 
through a hole 
of the inlet tube 
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Figure 6.8 Outlet port filter system 
A filter directly attached to the outlet port resulted in filter blockage. By increasing the filter area 
and by keeping the filter away from the opening of the port, filter blockage was prevented. 
6.3.2.3 Increasing inlet tube lengths 
The original tube length was designed for cooling rates of approximately -0.1˚C 
/minute. However for faster cooling rates (> -0.5˚C) and higher inlet speed (up to 
150ml/minute) which were more appropriate for AELC, insufficient cooling was 
provided. Therefore the inlet tube length was increased from originally three meters to 
six meters to assure that the inlet temperature was close to the freezer temperature.  
200µm filter 
   plastic tube 
(r: 1.75cm) 
  
  
  
before: mesh (r =0.25cm) 
directly attached to the outlet 
port opening. 
  
outlet port 
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6.3.3 Automatic Liquidus Tracking cooling  
Materials 
Liquidus Tracker (Planer plc) 
Me2SO or CPA No.18 (see Chapter 5) 
1xPBS with Mg
2+
 and Ca
2+
 (Sigma, Cat. No. D8662) 
15ml Centrifuge tubes 
AELC 
6.3.3.1 Standard Planer Liquidus Tracking procedure 
Method 
The standard method was as following: 400ml of 15% (w/v) CPA containing AELC 
was added to the sample carrier. Larger volumes of beads were not always available and 
therefore 6ml of beads 12-15 days after encapsulation were used if not otherwise noted. 
The start temperature was set to 20˚C and a cooling rate of -0.5˚C/minute was chosen. 
The sample concentration was increased automatically by following the CfgPid curve 
(Table 6.1), pumping in a 80% (w/v) CPA solution into the sample carrier until a 
concentration of 65% (w/v) was reached. Once a temperature of -40˚C was reached the 
stirrer was stopped and aliquots of 2.5ml were added to 15ml Mircofuge tubes hold in a 
bucket of liquid nitrogen for vitrification and storage. 
                                    Table 6.1 CfgPid table (standard program) one-solution mode  
                                                      using 80% (w/v) Me2SO 
CfgPid modified 
Temperature (˚C) Concentration (%, w/v) 
4 15 
-1.84 21 
-4.84 26.96 
-9.04 32.96 
-14.8 38.96 
-22.41 44.96 
-32.18 50.96 
-44.53 56.96 
-59.72 62.96 
-65.35 65.96 
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6.3.3.2 Combined manual/automatic Liquidus Tracking 
Method 
To avoid outlet pump freezing and to maintain the sample temperature/concentration 
curve close to its liquidus curve a combined manual/automatic LT cooling approach 
was followed. First infusions were carried out by operating the pumps manually, while 
the outlet was primed with 50% (w/v) CPA and remained unused to avoid freezing. The 
freezer temperature was set on hold at -20˚C. Once a concentration of 35% (w/v) CPA 
was reached the automatic program (CfgPid curve) was started (for details see 
Appendix 6.3.3.2). 
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6.4 Results 
6.4.1 The temperature-concentration curve 
For each LT run the temperature/concentration (T/C) curve was determined by 
measuring the refraction index of the extracted solution and by correlating this value to 
the sample temperature reached at the end of the extraction cycle. For this the CPA 
concentration of the collected sample, had to coincide with the CPA concentration of 
the sample inside the sample carrier. For the first runs this was not the case as the 
extraction volume at the beginning of the LT cooling procedure was lower than the 
outlet tube volume of originally 80ml, which led to a deviation to the predicted T/C 
curve. The outlet tube was therefore shortened to a minimum length of 60cm and an 
outlet tube volume of 35ml, which exceeded the minimum outlet volume by 5ml. For 
approximation the CPA sample concentration was calculated by using the inlet volume 
and concentration and the sample volume and concentration. The calculation was based 
on the assumption that perfect mixing was achieved (Figure 6.9). 
  
Figure 6.9 The temperature/concentration curve 
The graph shows the temperature/concentration curve of a LT run for which the outlet tube 
volume was higher than the extraction volume. Measured refraction index values (used to calculate 
the Me2SO concentration) did not correspond to the Me2SO concentration inside the sample carrier 
and the temperature measured at the beginning of the inlet cycle. This lead to strong deviations to 
the predicted T/C curve (blue curve), which had been calculated by using the known inlet volume 
and concentration and the known sample volume and concentration. 
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6.4.2 Devitrification 
An initial concentration of 60% (w/v) Me2SO to vitrify a volume of 400ml CPA 
solution using automatic LT was insufficient to prevent devitrification. An increase to 
62.5% (w/v) was needed to prevent any visual ice formation. However this was 
insufficient for the same solution with addition of 200ml of alginate beads. By visual 
inspection it was observed that beads became opaque during the warming process 
before the ice started to form in the surrounding solution, obviously reacting as a 
nucleation centre. To avoid devitrification the final CPA concentration had to be 
increased to 64% (w/v). Stirring could not be carried out at temperatures below -40˚C 
for Me2SO (<-35˚C for CPA No.18) due to increased CPA viscosity. As the temperature 
was gradually decreased, a gradual CPA increase had to be followed which resulted in a 
stronger deviation of the CfgPid curve from the liquidus curve (Figure 6.10). 
A.                                                                  B. 
 
Figure 6.10 Devitrification during the warming process 
Figure A shows the sample carrier filled with 60% Me2SO (w/v) that was cooled down to -130˚C. 
Ice formed during the warming process (at room temperature) when the sample temperature was 
between -90˚C and -60˚C. The CPA concentration for samples with beads had to be increase to 64% 
(w/v) Me2SO to prevent devitrificatio. Figure B shows the change made to the original CfgPid 
profile (dashed line in blue) used by Planer. The final inlet temperature was maintained at -60˚C 
while the Me2SO concentration was gradually increased (dashed line in black), resulting in a 
stronger deviation to the Me2SO liquidus curve (line in red).  
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6.4.3 Liquidus Tracking temperature measure 
The concept of Liquidus Tracking (LT) is to keep temperature and concentration of the 
CPA solution close to its liquidus curve to minimize CPA toxicity. However, once 
thermocouples were used to measure the temperature of inlet, outlet and sample 
solution, it became evident that the temperature of the sample differed by more than 
15˚C from the temperature of the programmed profile (CfgPid curve) and was 
approximately 20˚C higher than the temperature of the liquidus curve. These results 
were achieved with a freezer cooling rate of -0.5˚C/minute. A freezer cooling rate 
of -0.1˚C/minute had previously been used to predict the temperature difference 
between freezer and sample. The predicted sample temperature was displayed by the 
controller and was seen to conform to the programmed CfgPid curve (Figure 6.11). 
 
 
Figure 6.11 CfgPid curve and sample T/C curve temperature difference 
The graph shows the difference between the programmed CfgPid curve (dashed black line) and the 
temperature/concentration (T/C) curve obtained when measuring the temperature inside the 
sample carrier (purple line -Pico Logger). The measured Me2SO concentration but in correlation 
with the temperature displayed by the controller (green line -controller)) overlaped with the 
programmed concentration (CfgPid curve).  The temperature difference between the T/C Pico 
Logger curve and the CfgPid curve reached from initially 10˚C to finally 20˚C. 
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6.4.4 Reducing the temperature difference between liquidus curve and 
temperature/concentration curve 
Without the option to change the volume of the sample and the geometry of the sample 
carrier, the only way to increase the sample cooling rate and to run a T/C profile closer 
to the liquidus curve was to reduce the freezer temperature. This was done by defining 
lower target temperatures for the same CPA concentrations in the 
temperature/concentration table of the CfgPid software tool. Over the first runs the 
freezer temperature was reduced by first 4˚C and then 6˚C in respect to the starting 
profile (A-1), while the freezer temperature was kept above the liquidus curve of 
Me2SO. The changes only had a marginal impact on the sample cooling rate - the 
difference to the liquidus curve remained above 18˚C (Figure 6.12 A).  
Subsequently the freezer temperature was set 20˚C below the temperature of the CfgPid 
A-1 profile and up to 10˚C below the Me2SO liquidus curve (B-1). The solution inside 
the outlet tube froze at a freezer temperature of -47˚C. The freezer temperature was 
therefore increased above the liquidus curve of Me2SO once the freezer reached a 
temperature of -44˚C (B-2). Additionally the outlet tube was isolated which helped to 
increase the temperature by approximately +5˚C in respect to the freezer temperature. 
The implemented measures did not prevent the outlet tube from freezing. This was 
finally achieved by further increasing the freezer temperature (B-3) in respect to the B-2 
profile (Figure 6.12 A). However, the T/C curve achieved with CfgPid B-3 was only 
5˚C closer to the Me2SO liquidus curve than the T/C curve of the starting CfgPid profile 
A-1 (Figure 6.13). 
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A. 
 
 
B.  
 
 
Figure 6.12 LT temperature/CPA concentration profiles 
Figure A and B show CfgPid profiles that were used for automatic LT. Figure A: The freezer 
temperature was programmed to remain above the liquidus curve of Me2SO. The freezer 
temperature was reduced (A-2 and A-3) to obtain a T/C curve that runs closer to the Me2SO 
liquidus curve. Figure B: The freezer temperature was programmed to be below or partially below 
the Me2SO liquidus curve. Using the profile CfgPid B-1 and B-2 resulted in outlet tube freezing. 
CfgPid B-3 was the profile with the lowest possible temperature that would not lead to outlet tube 
freezing. Table A and B summarize changes and outcome of changes made to the CfgPid profiles.  
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Table to Figure 6.11 A 
run change Temp. difference 
sample to  
liquidus curve 
A-1 Starting CfgPid 
curve 
approx. 20˚C 
A-2 CfgPid curve set 
4˚C below A-1 
curve 
approx. 18˚C 
A-3 CfgPid curve set 
6˚C below 
A-1 curve 
approx. 18˚C 
Table to Figure 6.11 B 
run change result 
B-1 -20˚C below 
CfgPid A-1 and 
below liquidus 
curve 
Outlet tube 
freezing at the 
end of the run 
B-2 As B-1but higher 
temperature at the 
end of the run 
Outlet tube 
freezing 
B-3 +8˚C above 
CfgPid B-1 below 
liquidus curve 
No outlet tube 
freezing 5˚C 
to 30˚C above 
the liquidus 
curve  
Chapter 6: The automatic Liquidus Tracker 
198 
 
 
Figure 6.13 Temperature/concentration curve achieved with LT CfgPid profile A-1 and B-3 
The graph shows the T/C curves achieved with Cfgpid profile A-1 and B-3. T/C curve B-3 (light 
blue dashed line) ran approximately 5˚C below the T/C curve A-1 (purple line). At a concentration 
of 50% Me2SO (w/v) the temperature difference started to equalize. T/C curve B-3 remained 5˚C to 
30˚C (from 15 to 65% (w/v) Me2SO) above the liquidus curve of Me2SO. 
6.4.5 The combined manual/automatic Liquidus Tracking approach 
Outlet tube freezing occurred when the freezer temperature fell below the melting point 
of the solution held inside the tube. The solution inside the sample carrier was not 
affected due to lower cooling rates, which were a result of the higher sample volume 
and the sample carrier geometry. The solution inside the inlet tube remained liquid, as it 
contained much higher concentrations of CPA. To prevent the outlet tube from freezing 
a combined manual and automatic approach was used. The outlet tube was primed with 
a highly concentrated CPA solution and was not used for the first four inlet cycles. The 
CPA concentration was increased manually by operating the pumps once the required 
sample temperature was reached. This way the T/C curve was kept close to the liquidus 
curve of the CPA solution especially at the beginning of the run (Figure 6.14). 
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Figure 6.14 Combined manual and automatic LT 
To increase the cooling rate of the sample inside the sample carrier the freezer temperature was set 
to -20˚C. The CPA concentration was increased manually over four inlet cycles (squares in grey) 
until a concentration of approximately 37% (w/v) CPA at -17˚C was reached, without operating the 
outlet pump to avoid outlet tube freezing. The automatic process (purple squares) was started to 
increase the CPA concentration from 37% to 65% CPA (w/v) by using a linear CfgPid profile 
(dashed black line). This way the sample T/C curve followed closely the Me2SO liquidus curve (red 
curve). 
6.4.6 Combined manual/automatic Liquidus Tracking temperature profile 
As a means to increase the sample cooling rate the freezer temperature was set to -20˚C 
while the manual inlet cycles were carried out. Due to the inlet tube lengths of six 
meters the inlet solution cooled down to the freezer temperature before passing the inlet 
port even at high inlet pump rates (up to 140ml/minute). The CPA solution inside the 
sample carrier cooled down as a result of the inlet solution temperature of -20˚C and as 
a result of the temperature difference between the freezer and the sample. Once manual 
inlet cycles were finished, automatic LT with a freezer cooling rate of -0.5˚C/minute 
was started. The freezer temperature was kept at -60˚C for 20 minutes to provide 
sufficient mixing before the freezer was set to -160˚C, which as a consequence 
increased the sample cooling rate to -3˚C/minute (from -40˚C to -125˚C). The outlet was 
not used until the automatic profile was started and therefore the temperature was the 
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same as the freezer temperature. Once the outlet was started, the sample solution which 
was of higher temperature increased the temperature inside the outlet tube. This, and the 
insolation around the outlet tube which helped to decrease the cooling rate, maintained 
the temperature above the solution’s melting point (Figure 6.15).  
 
 
Figure 6.15 Combined manual/automatic LT temperature profile 
The graph shows the freezer, inlet, outlet and sample temperature profiles of a typical 
manual/automatic LT run. The freezer temperature (dashed blue line) was kept at -20˚C until the 
automatic profile with a freezer cooling rate of -0.5˚C/minute was started. The sample temperature 
(blue line) decreased almost linear with an average cooling rate of -0.5˚C/minute until a 
temperature of -50˚C was reached,  then the cooling rate increased in response to the increased 
freezer cooling rate (-10˚C/minute) to -3˚C/minute. The temperature of the inlet solution (red line) 
closely followed the freezer temperature curve. The temperature of the outlet solution (green line) 
increased each time solution was extracted and then followed a faster cooling rate than the freezer, 
however remained above the Me2SO liquidus curve throughout the run. 
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6.4.7 First runs with dimethyl sulfoxide and CPA solution No.18 
First LT runs using the combined set-up with AELC using Me2SO as a single CPA 
resulted in no post-warming cell viability. When the newly developed CPA solution 
CPA No.18 (Chapter 5) was used, cell viability was increased to approximately 40% 
(Figure 6.16). 
 
Figure 6.16 Automatic Liquidus Tracking-Me2SO vs. CPA No.18 
Cell viability increased from 1.0% +/- 0.1 to 40% +/- 7.7 when combined manual/automatic LT was 
carried out using CPA No.18 instead of Me2SO. After cooling to -40˚C, aliquots of 2.5ml were 
immediately vitrified (6.3.3.1). A two-step warming protocol (from 65% to 44% (w/v) CPA 
at -20˚C, then to 20% (w/v) glucose at 0.5˚C) was used and AELC were cultured for 24 hours in 
complete media at 37˚C before measuring viability. Data are n=3 +/- SD **p<0.01. 
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6.5 Discussion 
The first part of this chapter was to install the Liquidus Tracker and to run the Planer 
Liquidus Tracking (LT) cooling protocol. This pre-set method uses high concentrated 
dimethyl sulfoxide (80% (w/v) Me2SO) to increase the sample CPA concentration 
(single solution mode). It is important to mention that this standard method but also the 
design of the stirrer and the sample carrier were developed to meet the requirements for 
cryopreserving larger constructs, and in particular articular cartilage (connected to 
chunks of bones). Me2SO was chosen as a single cryoprotectant as promising results 
had previously been achieved for cartilage preservation using manual LT (Pegg et al., 
2006; Wang et al., 2007). Thus, Me2SO was used by Planer to develop the pump and 
stirring system and the LT cooling protocol.  
One of the main issues for the development of the Liquidus Tracker was the increasing 
viscosity of Me2SO at decreasing temperatures. Pump cycles had to be adjusted as it 
was shown that the extraction cycle at low subzero temperatures became increasingly 
inaccurate. The outlet time was therefore set to 180 seconds - three times longer than the 
inlet cycle - to allow a slower pump rate and reduce air bubbles that were distorting the 
extraction volume. The minimum temperature at which the stirrer operated flawlessly in 
respect to viscosity had been defined and translated to the temperature and 
concentration profile (CfgPid table) the sample was supposed to follow. To avoid the 
need to re-develop these parameters, viscosity was selected as the first limiting factor 
when a new CPA solution (CPA No.18 - Chapter 5) was developed.  
Although manual LT experiments (Chapter 4) already demonstrated better suitability of 
CPA No.18 to cryopreserve AELC, Me2SO was used to improve the LT system. On the 
one hand as it had been used by Planer for the development of the LT system, but also 
because the preparation was faster (no dilution of glucose), it was cheaper and the 
solution could easily be reused by simply adding more Me2SO until the required 
concentration (measured with the refractometer) was reached. As for the large amounts 
of CPA needed for one LT run (approximately 1l of 80% (w/v) CPA) and the numerous 
LT runs that were carried out, this was a considerable time and cost-saving measure. 
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Contrary to larger constructs for which the system had been designed, alginate beads are 
not held in a fixed position, which made it necessary to introduce a filter system. The 
first filter, of the size of the outlet port (d=0.5cm) and directly attached to the outlet port 
opening was blocked with beads shortly after the start of the LT cooling procedure. 
Initially it was tried to unblock the filter by occasionally reversing the outlet flow, 
however the success was limited due to the following reasons: firstly the original filter 
area was small in comparison to the number of beads (approximately 300ml of settled 
beads) and the volume that had to be extracted (up to 140ml in 3 minutes). Secondly 
alginate beads became increasingly sticky at higher CPA concentrations. Thus, to 
overcome filter blockage the filter area was substantially increased whilst the mesh was 
hold several centimetres away from the opening of the outlet port. With several 
centimetres and solution between the opening of the port and the filter, the suction was 
distributed more evenly over the whole mesh. As a result suction per filter area was 
reduced sufficiently to allow the cross-flow produced by the stirring system to keep the 
filter free of beads. Due to the geometry of the stirrer, space inside the sample carrier 
was limited, which restricted the size of the filter system. To increase the filter area, two 
meshes, connected with a plastic ring, one above and one below the outlet port opening, 
were used.  
A surprising but positive effect encountered with CPA solution No.18 in comparison to 
Me2SO was that beads were less sticky at high CPA concentrations. This was 
advantageous in respect to outlet filter blockage and the filter area needed. This is also 
an important aspect in terms of upscaling. In order to keep the same cooling rate much 
higher volumes have to be pumped though the system, as cooling will mainly be 
achieved by the low temperature of the inlet solution (convection) and not by 
conduction (heat transfer from sample to sample carrier to the freezer). This means that 
the filter system has to be substantially increased though with the requirement not to 
interfere with the stirrer system.    
One of the main issues that was encountered when using the pre-set Planer method was 
the substantial difference between the freezer cooling rate and the cooling rate of the 
sample solution inside the sample carrier. First runs performed with the Planer standard 
CfgPid profile for Me2SO with a freezer cooling rate of -0.5˚C/minute resulted in a 
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temperature offset from the melting point by +20˚C, which meant that an already critical 
Me2SO concentration of 40% (w/v) (melting point of -25˚C) was reached at 0˚C. In an 
attempt to increase the sample cooling rate, the freezer temperature was decreased and 
set closer to the Me2SO liquidus curve. At first the freezer temperature was maintained 
above the temperature of the sample liquidus curve, but the effect on the sample cooling 
rate was negligible. In a different approach the freezer temperature was set 15˚C below 
the sample liquidus curve to maintain the sample temperature 5˚C above its melting 
point to avoid any freezing inside the sample carrier. The sample solution remained 
liquid but ice formed inside the outlet tub, so that the experiment had to be stopped. The 
solution inside the outlet tube being from the previous extraction cycle contained the 
lowest CPA concentration within the LT system; however the cooling rate inside the 
tube was comparable to the freezer cooling rate due to the tube geometry and material. 
Insolating the outlet tube reduced the cooling rate but did not prevent freezing, manual 
priming the outlet tube after each extraction cycle with high concentrated CPA strongly 
interfered with the automatic program and again did only delay freezing but would not 
completely prevent it. As a consequence the freezer temperature was increased until 
outlet freezing was avoided, but the sample cooling rate that was achieved with the new 
CfgPid profile was comparable to the original Planer profile. 
AELC incubated in CPA concentrations of up to 55% (v/v) demonstrated high survival 
rates when the incubation temperature was set to -10˚C or -20˚C (Chapter 4). Thus, the 
conclusion was drawn that it was especially important at the begging of the cooling 
process - at temperature above -10˚C - to keep the sample temperature close its melting 
point. To prevent the outlet tube from freezing a combined manual and automatic 
approach was used.  The outlet tube was primed with a high concentrated CPA solution 
and was not used for the first four inlet cycles until a concentration of 35% (w/v) and a 
temperature of -12˚C were reached. The CPA concentration was increased manually by 
operating the pumps once the required sample temperature was reached. This way the 
sample temperature was kept close to its melting point (liquidus curve) and outlet 
freezing was avoided.  
Although the combined manual/automatic LT kept the sample 
temperature/concentration curve close to the liquidus curve and despite the fact that 
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automatic LT increased the CPA concentration continuously and without the 
temperature fluctuation seen for manual LT, no viability was detected when Me2SO was 
used as a single CPA. However when Me2SO was replaced with the newly developed 
CPA No.18 solution (Chapter 5) viability was increased to approximately 40%.  
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6.6 Conclusion 
The Liquids Tracker was set-up and a new LT protocol of faster sample cooling rate as 
well as a filter system was established and tested. Viability was increased from 0% to 
40% post-warming by using the newly developed CPA solution No18 instead of 
Me2SO. Despite these improvements, recovery is insufficient for AELC to be used 
within a bioartificial liver device. Therefore, the aim of the next chapter was to identify 
other mechanisms to improve recovery and in addition, to establish the warming 
protocol, so that the complete LT process, including cooling, vitrification and warming, 
could be tested. 
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7 CHAPTER 7 
Automatic Liquidus Tracking 
7.1 Introduction 
In Chapter 6 it was described how the Liquidus Tracker was set up and the system was 
adapted for the use of encapsulated liver cells (AELC). Apart from installing a filter 
system to retain AELC in the sample carrier, the cooling rate was increased so that the 
sample would run closer to the samples liquidus curve. Nevertheless, no post-warming 
viability was detected when Me2SO was used to vitrifiy AELC. Viability increased to 
40% when the newly developed cryoprotectants agent (CPA) solution No.18 (Chapter 
5) was used instead. However recovery was still too low for a potential use of AELC in 
a bioartificial liver device. 
Further possibilities to increase cell recovery could be the use of organ preservation 
solutions like Viaspan (University of Wisconsin solution) or HTK instead of PBS as a 
CPA carrier solution. Those solutions were designed to reduce chilling injury during 
hypothermic storage and could therefore be useful to maintain cell viability through the 
lengthy LT cooling and warming process. Additionally important is to investigate 
whether sufficient CPA penetration is provided during the cooling process and what 
effect stirring has on cell survival. 
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7.2 Aims 
The aim of this chapter was to identify other potential mechanisms to increase cell 
recovery following cryopreservation. For this a simplified manual Liquidus Tracking 
(LT) procedure to pre-test conditions for automatic LT was established. Finally the 
automatic warming LT process had to be established in order to test the complete LT 
process including cooling and vitrification on warming. 
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7.3 Methods and Materials 
7.3.1 The 50-60-66% CPA inlet 
Materials 
Liquidus Tracker (Planer plc) 
CPA No.18 (see Chapter 5) 
1xPBS with Mg
2+
 and Ca
2+
 (Sigma, Cat. No. D8662) 
15ml Centrifuge tubes 
AELC 
 
Method 
AELC in 280ml of PBS were added to the sample carrier and both inlet and outlet were 
primed with 50% (w/v) CPA. 
Delta T program: 
Freezer start temperature was set to 1˚C (on hold) 
Manual inlet: 
First 50% (wv) CPA was manually pumped in until a sample concentration of 40% 
(w/v) was reached. Then a 60% (w/v) CPA solution was used to increase the sampel to 
50% (w/v) and finally a 66% CPA solution was added to reach a final sample 
concentration of 65% (w/v) (for details see Appendix 7.3.1). 
7.3.2 Automatic Liquidus Tracking warming 
Materials 
Liquidus Tracker (Planer plc) 
vitrified AELC 
CPA No.18 (see Chapter 5) 
1xPBS with Mg
2+
 and Ca
2+
 (Sigma, Cat. No. D8662) 
7.3.2.1 The single solution reverse mode 
Method 
Vitrified AELC were added to a pre-cooled solution (-25˚C) of 65% (w/v) CPA No.18. 
The freezer temperature was set to -25˚C. Once the sample (volume 400ml at 65% (w/v) 
Chapter 7: Automatic Liquidus Tracking 
210 
 
CPA No.18) reached a temperature of -25˚C, manually 60ml PBS (at room temperature) 
were pumped through the outlet port into the sample carrier. The outlet port with a 
inside freezer tube length of 40cm (inlet tube length = 6m), was used to avoid any 
freezing while pumping in PBS at subzero temperatures. An inlet pump speed of 
20ml/minute was used. After one minute of stirring, 60ml were pumped out to prevent 
the outlet port from freezing, to reduce the sample volume and to measure the refraction 
index. During the addition the temperature increased and time was given until the 
temperature decreased again (Table 7.1). The warming procedure, when started at -25˚C 
took approximately one hour. 
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Table 7.1 One solution mode warming protocol 
Freezer 
temperature 
Sample 
temperature 
 CPA concentration  
(%, w/v) 
-25˚C -25˚C  65 
-25˚C -17˚C Inlet of 60ml 1xPBS 57 
-25˚C -22˚C Wait 12 minutes 57 
-25˚C -16˚C Inlet of 60ml 1xPBS 49 
-25˚C -20˚C Wait 12 minutes 49 
-25˚C -13˚C Inlet of 60ml 1xPBS 42 
-25˚C -20˚C Wait 12 minutes 36 
-25˚C -13˚C Inlet of 60ml 1xPBS 30 
-10˚C -13˚C Continuous inlet until a CPA concentration of 0% 
and temperature of 10˚C was reached. 
 
Finally 0.25ml of beads were added to a cell strainer and washed three times with fresh 
1xPBS (ice-cold) to remove all CPA. Finally AELC were incubated in 8ml of complete 
media at 37˚C until measurement. 
7.3.2.2 The four step reverse mode 
Method 
The freezer was set to -25˚C to warm up the sample temperature. Once the sample had 
reached a temperature of -35˚C the stirrer was started. The CPA solution inside the inlet 
tube was extracted and the tube was primed with 150ml of a 50% (w/v) CPA No.18 
solution. The freezer was set to -30˚C and the inlet was started once the inlet 
temperature had reached -30˚C. The inlet and outlet speed were set to 20ml/minute if 
not otherwise noted. After the addition of 250ml 50% (w/v) CPA No.18, the freezer 
temperature was set to -25˚C while the remaining 250ml of the 50% (w/v) CPA No.18 
solution was added. This helped to increase the sample temperature to 
approximately -25˚C. The freezer was set to -20˚C and 40% (w/v) CPA No.18 was 
added. After the addition of 250ml the freezer temperature was set to -15˚C while the 
remaining 250ml were added. This helped to increase the sample temperature to 
approximately -15˚C. After the addition of 250ml 30% (w/v) CPA No.18, the freezer 
temperature was set to -10˚C while the remaining 250ml of the 30% (w/v) CPA No.18 
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solution was added. The sample temperature increased to approximately -10˚C and 1L 
PBS hold at room temperature was added at an inlet speed of 40ml/minute. The outlet 
speed was also increased to 40ml/minute. 
7.3.3 The complete Liquidus Tracking procedure 
The LT process was divided into: LT cooling to -40˚C (cooling rate -0.5˚C CPA 
increase from 0% to 65% (w/v), fast cooling to -125˚C (below the expected glass 
transition point), slow warming to -95˚C, in order to obtain a homogenous temperature 
across the sample before the fast warming phase was started, fast warming to -40˚C and 
the LT reverse warming process from -40˚C to >4˚C (CPA decrease from 65% to 0% 
(w/v). When the vitrification cooling step was included the whole process was carried 
out, as otherwise the sample carrier had to be disconnected from the inlet, outlet and 
overflow tube and be taken out from the sample holder. As this included additional 
challenges, the whole process was followed in the one run. The amount of one liquid 
nitrogen drewar (35L) was insufficient to support the entire process. Therefore the tank 
was disconnected from the controlled rate freezer to be re-filled, once the sample had 
reached a temperature of -125˚C and the warming process was started. Slow cooling 
(warming rate +0.35˚C/minute) was obtained by disconnecting the liquid nitrogen tank 
from the freezer and keeping the freezer lid closed. Slow warming was chosen 
until -95˚C to equilibrate the temperature across the sample carrier before the freezer 
temperature was set to -25˚C. The reason for this was that devitrification had been 
observed at a temperature range between -95˚C and -60˚C, consequently a faster 
warming rate was chosen for temperature above -95˚C. At -40˚C the reverse LT 
warming process was started by putting the stirrer in operation (Figure 7.1).  
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Figure 7.1 Complete LT process 
The complete LT process consisting of: LT cooling to -50˚C, (duration: 2.5 hours), fast cooling to -
125˚C (duration: 1 hour), slow warming to -95˚C (duration: 1.5 hours), fast warming to -40˚C 
(duration: 30 minutes) and LT reverse warming process (duration 2.5 hours).  
7.3.4 Manual two-step Liquids Tracking  
Materials 
Liquidus Tracker (Planer plc) 
AELC 
15ml Centrifuge tubes 
50ml Centrifuge tubes 
100 um cell strainers (BD Bioscience, Cat. No. 352360) 
Ethanol (Fisher Chemicals, Cat. No. E/650DF/17) 
1xPBS with Mg
2+
 and Ca
2+
 (Sigma, Cat. No. D8662) 
CPA No.18 (see Chapter 5) 
for CPA No.18 variations: 
Me2SO (Sigma, Cat. No. 154938) 
Ethylene Glycol (Sigma, Cat. No. 293237) 
D+ glucose (Sigma, Cat. No. 66152) 
D+ Trehalose (Sigma, Cat. No. T95531) 
D+ Raffinose (Sigma, Cat. No. 83400) 
D+ glucose (Sigma, Cat. No. 66152) 
Sucrose (BDH, Cat. No. 102745C) 
for sample carrier variations: 
HEPES  (Gibco, Cat. No.15630) 
ViaSpan = UW solution: Belzer Germany 
HTK 
           2.5 hours                       1 hour                  1.5 hours           30 minutes              2.5 hours 
 LT cooling 
 to -40˚C 
(-0.5˚C/minute) 
fast warming 
to -40˚C  
(+2.35˚C/min.
) 
Reverse LT  
to 4˚C 
cooling  
to -125˚C 
(-3˚C/minute) 
slow warming  
to -95˚C 
(+0.35˚C/min.) 
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for pre-incubation experiments: 
Alginic acid albumin (Sigma, Cat. No. A2033)   
L-Proline (Sigma, Cat. No. P0380) 
D+ Trehalose (Sigma, Cat. No. T95531) 
Culture media (see Chapter 2) 
Method 
In order to process several samples at the same time and to pre-test conditions for 
automatic LT, a two-step manual cooling and warming protocol proved to be more 
practical than a multi-step manual LT protocol as used in Chapter 4 (manual LT) (for 
details see Appendix 7.3.4).  
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7.4 Results 
7.4.1 Pre-testing conditions with manual Liquidus Tracking 
Although the usage of CPA No.18 substantially improved cell recovery, viability was 
still low (40%). To increase post-warming viability several measures were taken. In a 
first attempt the concentration of the non-penetrating CPA glucose was increased while 
the penetrating CPA concentration (Me2SO) was decreased. When AELC were 
incubated for one hour at a temperature of 0.5˚C, cell viability was significantly higher 
in comparison to CPA No.18 but recovery was significantly lower when AELC were 
vitrified using the two-step manual LT protocol (Figure 7.2), but also when the 
automatic LT approach was used (Figure 7.3). Different results between the test systems 
pointed out the necessity of including the vitrification step in the cooling procedure 
when evaluating CPAs and sample carrier composition. As automatic LT was not 
suitable to screen a variety of different conditions, the two-step manual LT approach 
was used. 
A.                                                             B. 
 
Figure 7.2 Decreased Me2SO and increased glucose concentration  
A.) AELC incubation in CPA No.18 (Me2SO/EG/glucose ratio 40/20/10) for 1h at 0.5˚C was more 
toxic than a CPA solution with a ratio of 30/20/10 (Me2SO/EG/glucose ratio). Data was n=5+/-SD, 
**p<0.01. B.) Using a two-step manual LT protocol (from 0% to 40% (w/v) CPA at 0.5˚C, then to 
65% (w/v) at -20˚C, to LN at -40˚C; warming: from 65% to 44% (w/v) CPA at -22˚C, then to 20% 
(w/v) glucose at 0.5˚C), indicated significantly better post-warming results for CPA No.18 than for a 
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Me2SO/EG/glucose solution with a ratio 30/10/20. Data was n=5+/-SD, **p<0.01. A. and B: AELC 
were cultured for 24 hours in complete media at 37˚C before measuring viability. 
 
 
 
Figure 7.3 Automatic LT-decreased Me2SO and increased glucose concentration 
AELC vitrified using the combined manual/automatic LT approach showed much lower viability 
when the new CPA solution (Me2SO/EG/glucose ratio 30/20/20) was used instead of CPA No.18 
(ratio of 40/20/10). Each condition was tested once. Five sample were taken after the increase to 
40% CPA (w/v) and five samples were vitrified at -40˚C at a concentration of 65% (w/v) (n=5 +/- 
SD). Non-vitrified samples were warmed within one step (directly to 20% glucose at 0.5˚C). 
Vitrified samples were warmed in a two-step warming protocol (from 65% to 44% (w/v) CPA at -
22˚C, then to 20% (w/v) glucose at 0.5˚C). AELC were cultured for 24 hours in complete media at 
37˚C before measuring viability.  
 
In Chapter 5 it was shown that the combination of two sugars showed better cell 
recovery than the use of a single sugar when the incubation was carried out at 0.5˚C, 
however, no improvement was observed when the three best glucose combinations 
(glucose-trehalose, glucose-raffinose and glucose-sucrose) were compared in a two-step 
manual LT set-up. Exchanging 1xPBS with ViaSpan, HTK (Histidine-tryptophan-
ketoglutarate) or HEPES buffer did not show any improvement either. Adding 40mM 
proline to the culture media 24 hours pre-testing slightly decreased cell viability while 
the addition of 30mM (w/v) trehalose and an increased concentration of linoleic acid-
albumin by 2.5-fold (8.75mM) in the culture media increased cell viability slightly, but 
not statistically significantly. As no substantial improvements were noted, none of the 
conditions was re-tested using the automatic LT approach (Figure 7.4).  
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A.  
 
B.  
 
C.  
 
D.  
 
Figure 7.4 Pre-test of CPA No.18 variations, sample carrier solutions, pre-incubation additives 
Two-step manual LT (from 0% CPA to 40% CPA at 0.5˚C, then to 65% at -20˚C, to LN at -40˚C) 
was used to pre-evaluate sugars, buffers and pre-incubation additives. After warming (from 65% 
CPA to 45% CPA at -22˚C, then to 20% glucose at 0.5˚C), AELC were cultured for 24 hours in 
complete media at 37˚C before measuring viability. Graph A: Glucose alone or in combination with 
trehalose, sucrose or raffinose was used as a penetrating CPA for CPA No.18 (same w/v 
concentration for both sugars, Me2SO/EG/sugar ratio was 40/20/10). Graph B: As a CPA carrier 
1xPBS, ViaSpan or HTK was used. Graph C: As a buffer 1XPBS, 10mM and 25mM HEPES was 
used. Graph D: AELC were cultured in complete media for 24 hours prior testing, containing 
either 8.75mM linoleic acid-albumin, 40mM proline or 30mM trehalose. Changes made to the 
standard condition (CPA No.18 with 1xPBS) did not significantly improved post-warming viability. 
Data was n=5 +/-SD. 
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7.4.2 Minimum CPA addition and inlet temperature  
The usage of different sugars and buffers or the pre-incubation in sugars and proteins 
did not improve LT cell survival. Another consideration was therefore that the 
temperature of the sample was too low to provide sufficient CPA penetration to prevent 
intracellular ice formation or that the CPA toxicity was still too high.  Two-step manual 
LT was used to determine whether the CPA addition temperature had an effect on cell 
recovery. AELC first incubated in 40% and 50% CPA No.18 (w/v) at 0.5˚C (for 5 
minutes) were cooled at -2˚C/minute to -11˚C, -16˚C and -22˚C and to -22˚C, -27˚C and 
-33˚C, respectively before the CPA concentration was increased to 65%. Subsequently 
samples were cooled to -40˚C at -1˚C/minute before they were vitrified in liquid 
nitrogen. Cell recovery increased significantly at lower CPA addition temperatures from 
-11˚C to -22˚C, but remained equal between -22˚C and -27˚C and was reduced at -33˚C 
(Figure 7.5). Similar results were obtained for automatic LT. In a first experiment cell 
recovery was lower when the minimum inlet temperature was set to -15˚C, increased 
when set to -25˚C and clearly decreased at -37˚C. In a second experiment slightly lower 
viability was measured when the minimum inlet temperature was set to -33˚C instead to 
-25˚C (Figure 7.6). 
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A.                                                          B.        
 
Figure 7.5 Final CPA addition temperature – manual LT 
Graph A and B: CPA concentration was increased from 0% to 40% or 0% to 50% (w/v) CPA 
No.18 at 0.5˚C. Samples were then cooled at -2˚/minute to -11˚C, -16˚C and -22˚C or -22˚C, -27˚C 
and -33˚C, respectively, before the CPA concentration was increased to 65% (w/v) CPA No.18. 
Finally samples were cooled to -40˚C at -2˚/minute and introduced into LN. Viability significantly 
increased from -11˚C to -16˚C and from -16˚C to -22˚C, but was significantly reduced at -33˚C 
(n=5+/- SD** p<0.01). AELC were cultured for 24 hours in complete media at 37˚C before 
measuring viability.  
A.                                                             B. 
 
Figure 7.6 Final CPA addition temperature – automatic LT 
Graph A and B show two sets of automatic LT runs. For each run five samples were vitrified, 
warmed and viability measured (n=5 +/- SD). Combined manual/automatic LT with a maximum 
inlet temperature of -15˚C, -25˚C and -37˚C showed an improvement in viability from -15˚C 
to -25˚C but was lower at -37˚C. Samples were vitrified at -40˚C and were then warmed in a 
two-step warming protocol (from 65% to 45% (w/v) CPA at -22˚C, then to 20% (w/v) glucose at 
0.5˚C). AELC were cultured for 24 hours in complete media at 37˚C before measuring viability.  
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7.4.3 Impact of sample volume on cell viability 
Several litres of CPA were needed to perform a single automatic LT run. One aim was 
therefore to reduce the starting volume from initially 280ml to 140ml. This had an 
unexpected effect on cell viability as recovery was substantially reduced (Figure 7.7).  
 
 
Figure 7.7 Impact of sample volume on cell viability 
Lower viability was obtained when the sample volume was reduced from 280ml to 140ml. Each 
condition was tested once. Five samples were vitrified after being increased to 65% (w/v) CPA and 
after being cooled to -40˚C. Vitrified samples were warmed in a two-step warming protocol (from 
65% to 44% (w/v) CPA at -22˚C, then to 20% (w/v) glucose at 0.5˚C). AELC were cultured for 24 
hours in complete media at 37˚C before measuring viability. 
7.4.4 Inhomogeneous “cell per bead” survival 
AELC viability was observed after each LT run using the fluorescent microscope. It was 
noted that some of the beads contained a high proportion of viable cells, while others 
contained almost exclusively dead cells. This observation was independent of whether 
AELC were vitrified after the cooling process to -40˚C (at 65% (w/v) CPA) or directly 
warmed. It was assumed that the effect was caused by the temperature difference within 
the sample carrier (colder at the carrier wall, bottom or surface and warmer at the 
centre) or by the temperature difference between inlet and sample solution. Viability, up 
to a CPA concentration of 40% (w/v) remained high and inhomogeneous AELC 
viability in beads was not observed. The inlet temperature was therefore maintained 
at -15˚C once a CPA concentration of 35% (w/v) was reached. That way the freezer 
temperature and consequently the temperature inside the sample carrier and of the inlet 
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solution was maintained constant during the CPA addition process from 35% and 65% 
(w/v). Nevertheless strong variation between beads remained (Figure 7.8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.8 Inhomogeneous “cell per bead” survival 
AELC survival at 40% (w/v) CPA No.18 at -20˚C was high and there was visually little difference 
between the numbers of cells per bead that had survived the LT process. Once AELC were exposed 
to 65% CPA at -40˚C, beads strongly varied in their number of viable cells. This was also seen 
when the freezer and inlet temperature was restricted to -15˚C. The figure shows phase images, and 
images of live (green, stained with FDA) and dead (red, stained with PI) cells. 
7.4.5 High concentrated CPA inlet solution 
It was shown that a temperature gradient across the sample carrier did not cause the 
strong variation seen between beads in respect to AELC survival. In an initial 
experiment the inlet CPA concentration had been investigated with the prediction that 
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an inlet of 80% (w/v) CPA No.18 would cause immediate damage to AELC as a cause 
of strong CPA concentration differences between inlet and sample solution. Instead an 
inlet solution 50% (w/v) CPA No.18 was used to increase the sample concentration to 
40% (w/v). Viability and cell numbers were measured; however, both were only slightly 
higher when a 50% (w/v) CPA inlet solution was used. Changing the CPA composition 
from Me2SO/EG/glucose to EG/glucose (ratio 4/1) did not show any difference in 
viability or cell number to the 80% inlet (Figure 7.9). 
 
 
 
 
Figure 7.9 CPA inlet reduced from 80% to 50% (w/v)  
AELC were processed using the combined manual/automatic LT approach until a concentration of 
40% (w/v) CPA No.18 at -20˚C was reached. Viability and cell numbers 24 and 48 hours post-
warming were slightly higher when the concentration of the inlet solution was reduced from 80% to 
50% (w/v). Using a 50% (w/v) EG/glucose (ratio 4/1) solution had no beneficial effect. The data 
presents one run for each condition. For each run five samples (n = 5+/-SD) were warmed following 
a one-step warming protocol (from 40% (w/v) CPA No.18 at -20˚C to 20% (w/v) glucose at 0.5˚C). 
AELC were cultured for 24 and 48 hours in complete media at 37˚C before measuring viability and 
cell number. 
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Changing the initial inlet from 80% to 50% (w/v) CPA until a concentration of 40% was 
reached did not show a clear impact on cell survival. However, when the final inlet was 
reduced to a concentration of 66% (w/v), viability was substantially increased and 
“viable cell per bead” distribution was more homogenous. The inlet sequence was 
finally changed to a sequence of 50%, 60% and finally 66% (w/v) CPA to further 
improve cell viability (Figure 7.10). 
 
A.                                                                               B.  
 
Figure 7.10 Reduced inlet CPA concentration 
A: Viability increased by approximately 40% +/-4 when an inlet solution of 66% +/-10 instead of 
80% (w/v) CPA No.18 was used for combined manual/automatic LT. Data presents one run, for 
each run five samples were tested for viability (n=5 +/- SD). B: Instead of using an inlet of 80% 
CPA No.18, an inlet sequence of 50%, 60% and finally 66% (w/v) CPA No.18 was used which 
significantly increased viability from 42%+/-14  to 78%+/-11 The data presents four separate runs 
(n=4+/-SD,** p<0.01).  A and B: For each run five samples were vitrified and warmed following a 
two-step warming protocol (from 65% to 45% (w/v) CPA at -22˚C, then to 20% (w/) glucose at 
0.5˚C). AELC were cultured for 24 hours in complete media at 37˚C before measuring viability. 
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7.4.6 Reduced outlet port height 
The height of the outlet port was reduced to ensure that the filter system was submerged 
in CPA solution throughout the LT process. This was done to prevent alginate beads, 
stuck to the upper filter, being exposed to the temperature of the surrounding air, which 
was expected to be close to the freezer temperature and below the melting point of the 
solution inside the sample carrier (Figure 7.11). 
 
 
  
 
Figure 7.11 Long versus short outlet port design 
The outlet port was shortened to make sure that the filter unit was submerged in CPA throughout 
the LT process to prevent beads that stick to the upper filter from being exposed to the 
temperature of the surrounding air.  
7.4.6.1 Short outlet port-diminishes viability 
Changes made to the outlet system reduced viability from approximately 80% to 40%. 
Strong differences between the distribution of viable and dead cells per bead were 
noted, just as it was observed before the final inlet concentration was reduced from 80% 
to 66% (Figure 7.12). 
short outlet port long outlet port 
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Figure 7.12 Long versus short LT outlet port: impact on cell viability 
Viability was decreased when the outlet port was reduced. The data presents four separate runs 
(n=4+/-SD).  For each run five sample were taken after the increase to 40%, 58% and 65% (w/v) 
CPA No.18, five samples were vitrified at -40˚C. Non-vitrified samples were warmed within one 
step (directly to 20% (w/v) glucose at 0.5˚C). Vitrified samples were warmed in a two-step warming 
protocol (from 65% to 44% (w/v) CPA at -22˚C, then to 20% (w/v) glucose at 0.5˚C). AELC were 
cultured for 24 hours in complete media at 37˚C before measuring viability. 
7.4.6.2 Inhomogeneous CPA extraction 
Firstly we hypothesized that changing the filter height had an effect on the CPA 
component that would predominantly be taken out during the extraction process due to 
different densities of glucose, Me2SO and ethylene glycol. In a first attempt the glucose 
concentration was increased from a ratio of 40/20/10 to 35/20/15 (Me2SO/EG/glucose) 
for the 50% and 60% CPA inlet solution, but was kept as before for the 66% inlet 
solution (ratio 40/20/10). This was done to reduce CPA toxicity at higher temperatures 
and to improve vitrification properties by increasing the Me2SO concentration during 
the final inlet steps. However, this resulted in lower viability throughout the process. An 
increase in Me2SO to a ratio of 45/20/5 resulted in the same final viability obtained with 
CPA No.18 (Figure 7.13).  
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Figure 7.13 Inhomogeneous LT extraction 
Increasing the sugar to Me2SO and EG concentration decreased viability, while higher Me2SO 
concentrations did not have any effect. Each condition was tested once. Five sample were taken 
after the increase to 40%, 58%, 65% CPA (w/v) and five samples were vitrified (n=5 +/- SD) 
at -40˚C. Non-vitrified samples were warmed within one step directly to 20% (w/v) glucose. 
Vitrified samples were warmed in a two-step warming protocol (from 65% to 45% (w/v) CPA 
No.18 at -22˚C, then to 20% (w/v) glucose at 0.5˚C). AELC were cultured for 24 hours in complete 
media at 37˚C before measuring viability. 
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7.4.7 The Liquidus Tracking stirrer 
Increased concentrations of Me2SO or glucose in comparison to CPA No.18 did not 
improve cell recovery, suggesting that the changes made to the outlet port height did not 
affect the Me2SO/EG/glucose ratio of the CPA solution inside the sample carrier. 
Therefore the assumption was made that the mixing process in itself might have been 
changed by decreasing the inlet port height. Instead of the original stirrer a simple 
propeller stirrer was designed to achieve more homogenous mixing conditions. By 
using the propeller stirrer viability was significantly improved and strong variations in 
viable cell numbers per bead, as it was noted before, were no longer observed (Figure 
7.14, Figure 7.15).  
 
A.                                                                                                        B. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.14 Planer stirrer versus propeller stirrer 
A. The Planer stirrer was designed to hold larger constructs in the middle of the sample carrier 
while providing efficient CPA homogenisation. Strong differences between the sample carrier 
centre and on the outside (between the static pedals and the moving part of the stirrer) in respect to 
mixing behaviour and shear forces were expected to affect AELC. The propeller stirrer provided 
more homogenous mixing of beads and solution. B. The images show AELC after being warmed 
from vitrification using combined manual/automatic LT with the new propeller stirrer. Viable and 
non-viable cells were evenly distributed across alginate beads. The figure shows phase images, and 
images of live (green, stained with FDA) and dead (red, stained with PI) cells. 
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Figure 7.15 Propeller stirrer- increased cell viability 
Using a short outlet port in combination with a propeller stirrer, instead of the Planer stirrer, 
increased post-warming cell viability significantly from 38% +/-11.7 (n=4+/- SD) to 77% +/- 4.3 
(n=4 +/-SD), ** p<0.01. Comparable values were obtained with a long outlet port in combination 
with the Planer stirrer (78% +/- 11.1 (n=5 +/-SD) when the maximum inlet CPA concentration was 
to 66% (w/v). Viabilities were significantly lower when the Planer stirrer and a short outlet port 
(42%+/-13.8 (n=4 +/-SD) was used, ** p<0.01 For each run five samples were vitrified at -40˚C and 
warmed in a two-step warming protocol (from 65% CPA to 45% CPA at -22˚C, then to 20% 
glucose at 0.5˚C). AELC were cultured for 24 hours in complete media at 37˚C before measuring 
viability. 
7.4.8 Manual Liquidus Tracking warming process 
Different manual warming procedures were tested by using aliquots of vitrified AELC. 
The more steps were used to warm AELC and to reduce the CPA concentration, the 
higher was the post-warming viability. A two-step procedure (first to 40% (w/v) CPA18 
then to 20% (w/v)) glucose significantly improved post-warming viability in 
comparison to the one-step procedure (directly to 20% (w/v) glucose) and showed 
similar results to the three step procedure (50-40-20% (w/v) CPA) (Figure 7.16). A 20% 
(w/v) glucose solution was used as a last step to reduce osmotic stress while decreasing 
the concentration of penetrating CPAs.  
0
20
40
60
80
100
80% inlet-long outlet
port
66% inlet-long outlet
port
66% inlet-short outlet
port
66% inlet-short outlet
port
Planer stirrer Planer stirrer Planer stirrer Propellor stirrer
V
ia
b
il
it
y
 (
%
) 
** ** 
Chapter 7: Automatic Liquidus Tracking 
229 
 
 
Figure 7.16 Manual LT warming sequence 
The use of more warming steps resulted in higher AELC post-warming viability. Aliquots of 
vitrified AELC were warmed to -20˚C in the controlled rate freezer. Condition “50-40-20%”:  CPA 
No.18 concentration was reduced from 65% to 50% and then to 40% (w/v) CPA No.18 by adding 
35% (w/v) CPA No.18. Incubation at each step was 15 minutes at-20˚C. Samples were poured 
through cell strainers and placed in 8ml of ice cold 20% (w/v) glucose solution for 10 minutes 
before being washed 3 times with 1xPBS (ice-cold) to remove all CPA. Finally AELC were 
incubated in 8ml of complete media at 37˚C until measurement. Condition “40-20%”: as condition 
“50-40-20%” but the CPA No.18 concentration was reduced directly reduced from 65% to 40% 
(w/v). Condition “20% at 0.5˚C” and “20% at RT”: sample were warmed to -20˚C and poured 
through cell strainers and placed in 8ml 20% (w/v) glucose solution for 10 minutes either at 0.5˚C 
or room temperature. Data was n=5 +/-SD, ** p<0.01. 
7.4.9 Automatic Liquidus Tracking warming process 
It is more complicated to keep the sample temperature close to the melting point during 
automatic LT warming than during cooling. This is for the following reasons: in order 
to dilute the sample the inlet solution has to be of lower CPA concentration than the 
sample. To avoid freezing the freezer has to be set several degrees above the melting 
point of the inlet solution. The smaller the concentration difference is, between inlet and 
sample solution, the closer the sample can be kept to its liquidus curve. However, this 
means that more solutions steps have to be carried out.  
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7.4.9.1 The one solution reverse mode 
To simplify the LT warming procedure the attempt was made to use only 20% (w/v) 
glucose to reduce the sample CPA concentration while keeping the sample close to its 
liquidus curve. The method was based on the theory that two solutions of equal volume 
but of different temperature and CPA concentration do not freeze if the average 
temperature remains above the melting point. This was tested by pumping 20% glucose 
(at 20˚C) into a container holding 120ml of 65% (w/v) CPA No.18, while the solution 
was continuously mixed by a magnetic stirrer. Inlet was started at a sample temperature 
of either -35˚C, 30˚C or -25˚C, while the sample itself was kept at -25˚C during the inlet 
process. The temperature/concentration (T/C) profile closest to the liquidus curve for 
CPA No.18 was achieved with an initial sample temperature of -35˚C and an inlet speed 
of 20ml/minutes. Some ice formed when the initial sample temperature was set to -35˚C 
but disappeared once the sample reached a temperature of -20˚C. The process was 
successfully transferred to automatic LT, albeit the initial sample temperature had to be 
decreased from -35˚C to -25˚C to avoid ice formation. Strong ice formation was noted 
when stirrer and pumps stopped operating. Aliquots of vitrified AELC for which a 
maximum post-warming viability of 40% had been reached in previous experiments 
were used to test the one solution reverse LT mode, but no viability was measured 24 
hours post-warming (Figure 7.17). 
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Figure 7.17 PBS inlet into subzero CPA solution  
The graph shows T/C curves of samples that were warmed up by the inlet of 1xPBS (20˚C) while 
the surrounding temperature was kept at -25˚C. The initial CPA volume of the 65% (w/v) CPA 
solution was 120ml. Inlet temperature was started at a sample temperature of either -25˚C, 30˚C or 
35˚C while the inlet speed was set to either 20ml/minute or 25ml/minute. The T/C profile closest to 
the liquidus curve was achieved with an initial sample temperature of -35˚C and an inlet speed of 
20ml/minutes. 
7.4.9.2 The four-step reverse mode 
In a second approach the CPA concentration was reduced by adding in the following 
order 50%, 40%, 30% (w/v) CPA No.18 and 1xPBS. The freezer but also the sample 
temperature had to be maintained above the melting point of the inlet solution to avoid 
freezing, even though the average concentration of inlet and sample CPA concentration 
suggested a lower melting point for the incoming solution. The solution inside the inlet 
port froze several times as it did not mix with the higher concentrated sample solution 
but was cooled down by it. A temperature difference of 5˚C between sample and inlet 
solution was sufficient to initiate inlet port freezing as the inlet solution was already 
close to its freezing point before entering the sample carrier though the inlet port. To 
overcome this problem the inlet solution was used to increase the sample temperature 
before the next lower concentrated inlet CPA solution was connected to the inlet pump. 
This was achieved by setting the freezer temperature 4˚C above the melting temperature 
of the next lower inlet CPA solution whilst 200ml of the previous CPA solution still had 
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to be pumped in. Following this approach freezing was avoided while the T/C curve 
was kept close to the liquidus curve. When vitrified AELC were warmed with the four-
step warming method viabilities of 60% and higher were obtained (Figure 7.18).  
 
 A.                                                                 B. 
 
Figure 7.18 LT warming protocols 
A. When using a four-step LT warming protocol post-warming viabilities of 68% +/- 2.5 (n=4 +/-
SD) were achieved. B. Lower concentrated CPA No.18 solutions were used to reduce the sample 
CPA concentration while maintaining the sample T/C curve close to the liquidus curve of CPA 
No.18. 
7.4.10 CPA toxicity over time 
Both, the automatic cooling and the warming LT process for large volumes can take 
several hours depending on the volume that has to be vitrified. It is therefore of 
importance to know whether viability is diminished over time at a certain temperature 
and concentration when the conditions remain unchanged. For this reason AELC were 
incubated over time at -7˚C, -15˚C, -20˚C and -25˚C in 35%, 50% , 55% and 65% (w/v) 
CPA. Viability was reduced at -7˚C at a concentration of 35% (w/v) CAP20 after one 
hour but remained constant at -15˚C (50% CPA), -20˚C (55%) and -25˚C  (65%) (Figure 
7.19).  
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Figure 7.19 Toxicity over time using automatic LT 
Automatic LT was used to cool down AELC to -7˚C, -15˚C, -20˚C and -25˚C. Each time five 
samples were taken once the temperature was reached and after one hour of incubation. Samples 
incubated in 35% (w/v) CPA were warmed by adding AELC to 20% glucose at 0.5˚C (10 minutes). 
For samples incubated in 50-65% (w/v) CPA the two-step warming protocol was used. Viability 
was reduced after one hour at -7˚C (35% CPA) but remained constant at -15˚C (50% CPA), -20˚C 
(55%) and -25˚C (65%). Data was n=5 +/-SD. 
7.4.11 Cell density impacts cell survival 
AELC of high cell densities were less affected by LT treatment than AELC of low cell 
density which was shown when beads of high and low cell density were processed 
within the same run. Beads of either type were easily distinguished under the 
microscope, which made it possible to take images of single beads and determine the 
viability using the established FDA/PI method. Viabilities for high cell densities beads 
were significantly higher than for low cell density beads. Although this procedure 
allowed testing two populations of beads under exactly the same conditions, cell 
number and albumin production could not be measured because beads could not be 
physically separated (Figure 7.20, Figure 7.21). 
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Figure 7.20 High vs. low cell density beads for LT 
The phase image shows the three types of alginate beads that were processed at the same time in the 
sample carrier: empty beads with small pieces of silica (black circle), low cell density beads (circle 
in blue) and high cell density beads (circle in red). Cell numbers were 4*10
6
 cells/ml of beads for 
low cell density beads and 15*10
6
 cells/ml of beads for high cell density beads. High cell density 
beads showed better survival rates (strong FDA signal) than low cell density beads (low FDA signal 
but strong PI signal). 
 
 
 
Figure 7.21 Impact of low and high cell densities on post-LT viability 
Cell viability was significantly higher for beads of high cell density (-40˚C: 46% +/-11.5, n=17) and 
(-125˚C: 57%+/-9.7, n=17) than beads of low cell density (-40˚C: 12% +/-8.0, n=17) and (-125˚C: 
11+/- 6.9, n=17), ** p<0.01. This was independent of whether AELC were warmed up in a two-step 
warming process directly after reaching 65% CPA (w/v) and -40˚C or after being vitrified (cooled 
to -125˚C) and then warmed up. There was no difference in post-warming viability in respect to the 
minimum cooling temperature. 
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7.4.12 Complete automatic Liquidus Tracking procedure 
The complete LT process was carried out with AELC of increasing cell numbers. 
Higher cell density resulted in higher cell numbers, viability, albumin and alpha-
fetoprotein production with respect to the positive control. For cell densities of 17*10
6 
and 20*10
6
 cells/ml of beads)  viability was  70% and 90%, viable cell number  61% 
and 79% and albumin and alpha-fetoprotein production 48% and 54%, and 67% and 
75%, respectively (fraction of the untreated control after 48 hours of post warming) 
(Figure 7.22). 
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Figure 7.22 Impact of low and high cell densities on cell recovery 
The higher the cell number the higher was the post-warming viability, cell number, Albumin and 
Alpha-fetoprotein production. AELC were cooled to -40˚C and then vitrified using the combined 
manual/automatic LT approach and warmed using the four-step LT process. For each cell density 
one run was performed.  
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7.5 Discussion 
Although the combined manual/automatic LT approach kept the sample 
temperature/concentration curve close to the liquidus curve and despite the fact that 
automatic LT increased the CPA concentration continuously and without the 
temperature fluctuation seen for manual LT, no viability was detected when Me2SO was 
used as a single CPA (Chapter 6). When Me2SO was replaced with the newly developed 
CPA No.18 solution (Chapter 5) viability was increased to approximately 40%, 
suggesting that CPA toxicity was not fully suppressed by the automatic LT process. The 
possibility was considered that viability had mainly been compromised during the two-
step manual warming process and that an optimized warming procedure would result in 
high viabilities for Me2SO. However, for manual LT a similar warming process was 
used and post-warming viabilities between 20% and 50% were reached, whilst no viable 
cells were detected after the automatic LT cooling process, suggesting a stronger impact 
of automatic LT cooling than manual two-step warming.  
The question of whether cell viability is reduced during the cooling or warming process 
is important, but sometimes difficult to answer. One process cannot be carried out 
without the other, and there will always be some uncertainty at which step viability is 
reduced as long as viability is not increased substantially when trying different cooling 
or warming methods. Nevertheless, there might be some indication which process might 
be more detrimental. For example, different warming protocols were used to warm 
aliquots of AELC that had previously been vitrified by automatic LT (CPA No.18), but 
viability never increased to more than 40%. Manual warming can be considered to be 
subject to some deviation and some replicates were expected to be warmed up in a more 
beneficial way than others and should have exceeded 40% viability, if the cooling 
process had not already reduced viability close to this value. When, in combination with 
the two-step warming process, a two-step manual LT cooling approach was used instead 
of automatic LT cooling, viability was increased to more than 80%. This proved the 
suitability of the warming process but also demonstrated the necessity for a simplified 
manual LT process which can be easily modified and carried out rapidly to improve 
automatic LT. 
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CPA addition steps for the manual two-step cooling and warming set-up were based on 
several observations and considerations: firstly AELC had shown good tolerance to 
40% (w/v) CPA No.18 for up to one hour at an incubation temperature of 0.5˚C 
(Chapter 5). Moreover, 40% and 80% (w/v) CPA No.18 were still liquid enough 
at -20˚C to allow efficient mixing and accurate addition. An extra addition step at a 
concentration of 20% (w/v) CPA was carried out at -5˚C but proved to be of little 
benefit, as the additional procedure caused the temperature to increase close to 0˚C. 
Instead it was more practical to use a starting mixture of AELC at 0.5˚C (on ice water), 
and to increase the CPA concentration in two steps to 40% (w/v), before aliquots of 
AELC were added to precooled tubes (0˚C). Cooling was carried out at 0.5˚C/minute 
and the CPA concentration was increased to 65% (w/v) by adding 80% (w/v) at -20˚C. 
Samples were were further cooled and finally vitrified at -40˚C to simulate the 
automatic LT process. The warming step was also carried out at -20˚C by adding 50% 
(w/v) CPA to the sample (at 65% (w/v)). Although an additional step from 65% to 50% 
(w/v) CPA during the warming process resulted in higher post-warming viabilities, the 
two-step warming process was used for practical reasons. At temperatures below -20˚C, 
CPA No.18 was too viscous to be poured though a cell strainer. This meant that a lower 
concentrated CPA solution had to be added to decrease the sample CPA concentration. 
This as a consequence, increased the sample volume. However, when using the manual 
insulation system, 15ml microfuge tubes were used. The tube capacity was only 
sufficient to add 9ml of 50% (w/v) CPA to decrease the sample CPA concentration to 
44% (w/v). Increasing and decreasing the CPA solution only once at low subzero 
temperatures proved to be both more feasible and reliable. Manual LT includes the 
vitrification process in the procedure and was therefore superior to CPA toxicity testing 
at 0.5˚C. It was shown that changing the Me2SO/EG/glucose ratio towards more glucose 
was beneficial when AELC were incubated at 0.5˚C, but post-warming viability was 
decreased when AELC were vitrified. The same findings were obtained when the 
automatic LT process was used.  
Replacing half of the glucose amount with sucrose, raffinose or trehalose for their 
beneficial effects discussed in Chapter 5, did not improve cell viability. Viaspan and 
HTK, which are organ preservation solutions designed to reduce chilling injury during 
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hypothermic storage, were used to replace PBS as a carrier solution. Apart from 
different sugars to reduce osmotic stress (also contained in CPA No.18), HTK contains 
a histidine-HCL buffer with extended buffering capacity, tryptophan to support cell 
membrane integrity and alpha-ketoglutarate which serves as a substrate for aerobic 
energy production (HTK data sheet, www.custodiol.com, (Ringe et al., 2005), while 
Viaspan contains the antioxidant glutathione (Ceballos-Picot et al., 1996; Southard et 
al., 1990). Although both solutions have shown good results in liver and hepatocyte 
cold storage (Abrahamse et al., 2003; den Butter et al., 1995), they are not commonly 
used in vitrification procedures. HEPES buffer ((4-(2-hydroxyethyl)-
1piperazineethanesulfonic acid) at a concentration of 10mM and 25mM, which is within 
the suggested rate of 5mM and 30mM, was also used to replace PBS. HEPES has 
similar dissociation characteristics to water at low temperatures, and has shown superior 
buffering capacity at low temperatures (Baicu & Taylor, 2002; Swan et al., 1994; 
Taylor, 1982). Nonetheless, none of the solutions used to replace PBS indicated any 
advantage. The addition of other antioxidants such catalase (Michael et al., 2007; 
Paudel et al., 2010; Roca et al., 2005) and Trolox (water-soluble vitamin E) (Peña et al., 
2004; Thuwanut et al., 2008) which have been used successfully for cryopreservation of 
sperm cells from various species, or the use of a temperature independent pH buffer, 
designed for biomedical applications at low temperatures (Sieracki et al., 2008) might 
be more beneficial. However, it is questionable whether non-CPA components can 
reveal much of their specific effects at low sub-zero temperatures and high CPA 
concentrations. It is most likely that those effects are restricted to the beginning of the 
cooling and the end of the warming procedure when CPA levels are lower and 
temperatures higher. Yet, at these concentrations cell survival is still high and cell death 
negligible in comparison to the viability decrease noted when the CPA concentration is 
increased to 65% (w/v). 
Pre-incubating AELC in proline, tehalose or linoleic acid in order to “prepare” cells for 
the cooling procedure including the later phase of the process was therefore estimated as 
a more effective way to improve post-warming viability. Feeding the larva of the 
drosophilid fly Chymomyza costata proline-augmented diets before vitrification had 
increased their freeze tolerance significantly (Kostál et al., 2011). It is believed that 
prolin binds to remaining unfrozen water and thus, increases vitrification efficacy. 
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Promising results were also obtained when cells were pre-incubated in trehalose and 
linoleic acid-albumin before they were slowly cooled to subzero temperatures. 
Intracellular trehalose has reportedly improved the survival of cryopreserved 
mammalian cells (Eroglu et al., 2000) and the pre-incubation in linoleic acid-albumin 
has enhanced the post-thaw survival of in vitro-produced bovine embryos (Tominaga et 
al., 2000). However, none of the additives used for pre-incubation indicated any 
beneficial effect for AELC cryopreservation. The concentration of trehalose, proline and 
linoloic acid, although used in the range described in the literature, might not have been 
adequate. However, even after optimization benefit was expected to be low in respect to 
the 60% viability decrease noticed for AELC after automatic LT. 
As the viability loss during auomatic LT was high and mainly seen when the solution 
was increased from 40% to 65% (w/v) at temperatures below -20˚C it was assumed that 
the CPA addition temperature was too cold to provide sufficient CPA cell penetration or 
too high to sufficiently reduce CPA toxicity. Hence, different CPA addition 
temperatures (-11˚C, -16˚C, -22˚C, -25˚C, -33˚C) were tested at which the CPA 
concentration was manually increased either from 40% to 65% or 50% to 65% (w/v). 
Cell recovery was significantly higher when CPA addition was carried out at -25˚C 
(86%) than at -11˚C (54%) or -16˚C (71%), was comparable at -22˚C (65%) and -27˚C 
(65%) but was significantly reduced at -33˚C (50%). Similar results were obtained for 
automatic LT. In a first experiment viability was much lower at -37˚C (31%) than 
at -25˚C (44%). In a second experiment viability was slightly reduced from 57% (-25˚C) 
to 54% (-37˚C). Data suggested that CPA penetration was insufficient to prevent 
intracellular ice formation at temperatures below -27˚C (-25˚C). Fahy has used a similar 
minimum temperature (-22˚C) for the perfusion and vitrification of kidneys (Fahy et al., 
2004). No explanation was given why this temperature was chosen. It is known that at 
lower temperatures viscosity becomes higher and perfusion more challenging. However 
it is also possible that lower temperatures in respect to toxicity have not shown any 
beneficial effect. 
When AELC viability was determined using the fluorescent microscope, a markedly 
inhomogeneous distribution of viable and dead cells between alginate beads was 
observed. Whilst some beads contained mainly viable cells, others contained 
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exclusively dead cells. At first it was assumed that the following temperature 
differences had caused this effect. The inlet temperature during the cooling process is 
much colder than the sample temperature and there is also a temperature gradient across 
the sample carrier with lower temperatures at the outside and higher temperatures at the 
inside of the sample container. Inhomogeneous distribution of viable and dead cells was 
not noted for CPA concentrations below 40% (w/v), normally reached at -15˚C. 
Consequently the inlet and sample solution temperature was maintained at -15˚C, thus 
offsetting the temperature difference inside the sample carrier while the sample CPA 
concentration was increased from 40% to 65% (w/v). However, strong variations in the 
number of viable cells per bead were detected. It also seemed possible that bead 
inhomogeneity was caused by the difference in sample and inlet CPA concentration. In 
a first experiment the CPA concentration of the inlet solution was reduced from 80% to 
50% (w/v) to increase the sample concentration to 40%, but almost no difference in 
viability between the two conditions was noted. This changed once the inlet CPA 
concentration was reduced from 80% to 66% (w/v) to increase the sample concentration 
to 65%. Post-warming viability increased from approximately 40% to 80% and the 
distribution of viable and dead cells per bead demonstrated good homogeneity. Findings 
that a reduced inlet CPA concentration to 50% at the beginning of the run had no impact 
on cell survival, and the observation that viability was strongly reduced when the initial 
sample volume was reduced from 280ml to 140ml, might be explained thus; when the 
CPA concentration is low, high concentrated CPA can be diluted quickly enough to 
avoid CPA toxicity. This also applies for larger volumes in comparison to smaller 
volumes, when the inlet speed is kept the same.  
Surprisingly viability was reduced to its previous low level (40%) when the height of 
the outlet port was reduced from 8cm to 3cm. Firstly it was believed that the lower 
outlet level had changed the Me2SO/EG/glucose ratio of the sample solution as a result 
of different CPA densities. It was hypothesized that throughout the lengthy LT cooling 
and CPA addition procedure more glucose would accumulate at the bottom of the 
sample carrier and more Me2SO at the top of the sample solution. Increasing the Me2SO 
concentration while decreasing the glucose concentration or vice versa was predicted to 
either improve or reduce cell recovery, respectively. Ethylene glycol was not tested as it 
was assumed that a change in viability would mainly be caused by the penetrating to 
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non-penetrating CPA ratio and for this Me2SO and glucose concentrations were 
increased and reduced by 5% (w/v). Viabilities were strongly reduced when the glucose 
concentration was increased, which was in accordance with previous observations, 
whilst an increase in Me2SO had no impact on cell survival, suggesting extensive 
dehydration as likely cause of cell demage. 
Another possibility was that the outlet port height had changed the mixing conditions 
inside the sample container. With the longer outlet port the incoming CPA solution had 
been approximately at the same level as the inlet port which might have helped to draw 
the incoming CPA solution to the centre of the sample carrier. The Planer stirrer was 
designed to operate alongside the sample carrier wall to avoid any interference with 
larger, static constructs in the middle of the sample carrier. However this design implies 
strong differences across the sample carrier in respect to mixing behaviour and shear 
forces. For example, AELC trapped between the static pedals and the moving part of the 
stirrer are subject to stronger mixing and higher shear forces than AELC that are located 
at the centre of sample carrier. To overcome these mixing differences a self-made 
propeller stirrer was used instead. Findings were comparable to those obtained with the 
combination of long outlet port and Planer stirrer. Viabilities were increased to 80% and 
viable and non-viable cells were evenly distributed across alginate beads.  
When viabilities were increased from 40% to 80% by reducing the maximum inlet 
concentration to 66% (w/v) it was initially believed that this was due to the 80% (w/v) 
CPA No.18 solution not being diluted fast enough to prevent chemical or osmotic 
injury. However viabilities were at 40% when a 66% (w/v) CPA inlet solution in 
combination with the shorter outlet port was used, indicating that the inlet CPA 
concentration per se did not cause cell death. By using the 66% (w/v) CPA inlet a 
stronger flow through was created, which possibly helped to homogenize the inlet CPA 
solution. Higher viability as a result of improved homogenization is compliant with 
better suitability of the propeller stirrer as a more uniform mixing approach. Still, the 
question remained how cell viability was affected by the given mixing conditions.  
Viable cell per bead distribution was inhomogeneous although the temperature was 
maintained constant at -15˚C when the Planer stirrer was used. Chemical toxicity (Fahy 
et al., 1995), dehydration and osmotic stress (Song et al., 2009) as a result of 
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temperature was therefore excluded as a main cause for cell death, however those 
factors may have been reinforced through strong mixing. The inlet port being in close 
proximity to the Planer stirring system supports the theory that AELC located in the 
“intense mixing zone” and close to the inlet of high concentrated CPA, experience high 
intra- and extracellular CPA concentration differences and an enhanced mass transport 
across membranes as a result of high kinetic energy caused by intensive stirring. Wang 
demonstrated that stirring of the sample during LT cooling increases the Me2SO 
concentration in cartilage of osteochondral dowels. When no stirring was used, the 
Me2SO concentration in the tissue was 49.5 ± 6.9 % but when stirred the Me2SO 
concentration in the tissue increased to 58.9 ± 1.2% (Wang et al., 2007). 
Shear stress is also likely to cause cell death by membrane disruption (Park et al., 2011) 
and would account for a more homogenous distribution of viable and dead cells 
amongst beads when the propeller stirrer was used. In addition shear stress reportedly 
increases cell membrane fluidity. This effect is commonly seen in endothelial cells 
(Butler et al., 2001; Haidekker et al., 2000; Yamamoto & Ando, 2013) and L. 
polyedrum (Mallipattu et al., 2002). Higher membrane fluidity would allow for more 
CPA and water movement across the plasma membrane, thus excessive dehydration 
(Fathallah et al., 1995) but also hyperosmotic stress through an influx of non-
permeating solutes occuring are possible causes for cell death (Mazur et al., 1972). 
Most experiments used to improve the automatic cooling process were carried out by 
using the simplified two-step warming method. Once acceptable viabilities were 
reached an automatic LT warming process was developed. Attempts to solely use a 20% 
glucose solution, which was held at room temperature and pumped into the sample 
carrier at temperature between -25˚C and 0˚C, failed not because of ice formation but 
because no post-warming viability was detected. As a second approach the sample CPA 
concentration was reduced by adding in the following order 50%, 40%, 30% (w/v) CPA 
No.18 and 1xPBS while keeping the sample as close to its liquidus curve as possible. 
For practical reasons the difference of inlet and sample CPA concentration was selected 
to be at least 10% - similar to the cooling process - as otherwise the dilution process and 
the entire LT process would have taken too long. High viabilities similar to the two-step 
manual LT process were achieved.  
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An important aspect of LT, due to its overall time length is the question of whether cell 
survival is reduced over time once the conditions are maintained constant. For 
automatic LT it was shoen that viability was lower at higher CPA concentrations, but 
did not change over time at -15˚C, -20˚C and -25˚C at CPA concentrations of 50%, 
55%, and 65% (w/v). Only at -7˚C and 35% (w/v) CPA No.18 viability was 
significantly reduced after one hour. For the final LT cooling set up, 35% CPA is 
reached at approximately -12˚C and concentration over 50% at temperatures 
below -20˚C. It is therefore most likely that the time factor of the final cooling process 
is successfully suppressed which means that upscaling could be possible in principle.  
An interesting effect was seen when beads of varying cell densities were used for 
automatic LT. Low cell density beads tested in the same experiment and therefore 
undergoing exactly the same procedure than high cell density beads, showed 
significantly reduced cell survival. This was regardless whether AELC were cooled 
to -40˚C or below the glass transition point (-125˚C). To measure cell numbers and 
protein production exclusively beads of the same cell density had to be used, but the 
effect was the same. 3D cell cultures of higher cell density undergoing the complete 
automatic LT process including cooling to -40˚C, vitrification and warming, showed 
higher post-warming viability, cell number and protein production. For cell densities of 
17*10
6 
and 20*10
6
 cells/ml of beads, viability was  70% and 90%, viable cell number  
61% and 79% and albumin and alpha-fetoprotein production 48% and 54%, and  67% 
and 75%, respectively (fraction of the untreated control after 48 hours of post warming). 
Higher cell recovery of spheroid hepatocytes in comparison to single cell suspension 
following cryopreservation has previously been reported by Lee and colleagues (Lee et 
al., 2012). Higher cell activity as noted in 3-D cell cultures (Bokhari et al., 2007; 
Coward et al., 2009; Lee et al., 2012; Selden et al., 1999) has been previously linked to 
higher cell recovery following cryopreservation in single cell suspension. Cells cultures 
during their exponential growth are metabolically more active and showed higher post 
warming viability than cells cryopreserved when reaching the lag phase (Cho et al., 
2000). Vitrification studies by Magalhães have shown better post-cryopreservation 
viability for tissue-like culture than for single cells. They concluded that cell-to-cell 
contact is beneficial in the maintenance of viability (Magalhães et al., 2012). 
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In respect to shear forces created by the stirrer during LT, it can be expected that higher 
cell density is beneficial, as the outer cells may provide protection to those located 
closer to the centre. This also applies in respect to excessive dehydration. In 
3-dimensional cell constructs, water diffuses sequentially from one cell to its 
neighborhood. Cells in the surface layer respond to osmotic changes in the extracellular 
medium, interior cells respond only to osmotic changes in cells of surfaces, and thus are 
exposed to slower rates of dehydration (Levin et al., 1977). 
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7.6 Conclusion 
In this chapter the different parts of the LT process – cooling, vitrification and warming 
– were investigated and improved individually before they were finally set together to 
form the entire LT process. The set-up was changed from the “one-solution” to the 
“two-solution” mode for both the cooling and warming process. Important aspects of 
the automatic LT process were examined which included CPA toxicity over time, cell 
density and most importantly the mixing effects. Changes to the CPA No.18 solution 
and pre-incubation conditions showed little effect. Higher post-warming viability and 
performance are still expected for a further optimized stirring and CPA inlet system and 
for 3D cultures of higher cell density (< 20 million cells/ml beads). The addition of ice 
blockers or antifreeze proteins might provide an additional possibility to reduce the 
CPA concentration throughout the LT process and to further reduce CPA toxicity. 
Overall Liquidus Tracking can be regarded as a promising tool for large scale 
cryopreservation of 3D cell cultures. 
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8 CHAPTER 8 
General Discussion 
The overall aim of this thesis was to establish a large scale cryopreservation protocol for 
alginate encapsulated liver cells that would deliver high functional recovery sufficient to 
replace liver function when used within a bioartificial liver device. For this purpose the 
new technique of automatic Liquidus Tracking was applied, which allows to vitrify a 
volume of 500ml in a slow cooling process. 
8.1 Viability assessment 
The first aspect of this thesis was to establish a rapid and conclusive method to evaluate 
cell recovery after cryopreservation to improve the Liquidus Tracking (LT) process 
(Chapter 3). In this respect the use of a membrane integrity test proved to be the most 
suitable with the additional advantage that disaggregation of cell spheroids and 
dissolving of the alginate capsule was unnecessary. A digital imaging system, a 
combination of a microscope, a charge-coupled device (CCD) camera, a computer and 
an imaging software program, was used to detect and quantify the fluorescence signal of 
fluorescein and propidium iodide. It was shown that the standardized method was 
sufficiently reliable to describe post-stress viability to compare experimental conditions. 
This was verified by ELISA, cell count and MTT measurements. Similar to the digital 
imaging system a method for the use of a fluorescent plate reader was developed. 
Other possibilities to evaluate cell recovery are various and might give a more detailed 
estimation of cell death and vitality. For example, changes in protein kinase cascades 
and cell cycle but also markers for apoptosis and inflammation have previously been 
used to determine hepatocellular stress and injury (Beyer et al., 2007; de Longueville et 
al., 2003; Heinloth et al., 2004; Kiyosawa et al., 2006; Reilly et al., 2001). Gene 
expression patterns could be used to investigate those changes in an effective manner. 
DNA microarrays or reverse transcription quantitative real-time PCR (RT-qPCR) are 
reliable techniques and have been previously used for the validation of toxicity 
biomarkers (Guo et al., 2009; Rokushima et al., 2007). Two examples for HepG2 
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toxicity biomarkers are cytokine receptor IL-11RA which was strongly increased upon 
exposure to acetaminophen while the transcription factor Myc was reduced by 30% 
(Fox et al., 2010). However those systems are likely to be more time consuming and 
expensive and are therefore more useful to evaluate the LT method once fully 
established. For the developing process itself our system was considered the better 
choice. 
8.2 Cryoprotectant agents for Liquidus Tracking 
First experiments with alginate encapsulated liver cells (AELC) demonstrated strong 
Me2SO toxicity. By combining commonly used CPAs of relatively low viscosity 
(Chapter 5) so that effective mixing was provided at low subzero temperatures, nine 
particularly useful CPA solutions of low toxicity and viscosity were defined. Although 
developed to be first of low viscosity and then of low toxicity as well as being a good 
vitrifier, solution No18 (containing Me2SO, ethylene glycol and glucose in a ratio of 
4/2/1), resembled those vitrification solutions that are commercially available. It is 
therefore questionable whether a better CPA solution for LT can be developed by 
replacing one of these main components. 
However the addition of synthetic ice-blockers (SIB) to prevent heterogenous ice 
nucleation or antifreeze proteins (AFP) to modify ice growth creates the possibility of 
reducing the amount of toxic CPAs (Wowk et al., 2000). Examples of commonly used 
SIBs are 1,3 cyclohexanediol (1,3 CHD), 2,3 butanediol and polyethylene glycol (PEG-
400) (Eisenberg et al., 2012; Fahy, 2004). Most active AFPs so far have been found in 
insects (Knight, 2000; Lin et al., 2011). One of the most potent AFPs (RiAFP) was 
found in the longhorn beetle Rhagium inquisitor which can be supercooled to 
below -25°C (Hakim et al., 2013). However AFP from insects cannot be produced in 
sufficient quantities and AFPs from other sources such as fish or monoclonals are 
expensive and can only be used for small volume vitrification. Thus, for large scale 
cryopreservation synthetic ice blockers are a better choice.  
In general, SIBs and AFPs have a greater effect on influencing ice nucleation and 
growth than accounted for on a colligative basis, which favours reduced osmotic stress. 
This offers the possibility not only to replace toxic CPAs but also to reduce the amount 
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of CPAs needed to suppress ice formation during the LT process and to achieve a stable 
vitrified state. The addition of SIBs and AFPs might be especially valuable for the 
warming process, when devitrification has to be avoided. While in my studies a final 
concentration of 62% (w/v) Me2SO was sufficient to avoid visible ice formation during 
the cooling process to -125˚C for a volume of 400ml, the concentration had to be 
increased to 64% to avoid devitrification during warming. This points to important 
factors of the kinetics for ice nucleation at cryogenic temperatures which require further 
study. 
8.3 Liquidus Tracking  
Cryo-banking of larger structures, such as tissues or organs, remains elusive with only 
rare claims of success (Fahy et al., 2004) and dispersed, cellular systems, in volumes 
above 10ml, have required sample size manipulation (e.g. into a thin film volume 
format (Massie et al., 2014; Sputtek et al., 2011). For dispersed cell system of large 
volumes, inhomogeneous warming and cooling rates are problematic. When using a 
slow cooling protocol, cells that are cooled too fast may not dehydrate sufficiently to 
avoid intracellular ice formation and others may be exposed for too long to high 
concentrations of injurious CPAs (Karlsson et al., 1993; Koshimoto & Mazur, 2002; 
Pegg et al., 2006; Toner et al., 1990). During warming, devitrification and/or ice 
recrystallisation becomes more likely. For 3-dimensional structures the formation of 
extracellular ice in liquid spaces within the tissue, such as within small capillary blood 
vessels inside an organ (Hunt, 1984; Jacobsen et al., 1984; Pegg, 2010) physically 
destroys the internal structure.  
Ice formation can be avoided by vitrification but, high cooling rates must be imposed to 
avoid toxic effects. This is neither possible for tissues nor for tissue like cell constructs 
as enough time must be given for CPAs to penetrate into the cells, nor for large sample 
volumes (>1ml) where high cooling and warming rates cannot be achieved. Those 
obstacles are overcome by Liquidus Tracking (LT), a method of achieving vitrification 
at minimized toxicity by decreasing the sample temperature to just above the melting 
point before the CPA concentration of the sample is increased (Farrant, 1965a; Pegg et 
al., 2006; Wang et al., 2007). 
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8.4 Manual Liquidus Tracking 
To understand the LT process but also to pre-test conditions for automatic LT, different 
methods to carry out manual LT were established and evaluated (Chapter 4). The most 
practical approach to increase the sample CPA concentration was to add highly 
concentrated CPA (60-80%) while the sample was being cooled in a controlled rate-
freezer. The method was further improved by using an insulation thermal buffer system 
to reduce temperature fluctuation during the addition of new CPAs and a special stirrer 
was invented to increase mixing effectiveness of viscous solution. A two-step LT 
cooling and warming process proved to be more suitable to pre-test conditions for 
automatic LT than a multistep LT process. Although fewer addition and reduction steps 
were used, (higher CPA concentration at the same temperature) viabilities of up to 90% 
were reached. A two-step (possibly a three step process for cells that are more sensitive 
to CPAs) has the additional advantage, that the volume during CPA addition does not 
increase greatly and thus, making a reduction step at subzero temperatures unnecessary. 
Although this is possible for encapsulated cells, this is not suitable for single cells, 
which do not sink to the bottom of the sample carrier by gravity, so that the CPA 
solution on top can be taken off. In my work manual LT was only used for pre-testing 
purposes. However, to be used as an independent protocol for long-term preservation, 
sterility has to be maintained. For this either a cooled laminar flow or a small portable 
cooling system that can be placed under a conventional laminar flow could be used.  
8.5 Automatic Liquidus Tracking 
Automatic Liquidus Tracking (Chapter 6 and 7) provides a promising possibility to 
cryopreserve large volumes, tissues and organs in the future. Interestingly incubation 
temperature once below -20˚C, and incubation time had no or only a small impact on 
cell survival, whereas changes made to the mixing properties by using a propeller 
instead of a Planer stirrer or by changing the outlet port height, drastically increased 
post-warming viability by 40%. More work is required to fully characterize stirring 
effects, which could also enlighten the process of sample preparation for conventional 
vitrification. An investigation at the National Institute of Biological Standards and 
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Controls (NIBSC) has shown that cell recovery after vitrification varied considerably 
between technicians (Fleck et al., 2013). It is possible that mixing formed part of these 
differences. A better understanding could help to improve cell recovery and lead to 
better standardization of vitrification protocols. 
Changes made to the original automatic LT protocol developed by Planer, such as the 
use of a two-step instead of a single-step solution mode, would need to be automated. 
This would markedly facilitate the test procedure and enhance reliability. It also has to 
be considered whether it can be ensured that all CPAs are washed off from AELC 
before starting to treat the patient.  
Careful consideration ought to be given to how the process can be maintained under 
sterile conditions when disconnecting and reconnecting the sample carrier from the 
outlet and inlet tubes, to be stored at subzero temperatures. In addition benefits of 
different storage temperatures should be tested. While storage at -80˚C could be more 
accessible in laboratories and clinics and the CPA concentration could be potentially be 
reduced, ice formation during storage and thus recrystallization during warming could 
have an impact on cell survival especially for long-term storage.  
8.6 Improving the Liquidus Tracking procedure 
For the use in a bioartificial liver (BAL) device cell viability following cryopreservation 
by LT has to be further improved. At the moment the system can achieve viabilities of 
more than 70% and a alpha-fetoprotein production of approximately 70% when AELC 
with a cell densities of more than 17*10
6 
cells/ml of beads are used (fraction of the 
untreated control after 48 hours of post warming). However, for the use in a BAL 
viability and a protein production of more than 90% should be reached. As bioreactor 
size and thus, the bead volume are limited, high cell density and viability are required to 
deliver sufficient biomass to replace liver function. In addition debris and DNA from 
dead cells contained in the plasma may be returned to the patient and trigger an immune 
or inflammatory response. Hepatoblastoma HepG2 DNA poses an additional risk of 
tumourigenesis. Although a filter system will be part of the BAL circuit, less cell 
fragments within the plasma would reduce the risk of a filter overload and thus the 
potential risk to the patient.  
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To improve the LT system it would be highly advantageous if the intracellular CPA and 
water concentration over the LT process could be monitored. For example, if it can be 
shown that CPA toxicity is negligible once CPA and water flux are (nearly) reversed 
and in case this happens within the temperatures range (0 to -40˚C) of CPA addition 
and reduction, LT protocols could be adapted. The CPA concentration could be 
increased at a higher temperature to assure intracellular vitrification before cooling the 
sample to a temperature of reversed membrane flux. Once reached, the concentration 
needed to prevent devitrification during warming may be realised.  
Proton nuclear magnetic resonance spectroscopy (NMR) has been used to measure the 
Me2SO in rat liver and cornea (Fuller et al., 1989; Walcerz et al., 1995). A more recent 
approach makes use of the Me2SO sulfur atom which strongly increases the mass 
attenuation, making the concentration measurable by x-ray computed tomography (CT). 
This method has the advantage of being non-invasive and precise, making it possible to 
measure the concentration inside a single cell. In addition ice crystals are detectable so 
that CPA addition and cooling rate can be adjusted to provide sufficient CPA 
penetration (Sousa, 2013). The water content can be measured by differential scanning 
calorimetry (DSC) and Fourier transform infrared spectroscopy (FTIR) (Akhoondi et 
al., 2011; Devireddy et al., 1998). However, it is questionable as to how any of these 
applications could be used for “in-process” measurements of automatic large scale LT, 
but samples might be taken and vitrified in liquid nitrogen to be measured later at a 
predefined subzero temperature at which no further changes are expected or by warming 
the samples using DSC. Raman spectroscopy seems to be an even more promising 
method. Used to monitor sample quality during cold storage at temperatures as low 
as -140˚C, Raman is able to “visualize” single cells and distinguish between water, ice 
and different cryoprotectants (Dorr et al., 2012). 
Although not an option for manual LT, as it works with an open system, applying 
higher sample pressure (Fahy et al., 1984) could help to reduce CPA toxicity, provided 
that LT pumps and stirrer remain unaffected. The approach of supercooling facilitated 
by a variable magnetic field (Kobayashi & Kirschvink, 2014) seems promising and has 
shown good success for the vitrification of ovarian cortex tissue (Moriguchi et al., 
2012). Programmed freezers with an oscillating magnetic field have already been built 
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and used for human embryonic stem cells preservation (Lin et al., 2013), so the 
combination of LT and supercooling might be an interesting approach.  
However, at the moment still the most promising approach to improve LT cell recovery 
is the use of different stirrer types and speed; for example a higher speed would be 
useful to increase homogenisation and a lower speed would be preferable to reduce 
membrane permeability. 
8.7 Further methods to increase cell recovery 
Cell death can result following either apoptosis or necrosis. While necrotic cell death is 
uncontrolled and results from external influences, apoptosis (programmed cell death) is 
initiated by intracellular and extracellular signalling pathways. Apoptosis can be 
stimulated by cytokines and hormones but also by environmental stress factors. For 
example, apoptosis following cryopreservation was reported for liver cells and slices 
(Fujita et al., 2005; Martin et al., 2000; Vanhulle et al., 2006), embryonic stem cells (Xu 
et al., 2010) and sperm (Khan et al., 2009; Martin et al., 2007). The release of reactive 
oxygen species (ROS), is known to trigger apoptosis in liver (San-Miguel et al., 2006) 
and HepG2 cells (Oh & Lim, 2006) and oxidative stress following hypothermia was 
shown to lead to apoptosis (Fujita et al., 2005; Rauenet al., 1999). 
The addition of antioxidants such as Trolox and N-acetyl-cysteine to the 
cryopreservation media to reduce ROS is one approach to improve cell recovery and has 
been shown to be successful for sperm cells (Peña et al., 2004; Thuwanut et al., 2008) 
and rat hepatocytes (Vairetti et al., 2001). Although the use of Viaspan (containing 
glutathione as an antioxidant) instead of PBS (Chapter 6) did not increase cell viability 
after LT, the use of different types of antioxidants possibly at a different concentration 
might be more successful.  
Other possibilities to influence the signalling pathway or to reduce apoptosis-triggering 
factors might be more effective for LT. For example, the addition of caspase inhibitors 
proved successful for the cryopreservation of primary liver cells (Matsushita et al., 
2003; Yagi et al., 2001), porcine hepatocytes (Yagi et al., 2001), human haematopoietic 
stem cells (Stroh et al., 2002) and mice ovarian tissue (Zhang et al., 2009), while the 
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upregulation of heat shock proteins (HSPs) reportedly improved liver cell and tissue 
recovery after hypothermia (Chen & Gao, 2004; Kao et al., 2008). In addition, the 
hepatocyte growth factor (HGF) was  shown to be an effective anti-apoptotic agent for 
adult human hepatocytes (Saich et al., 2007; Schulze-Bergkamen et al., 2004). Rho-
associated kinase (ROCK) inhibitors have also been shown to reduce apoptosis and 
improve recovery of cryopreserved human stem cells (Gauthaman et al., 2010; Martin-
Ibañez et al., 2008). 
However, costs for the reagents have to be considered as large amounts are needed and 
due to the constant exchange of solution the best moment for addition has to be 
evaluated.  
8.8 Further applications for Liquidus Tracking 
Apart from our intended use to cryopreserve AELC for the use in a BAL, there are 
many more applications for encapsulated 3D cell cultures and the necessity for long-
term storage. It has been recognized that two-dimensional cell culture (2D) systems do 
not accurately reproduce the functions and physiology of living tissues. In recent years 
three-dimensional cell culture systems have been developed that better reflect complex 
tissue structures with normal differentiation, polarization, cell behaviour and 
intercellular interactions (Bokhari et al., 2007; O’Brien et al., 2006; Pampaloni et al., 
2007). Those 3D tissue-like cell cultures can provide valuable information for basic 
research but also for tissue organ engineering, stem cell research and drug discovery. In 
vitro cell types such as primary hepatocytes and immortalized cell lines are useful 
means for initial screening of the hepato-toxic effects of drugs, however culturing cells 
three-dimensional is more comparable to its natural architecture environment and was 
shown to improve the morphological characteristics of human HepG2 cells in culture 
(Khalil et al., 2001; Guillouzo & Guguen-Guillouzo, 2008).  
Moreover, encapsulation as a means to isolate transplanted cells from the patient’s 
immune system has generated an emerging interest in cell-based medicine for the 
treatment of diseases such as diabetes, liver failure, neurodegenerative, musculoskeletal, 
and cardiovascular diseases (Lim & Sun, 1980; Murua et al., 2008; Orive et al., 2003). 
The host immune rejection of transplanted donor cells is a problem that is often 
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addressed by administrating drugs for immunosuppression, but a suppressed immune 
system also puts the patient at risk for other diseases. Cell encapsulation with 
potentially higher cell density could offer an alternative to protect the transplanted cells 
from being damaged by the host’s immune system while allowing free diffusion of 
nutrients, metabolites and metabolic waste. In addition encapsulation protects the cells 
from physical damage, which is an important aspect of automatic LT, but also has the 
potential advantage of enhancing cell growth. Studies have focused on the use of stem 
cells and induced pluripotent stem cells for their potential in cellular therapy and the 
favorable effect that micro-environment has on survival and functioning (Yagi et al., 
2009). 
Another application for which the LT system might be useful is the preservation of skin 
allografts. Perfusion as needed for other organs is not required and the cell thickness of 
skin (2mm) is comparable to that of cartilage (7mm) and AELC (0.5mm). Skin 
transplants for the treatment of burns and other wounds are not always available in 
adequate quantities making skin graft preservation important in meeting the need for 
skin transplantation. Vitrification (Fujita et al., 2000) and slow freezing protocols (Ben-
Bassat et al., 1996, 2001) have been successfully used to cryopreserve cadaveric half 
skin but there is still a need to cryopreserve larger pieces of skin allograft and skin 
grafts of greater thickness (e.g full skin). 
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Appendices 
 
Appendix to Chapter 3: 
 
Table 3.3 Low FDA threshold 
cell number 
(cells/ml 
beads) 10.3*10
6
 14.88*10
6
 17.89*10
6
 20.22*10
6
 26.31*10
6
 
sample 1 2 1 2 1 2 1 2 1 2 
threshold 23 21 28 27 29 31 44 43 31 44 
 
21 26 31 30 36 32 45 44 46 41 
 
18 20 29 28 35 31 46 29 46 41 
 
26 26 33 28 34 33 43 38 43 42 
 
26 19 32 31 37 33 45 31 43 44 
average 22.8 22.4 30.6 28.8 34.2 32 44.6 37 41.8 42.4 
final 
threshold:       average  = 41 +/-3.2 SD 
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Table 3.4 Low PI threshold 
Cell number:  
20.22*10
6 
cells/ml 
Sum intensity FDA 
Aim sum Intensity of 
31748525* for PI 
Lower threshold PI 
sample 1 image 1 35187045 31187355 12 
sample 1 image 2 38169857 31797561 29 
sample 1 image 3 34900386 31271788 32 
sample 1 image 4 35053162 31184015 30 
sample 1 image 5 40404321 30165638 20 
average   24.6 
sample 2 image 1 29079423 31162474 36 
sample 2 image 2 41418401 31130723 33 
sample 2 image 3 19800704 31775390 20 
sample 2 image 4 29055327 31280522 27 
sample 2 image 5 14416622 31230720 33 
average 31748525* 
 
28.0 
Cell number:  
26.31*10
6
 cell/ml 
Sum intensity FDA 
Aim sum intensity of 
40262498* for PI 
Lower threshold for PI 
sample 1 image 1 21992407 40232118 42 
sample 1 image 2 50834677 40564241 44 
sample 1 image 3 47952834 40331949 40 
sample 1 image 4 35581092 40491603 48 
sample 1 image 5 36197089 40450072 65 
average   47.8 
sample 2 image 1 46908396 40249895 65 
sample 2 image 2 40175423 40094759 52 
sample 2 image 3 39859186 40518308 68 
sample 2 image 4 42406002 40969637 67 
sample 2 image 5 40717872 40202528 51 
average 40262498* 
 
58.4 
Final threshold 
average +/- SD   41 +/-16.1 
*sum intensity for PI had to be approximately the same as or FDA. This was achieved by adjusting 
the PI threshold. 
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Table 3.6 FDA and PI threshold setting (AELC one day after encapsulation, FDA exposure time: 
150ms, PI exposure time: 1s) 
encapsulation 1-4 day 1  
Low threshold 
FDA 
Sum intensity 
FDA 
Sum Intensity  
PI 
Low threshold 
PI 
encapsulation 1 image 1 16 3094206 4559859 21 
encapsulation 1 image 2 19 3609000 4470615 21 
encapsulation 1 image 3 23 5070708 4524616 19 
encapsulation 1 image 4 22 5755816 4452720 18 
encapsulation 1 image 5 23 5111211 4706646 20 
average 21 4528188 4542891 20 
encapsulation 2 image 1 18 4095644 5174288 22 
encapsulation 2 image 2 19 4858627 5242796 24 
encapsulation 2 image 3 27 5740505 5104872 24 
encapsulation 2 image 4 23 5236164 5170000 22 
encapsulation 2 image 5 21 5133087 5183549 11 
average 22 5012805 5175101 21 
encapsulation 3 image 1 15 3814405 5624252 19 
encapsulation 3 image 2 15 3847213 5684750 20 
encapsulation 3 image 3 26 7905982 5694455 18 
encapsulation 3 image 4 25 7032799 5582154 16 
encapsulation 3 image 5 N/A N/A 5629549 21 
average 20 5650100 5643032 19 
encapsulation 4 image 1 22 9023726 9635147 17 
encapsulation 4 image 2 24 11006639 9635779 17 
encapsulation 4 image 3 24 9278548 9694020 23 
encapsulation 4 image 4 21 8058352 9669975 21 
encapsulation 4 image 5 25 10985479 9590066 18 
average 23 9670549 9644997 19 
average +/- SD 21 +/- 1.3 
  
20 +/- 1.0 
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Table 3.9 Gain and equalization factor evaluation: Viability data of samples listed in Figure 3.11 
day 1 day 5 day 10 day 16 
600/ 
300 
900/ 
300 
1200/ 
300 
600/ 
300 
900/ 
300 
1200/ 
300 
600/ 
300 
900/ 
300 
1200/ 
300 
600/ 
300 
900/ 
300 
1200/ 
300 
90.03 88.26 87.73 87.09 86.23 86.22 88.47 87.05 87.24 86.26 84.42 84.97 
91.36 89.45 88.89 88.77 87.60 87.50 89.98 88.35 88.44 88.03 85.94 86.35 
81.86 81.53 80.41 77.13 78.63 78.22 79.31 79.80 79.70 75.84 76.10 76.45 
46.61 44.44 42.95 39.49 40.00 39.71 42.59 41.71 41.86 37.79 36.58 37.32 
            
600/ 
600 
900/ 
600 
1200/ 
600 
600/ 
600 
900/ 
600 
1200/ 
600 
600/ 
600 
900/ 
600 
1200/ 
600 
600/ 
600 
900/ 
600 
1200/ 
600 
90.57 88.79 88.77 89.63 87.91 88.08 89.84 88.57 88.74 88.98 86.98 86.98 
90.57 88.40 88.30 88.76 87.50 87.58 89.83 88.18 88.28 88.12 86.54 86.45 
80.33 79.82 79.42 77.05 78.42 78.30 78.98 79.48 79.38 75.93 76.95 76.54 
44.15 41.75 41.45 39.40 39.71 39.82 42.12 41.24 41.39 37.92 37.69 37.43 
            
600/ 
900 
900/ 
900 
1200/ 
900 
600/ 
900 
900/ 
900 
1200/ 
900 
600/ 
900 
900/ 
900 
1200/ 
900 
600/ 
900 
900/ 
900 
1200/ 
900 
86.87 84.50 84.47 84.25 83.13 83.32 85.01 83.37 83.59 81.71 80.09 80.09 
86.96 84.12 83.98 84.36 82.71 82.79 85.12 82.96 83.07 81.84 79.62 79.49 
74.39 73.78 73.29 70.14 71.77 71.58 71.35 72.11 71.98 66.24 67.49 66.98 
44.18 41.79 41.48 39.03 39.34 39.42 40.43 39.75 39.88 34.84 34.63 34.38 
            
Values in bold represent the PI/FDA combination. Viability was calculated with the corresponding 
equalization factor listed in Table 3.5. Sample 1 (positive control), sample 2 (AELC incubated in 40% 
Me2SO), sample 3 (AELC incubated in 50% Me2SO), sample 4 (AELC incubated in 80% Me2SO), listed 
from top to bottom. 
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Appendix to Chapter 6: 
 
6.3.3.2    Combined manual/automatic LT  
Delta T program: 
Start temperature was set to -20˚C (on hold) 
Manual inlet (inlet speed: 60 ml/minute): 
 Waited until sample temperature was at 12˚C, then inlet of 31ml of 50% (w/v) CPA. 
 Waited until sample temperature was at 4˚C, then inlet of 89ml of 50% (w/v) CPA. 
 Waited until sample temperature was at 0.5˚C, then inlet of 67ml of 50% (w/v) CPA. 
 252ml of sample were extracted and outlet re-primed with 35ml of 50% (w/v) CPA. 
 Waited until sample temperature was at -4˚C, then inlet of 50ml of 50% (w/v) CPA. 
 Waited until sample temperature was at -5˚C, then inlet of 75ml of 50% (w/v) CPA. 
 Waited until sample temperature was at -7˚C, then inlet of 125ml of 50% (w/v) CPA. 
 135ml sample solution was extracted and outlet was primed with 50% (w/v) CPA. 
Automatic Planer CfgPid profile started at -12˚C  
Delta Program: 
cooling rate: -0.5˚C/minute to -56˚C hold for 10 minute 
cooling rate -10˚C/minute to -160˚C hold for 20 minute 
Table 6.2 CfgPid profile for automatic LT 
CfgPid profile 
 
measured T/C curve (approximate) 
 
Freezer 
 temperature (C˚) 
sample CPA 
concentration (w/v) 
Sample 
 temperature (C˚) 
sample CPA 
concentration (w/v) 
-22.15 32.10 -14 41 
-27.65 37.50 -15 45 
-32.65 42.50 -19 51 
-36.65 46.49 -21 52 
-40.65 50.49 -26 57 
-44.65 54.48 -27 59 
-47.65 57.47 -32 62 
-50.65 60.47 -35 65 
-53.25 63.07 -38   
-55.85 65.66 -40   
 
The stirrer was stopped at -40˚C (Me2SO) or -35˚C (CPA No.18) and aliquots of 2.5ml 
of LT-processed AELC were added into a 15ml centrifuge tube held in a bucket of 
liquid nitrogen. Samples were stored at liquid nitrogen tempertures until warming. 
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Appendix to Chapter 7: 
 
7.3.1    The 50-60-66% inlet: 
Manual inlet with 50% (w/v) CPA 
 Waited until sample temperature was at 12˚C, then influx of 190ml of 50% (w/v) 
CPA at 12.5ml/minute. 
 Waited until sample temperature was at 7˚C, then freezer was set to -20˚C (on hold). 
 Waited until sample temperature was 2˚C, then 252ml were extracted at 25ml/minute 
and outlet was re-primed with 35ml 50% (w/v) CPA. 
 Waited until sample temperature was at -1.5˚C, then inlet of 250ml of 50% (w/v) 
CPA at 20ml/minute (temperature after inlet was -10˚C). 
 Waited until sample temperature was at -12˚C, then freezer was set to -25˚C (on 
hold) and inlet of 150ml (tube volume) of 50% (w/v) CPA at 20ml/minute while 
60% (w/v) CPA was primed in. Simultaneously 150ml were extracted (at 
20ml/minute). 
 Waited until sample temperature was at -16˚C, then freezer was set to -30˚C and 
samples were taken at -16˚C at a concentration of 40% (w/v) CPA. 
 Inlet of 60% (w/v) CPA at 20ml/minute until a sample CPA concentration of 50% 
(w/v) was reached. 
 Inlet of 150ml (tube volume) of 60% (w/v) CPA at 20ml/minute while 66% (w/v) 
CPA was primed in. Simultaneously 150ml were extracted (at 20ml/minute).  
 Inlet of 66% (w/v) CPA until a sample CPA concentration of 65% (w/v) was 
reached, then freezer temperature was set to -60˚C. 
 The stirrer was stopped at a sample temperature of -40˚C (Me2SO) or -35˚C (CPA 
No.18) and aliquots of 2.5ml were added into a 15ml centrifuge tube hold in a bucket 
of liquid nitrogen. Samples were stored at liquid nitrogen until warming. 
 Freezer setting for vitrification: at -10˚C/minute to-160˚C until the sample reaches a 
temperature of -125˚C. 
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7.3.4      The manual two-step LT approach 
Method: 
To obtain sufficient material for five repetitions the following pre-mix (all solutions 
at 0.5˚C - on ice water) was prepared: 6ml of 50% (w/v) CPA No.18 was added to 
1.5ml of settled beads contained in a total volume of 3ml of PBS. After mixing, an 
additional amount of 6ml of 50% (w/v) CPA No.18 was added to increase the 
concentration to 40% (w/v) CPA. After 3 minutes on ice while the beads settled to 
the bottom, the volume was reduced to 3.6ml by extracting the supernatant. The 
solution was mixed and 0.6ml of bead solution (0.25ml of settled beads) was added 
to a new 15ml centrifuge tube which was held in a 50ml centrifuge tube containing 
70% (v/v) ethanol for insolation as described in Chapter 4. Samples were placed into 
the controlled rate freezer and were cooled to -20˚C at -0.5˚C/minute. The sample 
concentration was increased to 65% CPA by adding 1ml of 80% CPA solution (at -
20˚C). Volumes were chosen to be equal or below 1ml to be able to use a 1ml 
pipette to perform pipetting in one step. 
The two-step warming process was as following: vitrified samples were taken from 
liquid nitrogen and placed inside the controlled rate freezer (at -20˚C). Samples 
were kept for 15 minutes until they were completely liquid. Then 8ml of 40% (w/v) 
CPA No.18 (at -20˚C) were added which decreased the sample CPA concentration 
to 44% (w/v). Samples were mixed by inversion and left in the freezer for 15 
minutes. Samples were poured through cell strainers which were then placed in 8ml 
of ice cold 20% (w/v) glucose solution for 10 minutes. The solution was exchanged 
three times with fresh PBS (ice-cold) to remove all CPA. Finally AELC were 
incubated in 8ml of complete media at 37˚C until measurement. This approach was 
used to test different variations of CPA No.18, for example replacing half of the 
glucose concentration with sucrose, raffinose or trehalose, pre-testing different 
sample carrier solutions such as HEPES, Viaspan or HTK and to test AELC that 
were incubated for 24 hours in complete media containing Proline, trehalose or an 
increased concentration of linoleic acid  
 
